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A B S T R A C T
Background
Oralmucositis is a side effect of chemotherapy, head andneck radiotherapy, and targeted therapy, affecting over 75%of high-risk patients.
Ulceration can lead to severe pain and difficulty with eating and drinking, which may necessitate opioid analgesics, hospitalisation and
supplemental nutrition. These complications may disrupt cancer therapy, which may reduce survival. There is also a risk of death from
sepsis if pathogens enter the ulcers of immunocompromised patients. Ulcerative oral mucositis can be costly to healthcare systems, yet
there are few preventive interventions proven to be beneficial. Cytokines and growth factors may help the regeneration of cells lining
of the mouth, thus preventing or reducing oral mucositis and its negative effects.
Objectives
To assess the effects of cytokines and growth factors for preventing oral mucositis in patients with cancer who are receiving treatment.
Search methods
Cochrane Oral Health’s Information Specialist searched the following databases: Cochrane Oral Health’s Trials Register (searched 10
May 2017); the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 4) in the Cochrane Library (searched 10May
2017); MEDLINE Ovid (1946 to 10 May 2017); Embase Ovid (7 December 2015 to 10 May 2017); CINAHL EBSCO (Cumulative
Index to Nursing and Allied Health Literature; 1937 to 10 May 2017); and CANCERLIT PubMed (1950 to 10 May 2017). The US
National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) and the World Health Organization International Clinical
Trials Registry Platform were searched for ongoing trials.
Selection criteria
We included parallel-design randomised controlled trials (RCTs) assessing the effects of cytokines and growth factors in patients with
cancer receiving treatment.
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Data collection and analysis
Two review authors independently screened the results of electronic searches, extracted data and assessed risk of bias. For dichotomous
outcomes, we reported risk ratios (RR) and 95% confidence intervals (CI). For continuous outcomes, we reported mean differences
(MD) and 95% CIs. We pooled similar studies in random-effects meta-analyses. We reported adverse effects in a narrative format.
Main results
We included 35 RCTs analysing 3102 participants. Thirteen studies were at low risk of bias, 12 studies were at unclear risk of bias, and
10 studies were at high risk of bias.
Our main findings were regarding keratinocyte growth factor (KGF) and are summarised as follows.
There might be a reduction in the risk of moderate to severe oral mucositis in adults receiving bone marrow/stem cell transplantation
after conditioning therapy for haematological cancers (RR 0.89, 95%CI 0.80 to 0.99; 6 studies; 852 participants; low-quality evidence).
We would need to treat 11 adults with KGF in order to prevent one additional adult from developing this outcome (95% CI 6 to 112).
There might be a reduction in the risk of severe oral mucositis in this population, but there is also some possibility of an increase in
risk (RR 0.85, 95% CI 0.65 to 1.11; 6 studies; 852 participants; low-quality evidence). We would need to treat 10 adults with KGF in
order to prevent one additional adult from developing this outcome (95% CI 5 to prevent the outcome to 14 to cause the outcome).
There is probably a reduction in the risk of moderate to severe oral mucositis in adults receiving radiotherapy to the head and neck
with cisplatin or fluorouracil (RR 0.91, 95% CI 0.83 to 1.00; 3 studies; 471 participants; moderate-quality evidence). We would
need to treat 12 adults with KGF in order to prevent one additional adult from developing this outcome (95% CI 7 to infinity). It is
very likely that there is a reduction in the risk of severe oral mucositis in this population (RR 0.79, 95% CI 0.69 to 0.90; 3 studies;
471 participants; high-quality evidence). We would need to treat 7 adults with KGF in order to prevent one additional adult from
developing this outcome (95% CI 5 to 15).
It is likely that there is a reduction in the risk of moderate to severe oral mucositis in adults receiving chemotherapy alone for mixed
solid and haematological cancers (RR 0.56, 95% CI 0.45 to 0.70; 4 studies; 344 participants; moderate-quality evidence). We would
need to treat 4 adults with KGF in order to prevent one additional adult from developing this outcome (95% CI 3 to 6). There might
be a reduction in the risk of severe oral mucositis in this population (RR 0.30, 95% CI 0.14 to 0.65; 3 studies; 263 participants; low -
quality evidence). We would need to treat 10 adults with KGF in order to prevent one additional adult from developing this outcome
(95% CI 8 to 19).
Due to the low volume of evidence, single-study comparisons and insufficient sample sizes, we found no compelling evidence of a
benefit for any other cytokines or growth factors and there was no evidence on children. There did not appear to be any serious adverse
effects of any of the interventions assessed in this review.
Authors’ conclusions
We are confident that KGF is beneficial in the prevention of oral mucositis in adults who are receiving: a) radiotherapy to the head and
neck with cisplatin or fluorouracil; or b) chemotherapy alone for mixed solid and haematological cancers. We are less confident about
a benefit for KGF in adults receiving bone marrow/stem cell transplant after conditioning therapy for haematological cancers because
of multiple factors involved in that population, such as whether or not they received total body irradiation (TBI) and whether the
transplant was autologous (the patients’ own cells) or allogeneic (cells from a donor). KGF appears to be a relatively safe intervention.
Due to limited research, we are not confident that there are any beneficial effects of other cytokines and growth factors. There is
currently insufficient evidence to draw any conclusions about the use of cytokines and growth factors in children.
P L A I N L A N G U A G E S U M M A R Y
Can cytokines and growth factors help prevent mouth soreness and ulcers (oral mucositis) in patients being treated for cancer?
Review question
This review has been produced to assess whether or not the use of cytokines and growth factors during cancer treatment, can help
prevent mouth soreness and ulcers.
Background
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Sore mouth and ulcers (oral mucositis) is a side effect of treatment for cancer including chemotherapy, head and neck radiotherapy,
and targeted therapy, affecting over 75% of high-risk patients. Ulcers can lead to severe pain and difficulty with eating and drinking.
Sufferers may need strong painkillers, possibly have to go into hospital and even be fed through a tube into their stomach or their veins.
These complications may disrupt their cancer therapy, meaning they are not receiving the best treatment, which may reduce survival.
Cancer patients have weakened immune systems due to their treatment and are less able to fight infections. An ulcer is an open wound
and there is a risk that bacteria can enter the body leading to infection or sepsis (a dangerous inflammatory reaction of the body to
infection).
Mouth soreness and ulcers can be costly to healthcare systems, yet there are few preventive interventions or treatments proven to be
beneficial. Cytokines and growth factors may help the regeneration of cells lining the mouth, thus preventing or reducing oral mucositis
and its negative effects.
Study characteristics
Authors from Cochrane Oral Health carried out this review of existing studies and the evidence is current up to 10 May 2017. It
includes 35 studies (published between 1993 and 2017) with 3102 participants, all patients being treated for cancer, aged from 1 to 87
years old. Review authors included studies comparing cytokines and growth factors for the prevention of oral mucositis. The studies
were carried out all over the world and often featured multiple sites, although most took place in high-income countries.
Main results
The main findings were regarding keratinocyte growth factor (KGF). KGF is likely to reduce the risk of oral mucositis in adults who
are receiving either radiotherapy to the head and neck with chemotherapy (cisplatin or fluorouracil), or chemotherapy alone for mixed
solid and blood cancers. KGF may also reduce the risk of oral mucositis in adults receiving bone marrow/stem cell transplant after
conditioning therapy for blood cancers, but these results are less clear because of multiple complicating factors. KGF appears to be a
relatively safe intervention. There did not appear to be any serious adverse effects of any of the interventions assessed in this review.
Due to limited research, review authors are uncertain of any beneficial effects of other cytokines and growth factors. There is currently
insufficient evidence to draw any conclusions about the use of cytokines and growth factors in children.
Quality of the evidence
For reducing oral mucositis in adults receiving radiotherapy to the head and neck with chemotherapy, review authors rated the evidence
for KGF as moderate to high quality. For reducing oral mucositis in adults receiving chemotherapy alone for mixed solid and blood
cancers, they rated the evidence for KGF as low to moderate quality. This evidence was downgraded due to there not being enough data
and because some results have not yet been published. For reducing oral mucositis in adults receiving bone marrow/stem cell transplant
after conditioning therapy for blood cancers, they rated the evidence for KGF as low quality because results were not similar across the
studies and some results have not yet been published. Evidence on side effects of KGF was poorly reported and inconsistent.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
KGF compared to placebo for preventing oral mucositis in adults with cancer receiving treatment
Patient or population: adults∗∗ receiving treatment for cancer (see subgroup for treatment type)
Setting: hospital
Intervention: KGF
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with KGF
Oral mucosit is (moder-
ate + severe)
BMT/ SCT af ter condit ioning for haematological
cancers
RR 0.89
(0.80 to 0.99)
852
(6 studies)
⊕⊕©©
LOW1
There might be a bene-
f it f or KGF in this popu-
lat ion
NNTB = 11 (95%CI 6 to
112)848 per 1000 755 per 1000
(678 to 839)
RT to head and neck with cisplat in/ 5FU RR 0.91
(0.83 to 1.00)
471
(3 studies)
⊕⊕⊕©
MODERATE2
There is probably a ben-
ef it f or KGF in this pop-
ulat ion
NNTB = 12 (95%CI 7 to
)
932 per 1000 848 per 1000
(773 to 932)
CT alone for m ixed cancers RR 0.56
(0.45 to 0.70)
344
(4 studies)
⊕⊕⊕©
MODERATE3
It is likely that there is
a benef it f or KGF in this
populat ion
NNTB = 4 (95% CI 3 to
6)
631 per 1000 353 per 1000
(284 to 441)
Oral mucosit is (severe) BMT/ SCT af ter condit ioning for haematological
cancers
RR 0.85
(0.65 to 1.11)
852
(6 studies)
⊕⊕©©
LOW4
There might be a bene-
f it f or KGF in this popu-
lat ion, but there is also
some possibility of an
increase in risk
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NNTB = 10 (95% CI 5
NNTB to 14 NNTH)677 per 1000 575 per 1000
(440 to 751)
RT to head and neck with cisplat in/ 5FU RR 0.79
(0.69 to 0.90)
471
(3 studies)
⊕⊕⊕⊕
HIGH
It is very likely that there
is a benef it f or KGF in
this populat ion
NNTB = 7 (95% CI 5 to
15)
700 per 1000 553 per 1000
(483 to 630)
CT alone for m ixed cancers RR 0.30
(0.14 to 0.65)
263
(3 studies)
⊕⊕©©
LOW5
There might be a bene-
f it f or KGF in this popu-
lat ion
NNTB = 10 (95%CI 8 to
19)
154 per 1000 46 per 1000
(22 to 100)
Adverse events Adverse events that were attributed to the study drugs rather than the cancer therapy were typically oral-related or skin-related. Events were most ly
mild to moderate with very few incidences of serious events. However, report ing was poor and inconsistent, meaning that it was not appropriate to
meta-analyse data
∗The risk in the intervent ion group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its
95%CI).
∗∗Only 1 study in the subgroup BMT/ SCT af ter condit ioning for haematological cancers’ included some children (but the median age of part icipants was 46 years)
∗∗∗The number of people that would need to receive KGF in order to prevent 1 addit ional person f rom developing the outcome. Calculated as 1 divided by the absolute risk
reduct ion (which is the control arm event rate minus the experimental arm event rate). NNTH means the number of people that would need to receive KGF to cause 1 addit ional
person to develop the outcome. All decimal places have been rounded up to the nearest whole number (i.e. 6.1 = 7).
: inf inity; 5FU: f luorouracil; BMT: bone marrow transplantat ion; CI: conf idence interval; CT: chemotherapy; KGF: kerat inocyte growth factor; NNTB: number needed to treat to
benef it∗∗∗; NNTH: number needed to treat to harm; RR: risk rat io; RT: radiotherapy; SCT: stem cell t ransplantat ion.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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1Downgraded by 1 level for inconsistency (substant ial heterogeneity: I2 = 50% to 90%, P < 0.1); downgraded 1 further level
for publicat ion bias as there are 2 references in Studies await ing classif icat ion that would be included in the condit ioning/
transplant subgroup, but the data are not available (NCT02313792; Spielberger 2001).
2Downgraded by 1 level for inconsistency (substant ial heterogeneity: I2 = 50% to 90%, P < 0.1).
3Downgraded by 1 level for publicat ion bias as there is 1 reference in Studies await ing classif icat ion that would be included
in the chemotherapy alone subgroup, but the data are not available (NCT00393822).
4Downgraded by 1 level for inconsistency (substant ial heterogeneity: I2 = 50% to 90%, P < 0.1); downgraded 1 further level
for publicat ion bias as there are 2 references in Studies await ing classif icat ion that would be included in the condit ioning/
transplant subgroup, but the data are not available (NCT02313792; Spielberger 2001); we did not downgrade for imprecision
because, despite the conf idence interval including a small chance of an increase in risk, it is a fairly narrow interval and a
rat ing of ’very low quality’ would seem an overly harsh rat ing for this body of evidence.
5Downgraded by 1 level for imprecision (wide conf idence interval, small sample size and low event rate); downgraded 1 further
level for publicat ion bias as there is 1 reference in Studies await ing classif icat ion that would be included in the chemotherapy
alone subgroup, but the data are not available (NCT00393822).
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B A C K G R O U N D
Description of the condition
Treating cancer with chemotherapy, radiotherapy of the head
and neck, or targeted therapy can cause toxic oral side effects
(Al-Dasooqi 2013; Scully 2006; Sonis 2004). Perhaps the most
widely researched of these side effects is oral mucositis (Al-Dasooqi
2013), which affects at least 75% of high risk patients (those re-
ceiving head and neck radiotherapy or high-dose chemotherapy)
(Scully 2006). Oral mucositis may be under-reported in lower risk
groups for various reasons: their tendency to be outpatients with
less observation; less reporting of moderate mucositis; or patients
and clinicians wishing to avoid any disruption to optimal cancer
treatment (Scully 2006).
Simply put, oral mucositis affects the oral mucosa (the mucous
membrane ofmoist tissue lining the oral cavity) and can lead to the
development of lesions (ulcers). However, the process that leads
to oral mucositis is complex and multifactorial, with Sonis’ five-
phase model being a widely accepted description of the sequence
of events underlying the condition (Sonis 2004; Sonis 2009).
1. Initiation: DNA damage caused by chemotherapy or
radiotherapy results in the loss of ability to proliferate in the
basal cells of the epithelium (the external layers of cells lining the
oral mucosa). This produces reactive oxygen species (ROS).
2. Primary damage response: radiotherapy, chemotherapy,
ROS, and DNA strand breaks all contribute to the activation of
transcription factors such as nuclear factor kappa beta (NF-Kβ),
and sphingomyelinases. All this leads to the upregulation of pro-
inflammatory cytokines (e.g. tumour necrosis factor alpha -
TNF-α), nitric oxide, ceramide, and matrix metalloproteinases,
resulting in the thinning of the epithelium through tissue injury
and cell death, culminating with the destruction of the oral
mucosa.
3. Signal amplification: some of the molecules in the previous
phase can lead to the exacerbation and prolonging of tissue
injury through positive or negative feedback (e.g. TNF-α can
positively feedback on NF-Kβ thus inducing more pro-
inflammatory cytokine production).
4. Ulceration: bacteria colonise ulcers and their cell wall
products infiltrate the submucosa (the connective tissues beneath
the oral mucosa), activating tissue macrophages (white blood
cells that respond to infection or damaged/dead cells), which
results in further production of pro-inflammatory cytokines,
inflammation, and pain.
5. Healing: signalling from the extracellular matrix of the
submucosa results in epithelial proliferation and differentiation,
and thus a thickening of the epithelium. The local oral flora are
reinstated.
However, there remains a lack of clarity around mechanisms and
risk factors for oral mucositis, particularly areas such as genetic
predisposition and microbial effects. Understanding of the patho-
biology leading to mucosal toxicity as a result of targeted ther-
apies (e.g. mammalian target of rapamycin (mTOR) inhibitor-
associated stomatitis - mIAS) is also currently limited, but it is
thought to differ from chemotherapy- and radiotherapy-induced
mucositis, and the clinical presentation of the ulcers is more sim-
ilar to aphthous stomatitis (Al-Dasooqi 2013; Boers-Doets 2013;
Peterson 2015).
Oral mucositis is an acute condition and, when caused by chemo-
therapy, ulceration normally occurs one week after treatment and
resolves within three weeks of treatment (Sonis 2009). Radiother-
apy-induced oral mucositis takes longer both to develop and to
heal, with ulceration normally occurring around two weeks into
a seven-week treatment cycle, and resolving three to four weeks
after treatment has ended (Sonis 2009).
Ulceration is the most significant phase as it leads to pain of vary-
ing severity, and difficulties with eating, swallowing, and talking
(Scully 2006). This in turn leads to the consumption of pain
relief medication, nutritional support (i.e. nasogastric or intra-
venous feeding), treatment of the oral mucositis, specialist oral
hygiene care, increased medical appointments and use of staff and
resources, and, in some instances, hospitalisation (Jensen 2014;
Miller 2001; Trotti 2003). Thus the negative impact on the qual-
ity of life of cancer patients, when they are already suffering, is
severe (Elting 2008; Epstein 1999). Further problems can occur in
immunosuppressed patients if whole bacteria on the ulcer surface
cross into the underlying submucosa, potentially leading to bac-
teraemia and sepsis, which require antibiotics and hospitalisation,
and can cause death (Jensen 2014; Peterson 2015; Scully 2006).
Therefore, oral mucositis can be a dose-limiting condition, dis-
rupting a patient’s optimal cancer treatment plan (Jensen 2014;
Peterson 2015; Sonis 2004). The additional costs associated with
oral mucositis are significant, with one study reporting a median
incremental cost ofUSD18,515per patient (Nonzee 2008). These
costs have been reported to be as much as USD 42,749 more per
patient when ulcerative oral mucositis is present (Sonis 2001).
Description of the intervention
As described above, oral mucositis occurs partly as result of the loss
of regenerative ability of the oral epithelial cells. Growth factors
and anti-inflammatory cytokines are used to counteract the biolog-
ical processes leading to this loss of proliferative ability.Growth fac-
tors and anti-inflammatory cytokines include (Raber-Durlacher
2013):
• keratinocyte growth factor;
• colony-stimulating factors;
• epidermal growth factor;
• transforming growth factor-beta;
• whey-derived growth factor;
• interleukin-11;
• ATL-104;
• trefoil factor.
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How the intervention might work
The growth factors described here are proteins that bind to recep-
tors of target cells and either increase the proliferationof the epithe-
lial cells that form the mucous membrane lining of the oral cavity,
or promote the recovery of the white blood cells that contribute to
themaintenance of oral health following conventional or high dose
chemotherapy (with or without radiotherapy) (Raber-Durlacher
2013). Anti-inflammatory cytokines are also proteins or glycopro-
teins that bind to receptors of target cells, and are thought to al-
ter the complex balance of pro- and anti-inflammatory cytokines
involved in the pathogenesis of oral mucositis (Raber-Durlacher
2013).
Currently, evidence-based guidelines recommend growth factors
for the prevention of oral mucositis in patients with haema-
tological cancers undergoing high-dose chemotherapy and total
body irradiation prior to haematopoietic stem cell transplanta-
tion (Lalla 2008). It has been postulated that tumour cells may
also have receptors accommodating cytokines and growth factors,
thus encouraging the proliferation of cancer cells in solid tumours
(Lalla 2008; von Bültzingslöwen 2006). A 2010 systematic re-
view suggested that the risk of acute myeloid leukaemia (AML)
or myelodysplastic syndrome (MDS) is increased in people with
various cancers receiving chemotherapy with granulocyte colony-
stimulating factor (G-CSF) when compared to those receiving
chemotherapy without G-CSF (Lyman 2010). The authors con-
cluded that it was not clear whether the increased AML/MDS risk
was due to G-CSF or due to the increased chemotherapy dose-
intensity in those patients. However, the review also reported a
reduction in overall mortality for those receiving G-CSF.
Why it is important to do this review
This Cochrane Review is part of a series that will replace the pre-
viously published Cochrane Review covering all interventions for
the prevention of oral mucositis in patients with cancer receiv-
ing treatment (Worthington 2011). The Mucositis Study Group
(MSG) of the Multinational Association of Supportive Care in
Cancer/International Society of Oral Oncology (MASCC/ISOO)
is a group that was set up in 1998 for the purpose of producing
international evidence-based clinical practice guidelines for man-
aging mucositis (both oral and gastrointestinal), which they first
published in 2004, with the latest update published in 2014 (Lalla
2014). In order to facilitate the future updating of Cochrane Re-
views on this topic, and also to make them more usable to clin-
icians, guideline developers, and consumers, we have decided to
divide the original Cochrane Review into the same intervention
categories as those used by MASCC/ISOO, which are as follows:
• basic oral care/good clinical practice;
• growth factors and cytokines;
• anti-inflammatory agents;
• antimicrobials, mucosal coating agents, anaesthetics, and
analgesics;
• laser and other light therapy;
• cryotherapy;
• natural and miscellaneous agents;
• amifostine.
We believe that following theMASCC/ISOO structure will better
enable the Cochrane Reviews to feed into such guidelines. We
can also be more thorough and rigorous in our assessment and
summarising of the evidence in each of the categories, which was
not feasible in a singleCochraneReview approaching150 included
studies.
It is also important to do this review as it is consistently shown to be
themost used review produced byCochraneOralHealth (in terms
of full-text downloads). It was also rankedby an expert panel of oral
medicine specialists as being the most important topic in the field
of oral medicine in an international prioritisation exercise carried
out by Cochrane Oral Health in 2014 (Worthington 2015).
O B J E C T I V E S
To assess the effects of cytokines and growth factors for preventing
oral mucositis in patients with cancer who are receiving treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials (RCTs) of parallel
design. It is possible to conduct cross-over studies in this area as
patients may receive several treatment sessions/cycles, with any
mucositis completely healing in the periods between the sessions.
However, we did not include cross-over data as we could not dis-
count any period effects, with mucositis risk increasing as patients
receive further cycles of treatment (Scully 2006; Sonis 2009). In-
stead, we used the first-period data only and treated such studies
as parallel group studies.
Types of participants
We included all patients with cancer whowere receiving treatment.
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Types of interventions
We included studies comparing growth factors and cytokines for
the prevention of oral mucositis (we would also have included
targeted therapy-induced stomatitis had such studies been identi-
fied) against usual care, no treatment, or any other treatment to
prevent oral mucositis. We also included studies comparing differ-
ent growth factors and cytokines or different regimens of growth
factors and cytokines against each other (head-to-head studies).
We excluded studies with ’complex’ interventions for the preven-
tion of mucositis, such as lasers plus growth factors and cytokines
versus lasers. This is because it is difficult to attribute any effect
shown to any particular component of the intervention. We ex-
cluded studies assessing different cancer treatments where the pri-
mary outcome was survival/cure, with mucositis as a toxicity.
Types of outcome measures
We are in agreement with Williamson 2012 that, if clinical trials
and systematic reviews are to be utilised, the outcomes assessed
should be those considered important to patients, healthcare pro-
fessionals, and other key stakeholders. If outcomes and outcome
measures are inconsistent across studies, it will not be possible to
compare and summarise research, and there is potential for out-
come reporting bias, with the selective reporting of results based
on statistical significance and favourability (Clarke 2007; Dwan
2008; Williamson 2005). This can lead to exaggerated estimates
of effect in systematic reviews of interventions, leading to an in-
correct belief that an intervention is more beneficial that it truly is
(Clarke 2007). It is thought that the way to address this problem
is to develop disease- or condition-specific core outcome sets to be
used as a minimum when conducting and reporting clinical trials
(Clarke 2007; Williamson 2012).
Therefore we used the core outcome set produced by Bellm
2002, which is registered on the COMET (Core Outcome Mea-
sures in Effectiveness Trials) Initiative’s website (www.comet-
initiative.org), and is the only core outcome set for oral mucosi-
tis known to us. We added the outcomes ’interruptions to cancer
treatment’ and ’adverse events’.
Primary outcomes
Mucositis incidence of any severity. We used mucositis measured
on a 0 to 4 point scale (none to severe) and dichotomised it as
any mucositis (0 versus 1+), moderate to severe mucositis (0 to 1
versus 2+), and severe mucositis (0 to 2 versus 3+).
Some studies measure the effects of mucositis using a composite
scale. If it was possible to extract the ’mucositis only’ data from
the total score, we would have included the data in the analyses.
If it was not possible, we would have recorded the composite data
in an additional table.
Secondary outcomes
• Interruptions to cancer treatment.
• Oral pain.
• Quality of life.
• Normalcy of diet (including use of percutaneous
endoscopic gastrostomy (PEG) feeding tubes or total parenteral
nutrition (TPN)).
• Adverse events.
• Number of days in hospital.
• Number of days of treatment with opioid analgesics.
• Number of days unable to take medicine orally.
Search methods for identification of studies
Electronic searches
Cochrane Oral Health’s Information Specialist conducted system-
atic searches in the following databases for randomised controlled
trials and controlled clinical trials without language or publication
status restrictions:
• Cochrane Oral Health’s Trials Register (searched 10 May
2017) (Appendix 1);
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 4) in the Cochrane Library (searched
10 May 2017) (Appendix 2);
• MEDLINE Ovid (1946 to 10 May 2017) (Appendix 3);
• Embase Ovid (7 December 2015 to 10 May 2017)
(Appendix 4);
• CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature; 1937 to 10 May 2017) (Appendix 5);
• CANCERLIT (Cancer subset within PubMed; 1950 to 10
May 2017) (Appendix 6).
Subject strategiesweremodelled on the search strategy designed for
MEDLINE Ovid. Where appropriate, they were combined with
subject strategy adaptations of the highly sensitive search strategy
designed by Cochrane for identifying randomised controlled trials
and controlled clinical trials as described in theCochrane Handbook
for Systematic Reviews of Interventions Chapter 6 (Lefebvre 2011).
Due to the Cochrane Embase Project to identify all clini-
cal trials in the database and add them to CENTRAL, only
most recent months of the Embase database were searched.
See the searching page on the Cochrane Oral Health website for
more information. No other restrictions were placed on the date
of publication when searching the electronic databases.
Searching other resources
We searched the following trial registries for ongoing studies:
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (clinicaltrials.gov; searched 10 May 2017)
(Appendix 7);
9Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch; searched 10 May
2017) (Appendix 8).
We included only handsearching done as part of the Cochrane
Worldwide Handsearching Programme and uploaded to CEN-
TRAL.
We searched the reference lists of included studies and relevant
systematic reviews for further studies.
We did not perform a separate search for adverse effects of inter-
ventions used, we considered adverse effects described in included
studies only.
Data collection and analysis
Selection of studies
Two review authors independently screened the titles and abstracts
retrieved from the electronic searches.We obtained full-text copies
of all studies that appeared to meet the inclusion criteria of the
review, or where there was insufficient information in the title or
abstract to make a clear judgement. Two review authors indepen-
dently assessed the full-text copies for eligibility and attempted
to resolve any disagreements through discussion. We consulted a
third review author whenwe were unable to resolve disagreements.
On assessing the full-text article, we discarded any studies that
clearly did not meet the inclusion criteria. We recorded all other
studies that did not meet the inclusion criteria, along with reasons
for exclusion, in the Characteristics of excluded studies table.
Data extraction and management
Two review authors independently extracted the data from each
included study using a specially designed data extraction form,
which we first piloted on a small sample of studies. We contacted
study authors for clarification or missing data where necessary and
feasible. We resolved any disagreements through discussion, con-
sulting a third review author to achieve consensus when necessary.
We recorded the following data for each included study in the
Characteristics of included studies table.
• Trial design, location, number of centres, recruitment
period.
• Inclusion/exclusion criteria, age and gender of participants,
number randomised/analysed, any other potentially important
prognostic factors (e.g. cancer type, cancer treatment, etc.).
• Detailed description of the intervention and comparator,
including timing and duration. Information on compliance with
the intervention.
• Details of the outcomes reported, including method of
assessment and time(s) assessed.
• Details of sample size calculations, adverse effects, funding
sources, declarations/conflicts of interest.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
included study using the Cochrane domain-based, two-part tool
as described in Chapter 8 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We contacted study au-
thors for clarification or missing information where necessary and
feasible. We resolved any disagreements through discussion, con-
sulting a third review author to achieve consensus when necessary.
We completed a ’Risk of bias’ table for each included study. For
each domain of risk of bias, we first described what was reported
to have happened in the study. This provided the rationale for our
judgement of whether that domain was at low, high, or unclear
risk of bias.
We assessed the following domains:
1. sequence generation (selection bias);
2. allocation concealment (selection bias);
3. blinding of participants and personnel (performance bias);
4. blinding of outcome assessment (detection bias);
5. incomplete outcome data (attrition bias);
6. selective outcome reporting (reporting bias);
7. other bias.
We categorised the overall risk of bias of individual studies. Stud-
ies were categorised as being at low, high, or unclear risk of bias
according to the following criteria:
• low risk of bias (plausible bias unlikely to seriously alter the
results) if all domains were at low risk of bias;
• high risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more domains were at high
risk of bias; or
• unclear risk of bias (plausible bias that raises some doubt
about the results) if one or more domains were at unclear risk of
bias.
We also presented the ’Risk of bias’ summary graphically.
Measures of treatment effect
For continuous outcomes (e.g. oral pain on a visual analogue
scale) where studies used the same scale, we used the mean val-
ues and standard deviations (SDs) reported in the studies in order
to express the estimate of effect as mean difference (MD) with
95% confidence interval (CI). Where different scales were used,
we expressed the treatment effect as standardised mean difference
(SMD) with 95% CI.
For dichotomous outcomes (e.g. mucositis of any severity/no mu-
cositis), we expressed the estimate of effect as a risk ratio (RR) with
95% CI.
We did not use area under the curve (AUC) data due to variation
in length of follow-up for outcome assessment, variation in the
length of the scale used to measure the outcome and also variation
or lack of clarity whether the results were reported in terms of total
area under the curve or average over the time period.
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Unit of analysis issues
The participant was the unit of analysis.
Dealing with missing data
We attempted to contact the author(s) of all included studies,
where feasible, for clarification, and missing data. We would have
used themethods described in Section7.7.3 of theCochrane Hand-
book for Systematic Reviews of Interventions to estimate missing SDs
(Higgins 2011). We did not use any other statistical methods or
perform any further imputation to account for missing data.
Assessment of heterogeneity
When a sufficient number of studies were included in any meta-
analyses, we assessed clinical heterogeneity by examining the char-
acteristics of the studies, the similarity between the types of par-
ticipants, the interventions, and the outcomes. We also assessed
heterogeneity statistically using a Chi2 test, where a P value < 0.1
indicates statistically significant heterogeneity. We quantified het-
erogeneity using the I2 statistic. A guide to interpretation of the
I2 statistic given in Section 9.5.2 of the Cochrane Handbook for
Systematic Reviews of Interventions is as follows (Higgins 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
If at least 10 studies were included in a meta-analysis, we planned
to assess publication bias according to the recommendations on
testing for funnel plot asymmetry (Egger 1997), as described in
Section 10.4 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). If asymmetry were identified, we
would have examined possible causes. We were not able to assess
publication bias in this way because, although we had a sufficient
number of studies in our meta-analyses for the primary outcome
in one comparison, they were split into subgroups containing less
than 10 studies, with no pooling of the subgroup totals.
Data synthesis
We only carried out meta-analyses where there were studies of
similar comparisons reporting the same outcomes. We combined
MDs for continuous data, and RRs for dichotomous data. Our
general approach was to use a random-effects model. With this
approach, the CIs for the average intervention effect were wider
than those that would have been obtained using a fixed-effect
approach, leading to a more conservative interpretation.
We used an additional table to report the results from studies not
suitable for inclusion in a meta-analysis, but only for the primary
outcome.
Subgroup analysis and investigation of heterogeneity
We carried out subgroup analyses according to type of cancer treat-
ment. We also would have considered age group (children versus
adults) as a category for subgroup analyses, if there had been suf-
ficient numbers of studies with these differing populations.
Sensitivity analysis
If there had been sufficient numbers of studies in the meta-analy-
ses, we would have tested the robustness of our results by perform-
ing sensitivity analyses based on excluding the studies at unclear
or high risk of bias from the analyses.
If any meta-analyses had included several small studies and a sin-
gle very large study, we would have carried out a sensitivity anal-
ysis comparing the effect estimates from both random-effects and
fixed-effect models. If these were different we would have reported
on both analyses as part of the results section, and considered pos-
sible interpretation.
Presentation of main results
We produced a ’Summary of findings’ table for each comparison
in which there was more than one study in at least one of the sub-
groups based on cancer treatment. We included the incidence of
moderate to severe oral mucositis, the incidence of severe oral mu-
cositis and adverse events. We used GRADE methods (GRADE
2004), and theGRADEproGDTonline tool for developing ’Sum-
mary of findings’ tables (www.guidelinedevelopment.org). We as-
sessed the quality of the body of evidence for each comparison and
outcome by considering the overall risk of bias of the included
studies, the directness of the evidence, the inconsistency of the
results, the precision of the estimates, and the risk of publication
bias. We categorised the quality of each body of evidence as high,
moderate, low, or very low.
R E S U L T S
Description of studies
Results of the search
Our electronic searches identified 5125 records. After removing
duplicates, this number was reduced to 3145. We examined the
titles and abstracts of these records anddiscarded3042, leaving 103
records to examine in more detail. Where possible, we obtained
full-text copies of these potentially relevant records and linked any
references pertaining to the same study under a single study ID.
These 103 records represented 73 studies. We excluded 24 studies
at this stage. The remaining 49 studies met our inclusion criteria
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and we included 35 of these studies in the review. The remaining
14 studies are awaiting assessment because we do not have enough
information to be able to include them in the review. We present
this process as a study flow chart in Figure 1.
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Figure 1. Study flow diagram.RCT = randomised controlled trial.
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Included studies
We included 35 studies in this review. For further information see
the Characteristics of included studies tables.
Characteristics of the trials
Study design
One study was a cross-over design that reported the first-period
data separately (Chi 1995), whilst the remaining studies all used
a parallel design.
Number of arms
Twenty-seven studies had two arms, three studies had three arms
(Blijlevens 2013; Freytes 2004; Peterson 2009), one study had four
arms (Wu 2009), two studies had five arms (Cartee 1995; Linch
1993), and two studies had seven arms (Blazar 2006; Meropol
2003). Where studies had more than two arms, this was because
they tested a range of doses of the cytokine/growth factor. In such
instances we combined the arms testing different doses to make
pairwise comparisons against the control group. Where possible,
we also made head-to-head comparisons of doses (Blijlevens 2013;
Cartee 1995; Freytes 2004; Meropol 2003; Peterson 2009).
Country
Nine studies were conducted in the USA (Blazar 2006; Cartee
1995; Crawford 1999; Freytes 2004; Meropol 2003; Schneider
1999; Spielberger 2004; Su 2006; Vadhan-Raj 2010), four in Italy
(Cesaro 2013; Dazzi 2003; Lucchese 2016a; Lucchese 2016b),
two in each of South Korea (Kim 2017;Wu 2009), the UK (Linch
1993; McAleese 2006), Iran (Gholizadeh 2016; Hosseinjani
2017), Finland (Makkonen 2000; Saarilahti 2002), and one in
each of the Netherlands (van der Lelie 2001), Russia (Peterson
2009), Japan (Katano 1995), Germany (Fink 2011), China (Chi
1995), Australia (Bradstock 2014), and France (Antoun 2009).
The remaining seven studies were conducted across more than
one country: USA and Australia (Jagasia 2012; Rosen 2006);
USA and Canada (Nemunaitis 1995); Australia, Canada and the
USA (Brizel 2008); Australia, Canada and Europe (Henke 2011);
Canada, USA and Europe (Le 2011); and 14 European countries
(Blijlevens 2013).
Number of centres
Fifteen studies were conducted at a single-centre (Antoun 2009;
Cartee 1995; Chi 1995; Dazzi 2003; Fink 2011; Hosseinjani
2017; Katano 1995; Kim 2017; Lucchese 2016a; Lucchese 2016b;
McAleese 2006; Saarilahti 2002; Su 2006; Vadhan-Raj 2010; van
der Lelie 2001). Eighteen studies were multicentric, ranging from
two sites (Blazar 2006; Makkonen 2000) to 46 sites (Le 2011).
It was unclear how many centres were involved in the remaining
two studies (Gholizadeh 2016; Schneider 1999).
Trials registries
We were able to find a trials registry number for 13 stud-
ies (Blijlevens 2013; Bradstock 2014; Cesaro 2013; Fink 2011;
Gholizadeh 2016; Henke 2011; Hosseinjani 2017; Jagasia
2012; Kim 2017; Le 2011; McAleese 2006; Spielberger 2004;
Vadhan-Raj 2010), although only six studies mentioned it in the
study report (Bradstock 2014; Cesaro 2013; Gholizadeh 2016;
Hosseinjani 2017; Kim 2017; Vadhan-Raj 2010), whilst a further
study mentioned an obsolete number (Jagasia 2012).
Sample size calculation
Twenty-one studies reported details of sample size calculations,
but four of these were not based on oral mucositis (Cesaro 2013;
Crawford 1999; Jagasia 2012; Su 2006). One further study stated
that 36 participants “should be enough to demonstrate a clinically
significant difference”, with no details reported (van der Lelie
2001).
Funding and conflicts of interest
This information is difficult to summarise as it was not always
adequately reported.
Nineteen studies appeared to be funded by industry alone i.e. it
was explicitly stated that they received industry funding or that
industry supplied the interventions or both. Five studies appeared
to be funded by government/public sector alone and did not state
whether or not the interventionswere supplied by industry (Cartee
1995; Lucchese 2016a; Lucchese 2016b; Su2006;Wu2009). Four
studies reported both government and industry funding, three of
which stated that industry provided the interventions (Bradstock
2014; Chi 1995; Kim 2017), and one of which was not clear
(Blazar 2006). Two studies stated that there was no funding for the
study (Cesaro 2013;Hosseinjani 2017). The remainingfive studies
did not mention funding (Dazzi 2003; Freytes 2004; Gholizadeh
2016; McAleese 2006; Saarilahti 2002).
Ten studies, all industry funded, declared conflicts of interest for
reasons such as board membership of the funder, employment or
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leadership roles with the funder, receipt of lecture fees or con-
sultancy fees or research funding or honoraria from the funder
(Antoun 2009; Blijlevens 2013; Brizel 2008; Henke 2011; Jagasia
2012; Le 2011; Peterson 2009; Rosen 2006; Spielberger 2004;
Vadhan-Raj 2010). Six of those studies also declared that some
authors owned equity/stock with the funder (Brizel 2008; Henke
2011; Jagasia 2012; Le 2011; Rosen 2006; Spielberger 2004).
Three studies did not explicitly declare conflicts of interest, but
some authors were employed by the funder (Crawford1999; Linch
1993; Nemunaitis 1995). Eight studies stated that there were no
conflicts of interest (Bradstock 2014; Cesaro 2013; Gholizadeh
2016; Hosseinjani 2017; Kim 2017; Lucchese 2016a; Lucchese
2016b; Su 2006). The remaining 14 studies did not mention con-
flicts of interest.
Characteristics of the participants
Number randomised/analysed
The studies randomised 3218 participants, of whom 3102 were
included in the studies’ analyses (the latter number does not in-
clude any participants fromMakkonen 2000, as this study did not
report how many of the 40 randomised participants were anal-
ysed).
Age and sex
The age of the participants ranged from 1 to 87 years, with four
studies only including children and young adults (i.e. up to 18
years) (Cesaro 2013; Gholizadeh 2016; Lucchese 2016a; Lucchese
2016b). Of the 31 studies including adult participants, one had
a median age of 29 (Dazzi 2003), two had mean or median ages
in their 30s (Linch 1993; Nemunaitis 1995), nine in their 40s (
Blazar 2006; Bradstock 2014; Cartee 1995; Chi 1995;Hosseinjani
2017; Jagasia 2012; Spielberger 2004; Vadhan-Raj 2010; van der
Lelie 2001), 11 in their 50s (Blijlevens 2013; Brizel 2008; Fink
2011; Freytes 2004; Henke 2011; Katano 1995; Kim 2017; Le
2011; Peterson 2009; Saarilahti 2002; Wu 2009), seven in their
60s (Antoun 2009; Crawford 1999; Makkonen 2000; McAleese
2006; Meropol 2003; Rosen 2006; Su 2006), and one study did
not report the age, although the inclusion criteria stated that they
must be at least 18 years old (Schneider 1999). In 24 studies, there
was a clear majority of male participants, whilst themale to female
ratio was roughly equal in seven studies. In three studies there
were more female participants, although two of these exclusively
includedbreast cancer patients (Cartee 1995;Katano1995), whilst
the third included colorectal cancer patients (Peterson 2009).
Cancer type
Fourteen studies enrolled participants with haematological can-
cers (Blazar 2006; Blijlevens 2013; Bradstock 2014; Fink 2011;
Freytes 2004; Gholizadeh 2016; Hosseinjani 2017; Jagasia 2012;
Kim 2017; Lucchese 2016a; Lucchese 2016b; Nemunaitis 1995;
Spielberger 2004; van der Lelie 2001). Eighteen studies enrolled
participants with solid cancers: head and neck (Brizel 2008; Chi
1995; Henke 2011; Le 2011; Makkonen 2000; McAleese 2006;
Saarilahti 2002; Schneider 1999; Su 2006; Wu 2009); colorec-
tal (Antoun 2009; Meropol 2003; Peterson 2009; Rosen 2006);
breast (Cartee 1995; Katano 1995); lung (Crawford 1999); and
sarcoma (Vadhan-Raj 2010). The remaining three studies enrolled
a mixture of participants with solid cancers and participants with
haematological cancers, two of which were 80% to 90% solid
(Cesaro 2013; Dazzi 2003), and the other study only 3% solid
(Linch 1993).
Cancer treatment
In 11 studies, the participants received chemotherapy only (
Antoun 2009; Bradstock 2014; Cartee 1995; Chi 1995; Crawford
1999; Gholizadeh 2016; Katano 1995; Meropol 2003; Peterson
2009; Rosen 2006; Vadhan-Raj 2010). Of the 15 studies in which
the participants received conditioning therapy prior to stem cell or
bone marrow transplantation, five of these involved chemotherapy
only (Blijlevens 2013; Dazzi 2003; Fink 2011; Hosseinjani 2017;
Kim 2017), and one involved total body irradiation (TBI) only
(Lucchese 2016b). In the remaining nine transplant studies, all the
participants had chemotherapy, but the proportion of participants
also receiving TBI differed: 100% (Lucchese 2016a; Nemunaitis
1995; Spielberger 2004); around 50% (Blazar 2006; Jagasia 2012;
van der Lelie 2001); 29% (Linch 1993); 10% or less (Cesaro 2013;
Freytes 2004). The remaining nine studies were all on head and
neck cancer patients where the participants either had radiother-
apy to the head and neck alone (Makkonen 2000;McAleese 2006;
Saarilahti 2002; Schneider 1999; Su 2006), or radiotherapy to the
head and neck plus chemotherapy (Brizel 2008; Henke 2011; Le
2011; Wu 2009), although in one of those studies only 50% of
participants had the chemotherapy (Wu 2009).
Of the 15 transplant studies, four involved allogeneic transplants
(Blazar 2006; Jagasia 2012; Lucchese 2016b; Nemunaitis 1995),
nine involved autologous transplants (Blijlevens 2013; Cesaro
2013; Dazzi 2003; Fink 2011; Freytes 2004; Hosseinjani 2017;
Kim2017; Lucchese 2016a; Spielberger 2004), with the remaining
two involving a mixture (Linch 1993; van der Lelie 2001).
In six studies, all participants received granulocyte-colony stimu-
lating factor (a growth factor) as part of the cancer treatment to
prevent neutropenia. Four of these studies were investigating ker-
atinocyte growth factor (Blazar 2006; Bradstock 2014; Spielberger
2004; Vadhan-Raj 2010), and two were investigating granulocyte-
macrophage colony-stimulating factor (Cartee 1995;Dazzi 2003).
Giving all participants this growth factor would have the potential
to lessen the impact of the study intervention.
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Characteristics of the interventions and comparisons
Keratinocyte growth factor (KGF)
Of the 16 studies investigating KGF, one study assessed KGF-2
(repifermin) (Freytes 2004), whilst the remaining studies assessed
KGF-1 (palifermin).
Fourteen studies used a placebo comparator (Blazar 2006;
Blijlevens 2013; Bradstock 2014; Brizel 2008; Freytes 2004;
Henke 2011; Jagasia 2012; Le 2011; Lucchese 2016a; Lucchese
2016b; Meropol 2003; Rosen 2006; Spielberger 2004; Vadhan-
Raj 2010), one was KGF plus standard care versus standard care
alone (Fink 2011), and the remaining study used a chlorhexidine
mouthwash comparator (Gholizadeh 2016).
In all studies, KGF was given intravenously. The most common
total dosage received was 360 µg/kg in seven studies (Bradstock
2014; Fink 2011; Gholizadeh 2016; Jagasia 2012; Lucchese
2016a; Lucchese 2016b; Spielberger 2004). The dosage varied
greatly in the other studies: 120 µg/kg (Rosen 2006); 180 µg/kg
(Vadhan-Raj 2010); 600 µg/kg (Brizel 2008); 840 µg/kg to 960
µg/kg depending on resection type (Henke 2011); 1440 µg/kg
(Le 2011). The dosages varied within the remaining studies due
to multiple arms receiving different doses: 3 µg/kg to 240 µg/
kg (Meropol 2003); 180 µg/kg to 360 µg/kg (Blijlevens 2013);
240 µg/kg to 720 µg/kg (Blazar 2006); 325 µg/kg to 650 µg/kg
(Freytes 2004).
The number of doses received ranged fromone (Vadhan-Raj 2010)
to 13 (Freytes 2004), but the most common was six (Blijlevens
2013; Bradstock 2014; Fink 2011; Gholizadeh 2016; Lucchese
2016a; Lucchese 2016b; Spielberger 2004).
Reporting of compliance varied too greatly to summarise suc-
cinctly but compliance was generally high (see Characteristics of
included studies).
Granulocyte-macrophage colony-stimulating factor (GM-
CSF)
Of the eight studies investigating GM-CSF, four used a placebo
comparator (Cartee 1995; Dazzi 2003; Nemunaitis 1995; van
der Lelie 2001), two used a no-treatment comparator (Chi 1995;
McAleese 2006), onewasGM-CSFplus sucralfate versus sucralfate
alone (Makkonen 2000), and the remaining study used a sucralfate
comparator (Saarilahti 2002).
In three studies, GM-CSF was given by subcutaneous injection (
Chi 1995;Makkonen 2000;McAleese 2006). InMakkonen 2000,
both arms received sucralfate mouthwash that was swallowed after
rinsing. In three studies, GM-CSF was taken as a mouthwash
(Cartee 1995; Dazzi 2003; Saarilahti 2002). In Saarilahti 2002,
both the GM-CSF and sucralfate comparator mouthwashes were
swallowed after rinsing. In one study, GM-CSF was given as an
oral gel and swallowed after holding in the mouth (van der Lelie
2001). In the remaining study, GM-CSF was given intravenously
(Nemunaitis 1995).
Total dosage varied greatly: 40 µg (Chi 1995); 2100 µg (McAleese
2006); 5250 µg/m2 (Nemunaitis 1995). The dosages ranged from
12.6 µg to 12,600 µg within one study due to multiple arms
receiving different doses (Cartee 1995). Another study reported a
mean total dosage of 3398 µg, but this total ranged from 300 µg
to 7200 µg depending on the participant’s weight and the length
of radiotherapy course (Makkonen 2000). In two studies, the dose
was 150 µg per day but the total received varied depending on
neutrophil recovery (Dazzi 2003), and the length of radiotherapy
course (Saarilahti 2002). In the remaining study, the dose was 300
µg per day but the total received varied depending on neutrophil
recovery (van der Lelie 2001).
As is obvious from the variation in total dosage, the number of
doses received varied greatly both between studies andwithin stud-
ies. Compliance was also reported inconsistently but was generally
high (see Characteristics of included studies).
Granulocyte-colony stimulating factor (G-CSF)
Of the six studies investigating G-CSF, four used a placebo com-
parator (Crawford 1999; Linch 1993; Schneider 1999; Su 2006),
one used a no-treatment comparator (Katano 1995), and the re-
maining study compared a type of G-CSF that is given as a sin-
gle dose (pegfilgrastim) with the standard G-CSF that is given in
multiple doses (filgrastim) (Cesaro 2013).
Four studies reported that G-CSF was given by subcutaneous in-
jection (Crawford 1999; Katano 1995; Schneider 1999; Su 2006),
whilst one did not specify, but was probably subcutaneous (Cesaro
2013), and the remaining study was intravenous delivery (Linch
1993).
Total dosage varied: 3220 µg/m2 (Crawford 1999); 3 µg/kg per
day with the total dependent on neutrophil counts and the length
of radiotherapy course (Schneider 1999; Su 2006); 2 µg/kg to 15
µg/kg per day due tomultiple arms receiving different dosages with
the total was depending on neutrophil recovery (Linch 1993); 125
µg per day with total depending on neutrophil recovery (Katano
1995); 100 µg/kg in the pegfilgrastim arm and at least 45 µg/kg
in the filgrastim arm (Cesaro 2013).
The number of doses received varied both between studies and
within studies. Compliance was reported as being 100% in one
study (Cesaro 2013), whilst one study only reported that the inter-
ventions were well tolerated (Schneider 1999), and the remaining
four studies did not report on compliance.
Epidermal growth factor (EGF)
Two studies investigated an oral spray of EGF, both using a placebo
comparator (Kim 2017; Wu 2009). Total dosage was unclear in
both studies but the daily dose was 50 µg/mL (six sprays twice
daily) in one study (Kim 2017), and 10 µg to 100 µg per day (due
to multiple arms receiving different dosages) in the other study
(Wu 2009). The number of doses varied depending on neutrophil
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recovery and resolution of oral mucositis in Kim 2017, whilst
participants in Wu 2009 received the interventions daily for five
weeks but it was not clear if that meant only on the radiotherapy
days (five days per week) or seven days per week. Compliance was
reported as a median of 93% and 92% in the EGF and placebo
groups respectively in Kim 2017, but compliance was not reported
in Wu 2009.
Intestinal trefoil factor (ITF)
One study investigated an oral spray of ITF using a placebo com-
parator (Peterson 2009). The ITFwas not expectorated. The study
included two ITF arms with total dosages of 336 mg and 2688
mg. The mode of administration was three sprays to the oral mu-
cosa eight times daily for 14 days. Patient-reported compliance
was 97%.
Erythropoietin
One study investigated a mouthwash of erythropoietin using a
placebo comparator (Hosseinjani 2017). Neither swallowing nor
expectoration was reported. The mouthwash was taken as 15 mL
(50 IU/mL) four times daily (daily dosage of 3000 IU) for 14 days
or until neutrophil recovery, whichever occurred first. Compliance
was reported narratively as being low but no reason was stated.
Transforming growth factor (TGF)
One study investigated TGF-beta(2) using a placebo comparator
(Antoun 2009). The dosagewas 2ngofTGFpermgproteinmixed
with cool boiled water at 0.23 g/mL (100 kcl/100 mL). During
each cycle participants received 750 mL to 1000 mL per day plus
any other food desired. The formula was administered for two
days before, two days during, and three days after chemotherapy
(seven days/cycle), for one to eight cycles. Compliance was poor
i.e. nine participants did not eat the formula and were excluded.
Characteristics of the outcomes
Primary outcome
For the primary outcome of oral mucositis, we were interested
in both the presence/absence of oral mucositis, and also different
levels of severity. All 35 studies assessed and reported the incidence
of oral mucositis. Twenty-two studies primarily used the WHO
(World Health Organization) 0 to 4 scale, whilst four used the
NCI-CTC (National Cancer Institute common toxicity criteria)
0 to 4 scale (Brizel 2008; Dazzi 2003; Freytes 2004; Kim 2017),
four used the RTOG (Radiation Therapy Oncology Group) 0 to
4 scale (Chi 1995; McAleese 2006; Saarilahti 2002; Wu 2009),
one used the CALGB (Cancer and Leukemia Group B) 0 to 4
scale (Cartee 1995), one used an unnamed 0 to 2 scale (Makkonen
2000), one used an unnamed 0 to 3 scale (Su 2006), one used
an unnamed 0 to 4 scale (Nemunaitis 1995), and the remaining
study did not mention a scale and only reported the incidence of
stomatitis (Linch 1993). The different oral mucositis assessment
scales are described in Appendix 9.
Twelve studies reported the data in our preferred format which was
themaximum oral mucositis score experienced by each participant
over the length of the study, allowing us to dichotomise the data
into various levels of severity as described in the section Primary
outcomes. Eighteen studies reported a particular level of severity
(e.g. grade 3 or above). One study reported the incidence of each
oral mucositis grade on multiple assessment days. We were unable
to use the data from the remaining four studies for analysis due
to unclear or lack of reporting (Linch 1993; Lucchese 2016a;
Lucchese 2016b; Makkonen 2000).
The frequency of oral mucositis assessment and the duration for
which it was assessed varied greatly across the studies, often de-
pending on whether the participants received radiotherapy, and
often depending on the speed of neutrophil recovery, resolution of
oral mucositis, or duration of hospitalisation. Four studies did not
report the frequency of assessment (Antoun 2009; Cesaro 2013;
Linch 1993; Nemunaitis 1995), whilst a further study was un-
clearly reported (Lucchese 2016b). Twelve studies reported daily
assessments, eight reported weekly assessments, with the remain-
der falling somewhere in between these two frequencies. Where
participants had multiple cycles of treatment, we only reported
the results for the first cycle if these data were available separately.
Secondary outcomes
Interruptions to cancer treatment
Six studies reported data that wewere able to use in analyses (Brizel
2008;Henke 2011; Le 2011; Saarilahti 2002; Su 2006;Wu2009),
whilst a further two studies assessed this outcome but either did
not report the interruption by treatment arm (Makkonen 2000),
or narratively reported that there were no differences, with no
numerical data (Schneider 1999).
Two studies reported this outcome as the incidence of unsched-
uled radiotherapy breaks of five or more days (Brizel 2008; Henke
2011; Le 2011). Two of those studies also reported on chemother-
apy delays/discontinuations (Henke 2011; Le 2011). The remain-
ing studies all reported on the incidence of interruptions to ra-
diotherapy treatment, one of which stated that interruptions were
specifically due to oral mucositis (Saarilahti 2002), and another
reporting the incidence of three or more consecutive days of in-
terruption (Wu 2009).
Oral pain
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Four studies reported data that we were able to use in analyses
(Dazzi 2003; Freytes 2004; Henke 2011; Le 2011). Two of these
studies used a 0 to 4 scale and reported the mean (Henke 2011;
Le 2011), whilst the other two studies used a 0 to 10 scale and
reported the mean worst score experienced (Dazzi 2003; Freytes
2004).
Of the 11 other studies that reported that oral pain was an out-
come of the study, five reported the results as area under the curve
(AUC) but, for reasons stated in the sectionMeasures of treatment
effect, we did not meta-analyse these data (Blijlevens 2013; Kim
2017; Lucchese 2016a; Rosen 2006; Spielberger 2004). Two stud-
ies reported medians, which are not suitable for meta-analysis
(Vadhan-Raj 2010; van der Lelie 2001). One study reported the
data graphically as a mean over time with no standard deviation
(Saarilahti 2002). One study narratively reported that there were
no differences, with no numerical data (Wu 2009). The remaining
two studies used two different scales: one reported as “no differ-
ence” and another reported on a graph with no standard deviation
(Makkonen 2000); both reported on a graph over time, with one
also reported as AUC (Meropol 2003).
Quality of life
Four studies assessed quality of life using various assessment scales:
European Quality Of Life Utility Scale - EQ-5D (Blijlevens
2013); modified Oral Mucositis Daily Questionnaire - OMDQ
(Kim 2017); Functional Assessment of Cancer Therapy - FACT
(Spielberger 2004); an unnamed 1 to 7 scale (Vadhan-Raj 2010).
We did not use the data in our analyses as theywere either reported
as AUC (Kim 2017; Spielberger 2004), as a median (Vadhan-Raj
2010), or the mean was reported at one very early time point with
no standard deviation (Blijlevens 2013).
Normalcy of diet - including use of percutaneous endoscopic
gastrostomy (PEG) feeding tubes or total parenteral nutrition
(TPN)
Fourteen studies reported data that we were able to use in analyses
in the form of: incidence of TPN (Blijlevens 2013; Cesaro 2013;
Fink 2011; Jagasia 2012; Kim 2017; Spielberger 2004; van der
Lelie 2001); incidence of PEG (Brizel 2008; Saarilahti 2002; Su
2006); incidence of TPN, PEG, nasogastric tube or intravenous
(IV) hydration (Henke 2011; Le 2011); incidence of “tube feed-
ing” (McAleese 2006); ability to eat using a 1 to 4 scale (Freytes
2004). Only one of these studies explicitly stated that supplemen-
tal feeding was due to oral mucositis (Henke 2011).
Two further studies only reported the duration of TPN (Lucchese
2016a; Lucchese 2016b), and another study used 0 to 4 scales to
assess difficulty in eating and drinking, but reportedmedian scores
(Vadhan-Raj 2010).
We combined studies reporting incidence of TPN, PEG, etc., in
meta-analyses of ’supplemental feeding’.
Adverse events
This outcome was very poorly reported with some studies report-
ing numerical data and some reporting narratively. Some studies
only reported adverse events if there was a minimum incidence
(which varied between studies) or if there was a specified differ-
ence in incidence between treatment arms. It was also difficult to
determine whether or not many adverse effects were due to the
study interventions, or due to the underlying cancer treatment.
We presented adverse event data/information only in an additional
table.
Number of days in hospital
Two studies reported data that we were able to use in analyses
i.e. mean and standard deviations (Blijlevens 2013; Hosseinjani
2017).
Five further studies reported medians (Cesaro 2013; Fink 2011;
Linch 1993; Nemunaitis 1995; van der Lelie 2001). One study
reported data graphically with no standard deviation or P value
(Crawford 1999). One study listed this as an outcome of the study
but did not actually report it (Kim 2017). One study reported the
incidence of hospitalisation (Saarilahti 2002).
Number of days of treatment with opioid analgesics
Two studies reported data that we were able to use in analyses
i.e. mean and standard deviations (Blijlevens 2013; Dazzi 2003;
Freytes 2004). Only one study specified that the opioid use was
due to oral mucositis (Freytes 2004).
Four further studies reported medians (Fink 2011; Kim 2017;
Lucchese 2016a; Spielberger 2004), whilst another study did not
state whether the data were means or medians, and there were no
standard deviations or P value (Lucchese 2016b). Three studies
reported total dose of opioid analgesic (Henke 2011; Le 2011;
Vadhan-Raj 2010), whilst four studies reported the incidence of its
use (Hosseinjani 2017; Jagasia 2012; Saarilahti 2002; van der Lelie
2001).One study stated that it assessed the use of opioid analgesics,
but did not specify whether this was in terms of duration, quantity
or incidence, and did not actually report any data (Wu 2009).
Number of days unable to take medicine orally
No studies reported this outcome.
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Excluded studies
We excluded 24 studies from this review for the following reasons.
• Not a randomised controlled trial or unclear (Foncuberta
2001; Gordon 1993; Horsley 2007; Hunter 2009; Iwase 1997;
Limaye 2013; Throuvalas 1995; Vitale 2014).
• Stomatitis incidence reported in adverse events table (Kubo
2016; Lee 2016; Nabholtz 2002; Tsurusawa 2016).
• Unclear if mucositis was oral or gastrointestinal (Jones
1996; Legros 1997; Pettengell 1992).
• Study stopped early with very few participants enrolled
(Antin 2002; NCT00360971; NCT00626639).
• Oral mucositis not mentioned and unknown if measured
(Gebbia 1994; Gladkov 2013).
• Some participants had oral mucositis at baseline (Ryu
2007).
• Cross-over study with no reporting of first-period data (de
Koning 2007).
• Results reported by cycle assuming independence (Karthaus
1998).
• Survival/cure was primary outcome with mucositis (unclear
if oral or gastrointestinal) as a toxicity (Ifrah 1999).
Risk of bias in included studies
Allocation
Random sequence generation
Nineteen studies described an adequate method of generating a
random sequence, so we assessed these as at low risk of bias. The
remaining 16 studies stated that they were randomised without
providing a description of how the random sequence was gener-
ated, so we assessed these as at unclear risk of bias.
Allocation concealment
Seventeen studies described a process that would have concealed
the random sequence from those involved in the study, thus al-
lowing it to be applied as it was generated. We assessed these 17
studies as at low risk of bias. The remaining 18 studies did not
describe any methods used to conceal the random sequence, so we
assessed them as at unclear risk of bias.
In total, 16 studies are at low risk of selection bias, meaning that
we assessed both of the above domains as low risk of bias. The
remaining 19 studies are at unclear risk of selection bias because
one or both of the above domains were rated as unclear.
Most studies were carried out in middle-income and high-income
countrieswith strict controls and regulations andwe feel thatmany
of them probably had adequate randomisation, and that the un-
clear ratings for these two domains were probably due to reporting
issues rather than actual bias. Therefore, when incorporating risk
of bias into our GRADE assessments, we did not downgrade any
evidence based on selection bias.
Blinding
Blinding of participants and personnel (performance bias)
We assessed 28 studies as at low risk of bias. Twenty-seven of these
studies used a placebo comparator and this ensured that blinding
was performed successfully.One further study comparedGM-CSF
with sucralfate, but the interventions were supplied as identical-
looking mouthwashes, the study was described as double-blind,
and there was no reason to suspect that participants or personnel
were not blinded (Saarilahti 2002).
We assessed seven studies as at high risk of bias. Three of these stud-
ies used a no-treatment comparator, so blinding was not possible
(Chi 1995; Katano 1995;McAleese 2006). Two other studies were
similar in that they compared KGF plus best supportive care with
best supportive care alone (Fink 2011), and GM-CSF plus sucral-
fate with sucralfate alone (Makkonen 2000). One study compared
intravenous KGF with a chlorhexidine mouthwash (Gholizadeh
2016). The remaining study compared two types of G-CSF, but
the dosing schedule was very different, ensuring that blinding was
not possible (Cesaro 2013).
Blinding of outcome assessment (detection bias)
Weassessed 29 studies as at low risk of bias.We assessed four studies
as at unclear risk of bias because blinding of outcome assessment
was notmentioned, but we judged that it would have been possible
to achieve (Cesaro 2013; Chi 1995; Katano 1995; Makkonen
2000).We assessed the remaining two studies as at high risk of bias
because they either stated that there was no blinding of outcome
assessors (Fink 2011), or it was implied by the description “single-
blind” (Linch 1993).
Incomplete outcome data
Attrition was generally very low and we assessed 31 studies as
at low risk of bias. We assessed two studies as at unclear risk of
bias because one did not report how many of the randomised
participants were included in the analyses (Makkonen 2000), and
the other did not report the attrition by treatment arm but there
was potential for bias if the dropouts were mostly from one arm
and had developed the outcome of severe oral mucositis (Cartee
1995). We assessed two studies as at high risk of bias because one
had very high attrition (Antoun 2009), and the other had 19%
attrition in one arm compared to none in the other arm (Fink
2011).
19Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Selective reporting
It is important to note that we have perhaps been quite lenient
when rating bias under this domain. We have tended to focus on
the primary outcome because the vast majority of the data are for
this outcome. Many studies have only reported a particular level
of oral mucositis severity, for example grade 2 to 4 (ulcerative/
moderate to severe), when they could have reported more usable
data by reporting the maximum grade experienced per patient, al-
lowing us to dichotomise this into all severities. Some readers may
consider this to be bias but we have reported all this information
transparently in the Characteristics of included studies tables, thus
allowing the reader to decide if they would judge the risk of bias
differently. Furthermore,many secondary outcomeswere reported
poorly or in a way that was not amenable to meta-analysis, which
in most cases is a reporting issue rather than a bias issue. This
highlighted the problem with the current Cochrane risk of bias
tool in that meta-analyses are being biased due to missing infor-
mation, but this is not being accounted for in the meta-analysis.
It does not seem appropriate to rate a study at high risk of bias
due to a secondary outcome when it is contributing data to the
meta-analysis for the primary outcome, and it is the meta-analysis
for the secondary outcome that is affected by bias. Again, all this
information is clearly reported in the Characteristics of included
studies tables.
We assessed 32 studies as at low risk of bias. We assessed the re-
maining three studies as at high risk of bias, two because there were
no usable data for the primary outcome (Linch 1993; Makkonen
2000), and one because several outcomes were assessed but not
reported (Wu 2009).
Other potential sources of bias
We did not consider there to be any issues arising from other
potential sources of bias in any of the studies and we therefore
assessed them all as at low risk of other bias.
Overall risk of bias
• Thirteen studies (37%) were at low overall risk of bias
(Blijlevens 2013; Dazzi 2003; Freytes 2004; Henke 2011;
Hosseinjani 2017; Kim 2017; Le 2011; Lucchese 2016a;
Lucchese 2016b; Saarilahti 2002; Schneider 1999; Su 2006;
Vadhan-Raj 2010).
• Twelve studies (34%) were at unclear overall risk of bias
(Blazar 2006; Bradstock 2014; Brizel 2008; Cartee 1995;
Crawford 1999; Jagasia 2012; Meropol 2003; Nemunaitis 1995;
Peterson 2009; Rosen 2006; Spielberger 2004; van der Lelie
2001).
• Ten studies (29%) were at high overall risk of bias (Antoun
2009; Cesaro 2013; Chi 1995; Fink 2011; Gholizadeh 2016;
Katano 1995; Linch 1993; Makkonen 2000; McAleese 2006;
Wu 2009).
Risk of bias can be viewed graphically in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison
Keratinocyte growth factor (KGF) compared to placebo for
preventing oral mucositis in adults with cancer receiving
treatment; Summary of findings 2 Granulocyte-macrophage
colony-stimulating factor (GM-CSF) compared to placebo/no
treatment for preventing oral mucositis in adults with cancer
receiving treatment; Summary of findings 3Granulocyte-colony
stimulating factor (G-CSF) compared to placebo/no treatment for
preventing oralmucositis in adults with cancer receiving treatment
We used GRADE methods to assess the quality of the body of
evidence for each comparison in which there was more than one
study in at least one of the subgroups based on cancer treatment.
We included the incidence of moderate to severe oral mucositis,
the incidence of severe oral mucositis and adverse events. These
assessments are presented in Summary of findings for the main
comparison; Summary of findings 2; Summary of findings 3.
Keratinocyte growth factor (KGF) versus placebo
Oral mucositis
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for haematological cancers
There was insufficient evidence from four studies, one at low (
Blijlevens 2013), two at unclear (Blazar 2006; Spielberger 2004),
and one at high risk of bias (Fink 2011), to determine whether
or not KGF reduces the risk of any level of oral mucositis: risk
ratio (RR) 0.96, 95% confidence interval (CI) 0.88 to 1.05; 655
participants (Analysis 1.1).
Six studies, two at low (Blijlevens 2013; Freytes 2004), three at
unclear (Blazar 2006; Jagasia 2012; Spielberger 2004), and one
at high risk of bias (Fink 2011), showed a reduction in the risk
of moderate to severe oral mucositis in favour of KGF: RR 0.89,
95% CI 0.80 to 0.99; 852 participants (Analysis 1.2).
The same six studies showed a possible reduction in the risk of
severe oral mucositis in favour of KGF, but there is also some
possibility of an increase in risk: RR 0.85, 95% CI 0.65 to 1.11;
852 participants (Analysis 1.3).
Heterogeneity present in these meta-analyses may partly be due
to differences between studies where transplants were autologous
or allogeneic.
Adults receiving radiotherapy to the head and neck with
cisplatin/fluorouracil (5FU)
Two studies, both at low risk of bias (Henke 2011; Le 2011),
showed a reduction in the risk of any level of oral mucositis in
favour of KGF: RR 0.95, 95% CI 0.90 to 1.00; P = 0.04; 374
participants (Analysis 1.1).
Three studies, two at low (Henke 2011; Le 2011), and one at
unclear risk of bias (Brizel 2008), showed a reduction in the risk
of moderate to severe oral mucositis in favour of KGF: RR 0.91,
95% CI 0.83 to 1.00; P = 0.04; 471 participants (Analysis 1.2).
The same three studies showed a reduction in the risk of severe
oral mucositis in favour of KGF: RR 0.79, 95% CI 0.69 to 0.90;
471 participants (Analysis 1.3).
Adults receiving chemotherapy alone for mixed cancers
Two studies, both at unclear risk of bias (Bradstock 2014; Rosen
2006), showed a reduction in the risk of any level of oral mucositis
in favour of KGF: RR 0.71, 95%CI 0.60 to 0.85; 215 participants
(Analysis 1.1).
Four studies, one at low (Vadhan-Raj 2010), and three at unclear
risk of bias (Bradstock 2014;Meropol 2003; Rosen 2006), showed
a reduction in the risk of moderate to severe oral mucositis in
favour of KGF: RR 0.56, 95% CI 0.45 to 0.70; 344 participants
(Analysis 1.2).
Three studies, one at low (Vadhan-Raj 2010), and two at unclear
risk of bias (Bradstock 2014; Rosen 2006), showed a reduction in
the risk of severe oral mucositis in favour of KGF: RR 0.30, 95%
CI 0.14 to 0.65; 263 participants (Analysis 1.3).
Interruptions to cancer treatment
Adults receiving radiotherapy to the head and neck with
cisplatin/fluorouracil (5FU)
There was insufficient evidence from three studies, two at low
(Henke 2011; Le 2011), and one at unclear risk of bias (Brizel
2008), to determine whether or not KGF reduces the risk of having
unscheduled radiotherapy breaks of five or more days: RR 1.01,
95% CI 0.65 to 1.59; 473 participants (Analysis 1.4).
There was insufficient evidence, from the same two studies at low
risk of bias, to determine whether or not KGF reduces the risk of
having chemotherapy delays/discontinuations: RR 0.96, 95% CI
0.62 to 1.47; 374 participants (Analysis 1.5).
Oral pain
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for haematological cancers
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There was insufficient evidence, from one study at low risk of
bias (Freytes 2004), to determine whether or not KGF reduces
the mean worst pain experienced on a 0 (no pain) to 10 (worst
pain) scale: mean difference (MD) -0.85, 95% CI -3.00 to 1.30;
42 participants (Analysis 1.6).
Adults receiving radiotherapy to the head and neck with
cisplatin
There was some evidence, from two studies at low risk of bias
(Henke 2011; Le 2011), that KGF might lead to a reduction in
the mean pain score on a 0 (no pain) to 4 (worst pain) scale: MD
-0.12, 95% CI -0.27 to 0.02; 374 participants (Analysis 1.6).
Normalcy of diet
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for haematological cancers
There was insufficient evidence from four studies, one at low (
Blijlevens 2013), two at unclear (Jagasia 2012; Spielberger 2004),
and one at high risk of bias (Fink 2011), to determine whether or
not KGF reduces the risk of total parenteral nutrition: RR 0.89,
95% CI 0.58 to 1.34; 714 participants (Analysis 1.7).
There was further insufficient evidence, from one study at low risk
of bias (Freytes 2004), to determine whether or not KGF reduces
the mean worst ability to eat score on a 1 (normal) to 4 (no solids
or liquids) scale:MD -0.50, 95%CI -1.21 to 0.21; 42 participants
(Analysis 1.8).
Adults receiving radiotherapy to the head and neck with
cisplatin/fluorouracil (5FU)
There was insufficient evidence from three studies, two at low
(Henke 2011; Le 2011), and one at unclear risk of bias (Brizel
2008), to determine whether or not KGF reduces the risk of re-
ceiving supplemental nutrition (total parenteral nutrition, percu-
taneous endoscopic gastrostomy, nasogastric tube or intravenous
(IV) hydration): RR 1.03, 95% CI 0.77 to 1.37; 473 participants
(Analysis 1.7).
Adverse events
This outcome was difficult to summarise due to poor and incon-
sistent reporting, and we did not meta-analyse any data. However,
there do not appear to be any serious concerns regarding adverse
effects of KGF. We have tabulated relevant information in Addi-
tional Table 1.
Number of days in hospital
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for haematological cancers
There was insufficient evidence, from one study at low risk of bias
(Blijlevens 2013), to determine whether or not KGF reduces the
mean number of days in hospital: MD 0.00, 95% CI -1.64 to
1.64; 281 participants (Analysis 1.9).
Number of days of treatment with opioid analgesics
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for haematological cancers
There was some imprecise evidence, from two studies at low risk
of bias (Blijlevens 2013; Freytes 2004), that KGF might lead to a
reduction in the mean number of days of treatment with opioid
analgesics: MD -1.41, 95% CI -3.33 to 0.51; 323 participants
(Analysis 1.10). The average effect is around 1.5 days reduction,
but the confidence interval is compatible with both a reduction of
almost 3.5 days and an increase of half a day.
No studies assessed the outcomes ’quality of life’ and ’number of
days unable to take medicine orally’.
Keratinocyte growth factor (KGF) dose comparisons
There was some inconsistent evidence from which no conclusions
can be drawn regarding different dosages of KGF (Analysis 2.1;
Analysis 2.2; Analysis 2.3; Analysis 2.4; Analysis 2.5; Analysis 2.6;
Analysis 2.7; Analysis 2.8).
Keratinocyte growth factor (KGF) versus
chlorhexidine
One study, at high risk of bias and analysing 90 children receiv-
ing mixed chemotherapy alone for acute lymphoblastic leukaemia
(Gholizadeh 2016), compared KGF by IV infusion with chlorhex-
idine mouthwash. There was weak evidence (due to risk of bias
and low sample size) that KGF performs better than chlorhexidine
in reducing the risk of any level of oral mucositis (RR 0.67, 95%
CI 0.54 to 0.85; Analysis 3.1), moderate to severe oral mucositis
(RR 0.12, 95% CI 0.05 to 0.28; Analysis 3.2), and severe oral
mucositis (RR 0.01, 95% CI 0.00 to 0.19; Analysis 3.3).
Granulocyte-macrophage colony-stimulating factor
(GM-CSF) versus placebo/no treatment
Oral mucositis
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Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for mixed cancers
There was some evidence, from one study at low risk of bias (Dazzi
2003), that GM-CSF might lead to a reduction in the risk of
any level of oral mucositis: RR 0.91, 95% CI 0.80 to 1.04; 90
participants (Analysis 4.1).
There was insufficient evidence, from one study at unclear risk of
bias (Nemunaitis 1995), to determine whether or not GM-CSF
reduces the risk of moderate to severe oral mucositis: RR 0.94,
95% CI 0.79 to 1.13; 109 participants (Analysis 4.2).
There was insufficient evidence from three studies, one at low
(Dazzi 2003), and two at unclear risk of bias (Nemunaitis 1995;
van derLelie 2001), to determinewhether or notGM-CSF reduces
the risk of severe oral mucositis: RR 0.74, 95% CI 0.33 to 1.67;
235 participants (Analysis 4.3).
Adults receiving radiotherapy to the head and neck
There was insufficient evidence, from one study at high risk of bias
(McAleese 2006), to determine whether or not GM-CSF reduces
the risk of any level of oral mucositis (RR 1.01, 95% CI 0.82 to
1.23; 29 participants; Analysis 4.1), moderate to severe oral mu-
cositis (RR 0.72, 95% CI 0.49 to 1.06; 29 participants; Analysis
4.2), or severe oral mucositis (RR 0.31, 95% CI 0.01 to 7.09; 29
participants; Analysis 4.3).
Adults receiving chemotherapy alone for mixed cancers
There was insufficient evidence from two studies, one at unclear (
Cartee 1995), and one at high risk of bias (Chi 1995), to determine
whether or not GM-CSF reduces the risk of severe oral mucositis:
RR 0.59, 95% CI 0.05 to 7.11; 65 participants (Analysis 4.3).
Oral pain
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for mixed cancers
There was insufficient evidence, from one study at low risk of bias
(Dazzi 2003), to determine whether or not GM-CSF reduces the
mean pain score on a 0 (no pain) to 10 (worst pain) scale: MD
0.60, 95% CI -0.85 to 2.05; 90 participants (Analysis 4.4).
Normalcy of diet
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for haematological cancers
There was insufficient evidence, from one study at unclear risk of
bias (van der Lelie 2001), to determine whether or not GM-CSF
reduces the risk of total parenteral nutrition: RR 1.10, 95% CI
0.63 to 1.91; 36 participants (Analysis 4.5).
Adults receiving radiotherapy to the head and neck
There was insufficient evidence, from one study at high risk of
bias (McAleese 2006), to determine whether or not GM-CSF re-
duces the risk of tube feeding: RR 0.31, 95% CI 0.01 to 7.09; 29
participants (Analysis 4.5).
Adverse events
This outcome was difficult to summarise due to poor and incon-
sistent reporting, and we did not meta-analyse any data. However,
there do not appear to be any serious concerns regarding adverse
effects of GM-CSF. We have tabulated relevant information in
Additional Table 2.
Number of days of treatment with opioid analgesics
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for mixed cancers
There was some evidence, from one study at low risk of bias (
Dazzi 2003), that GM-CSFmight lead to a reduction in the mean
number of days of treatment with opioid analgesics: MD -1.10,
95% CI -1.91 to -0.29; 90 participants (Analysis 4.6).
No studies assessed the outcomes ’interruptions to cancer treat-
ment’, ’quality of life’, ’number of days in hospital’ and ’number
of days unable to take medicine orally’.
Granulocyte-macrophage colony-stimulating factor
(GM-CSF) dose comparison
There is some very weak evidence, from one study at unclear risk
of bias and analysing 36 adults receiving mixed chemotherapy
alone for breast cancer (Cartee 1995), that a higher dose of GM-
CSF (range 1260 µg to 12,600 µg) reduces the risk of severe oral
mucositis when compared to a lower dose (range 12.6 µg to 126
µg): RR 2.75, 95%CI 1.07 to 7.04; 36 participants (Analysis 5.1).
Granulocyte-macrophage colony-stimulating factor
(GM-CSF) versus sucralfate
One study, at low risk of bias and analysing 40 adults receiving ra-
diotherapy to the head and neck (Saarilahti 2002), comparedGM-
CSF with sucralfate, both as a mouthwash. There was insufficient
evidence to determine whether GM-CSF or sucralfate perform
better in reducing the risk ofmoderate to severe oral mucositis (RR
0.96, 95% CI 0.80 to 1.14; Analysis 6.1), severe oral mucositis
(RR 0.54, 95% CI 0.24 to 1.21; Analysis 6.2), interruptions to
cancer treatment (RR 0.13, 95% CI 0.01 to 2.36; Analysis 6.3),
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or percutaneous endoscopic gastrostomy (RR 0.18, 95% CI 0.01
to 3.56; Analysis 6.4).
Granulocyte-colony stimulating factor (G-CSF)
versus placebo/no treatment
Oral mucositis
Adults receiving radiotherapy to the head and neck
There was insufficient evidence, from two studies at low risk of
bias (Schneider 1999; Su 2006), to determine whether or not G-
CSF reduces the risk of any level of oral mucositis: RR 1.02, 95%
CI 0.86 to 1.22; 54 participants (Analysis 7.1).
The same two studies showed weak evidence (due to a wide con-
fidence interval and low sample size) of a reduction in the risk of
severe oral mucositis in favour of G-CSF: RR 0.37, 95% CI 0.15
to 0.87; 54 participants (Analysis 7.3).
Adults receiving chemotherapy alone for mixed cancers
One study on lung cancer, at unclear risk of bias (Crawford 1999),
showed a reduction in the risk of any level of oral mucositis in
favour of G-CSF: RR 0.59, 95%CI 0.40 to 0.87; 195 participants
(Analysis 7.1).
One study on breast cancer, at high risk of bias (Katano 1995),
showed very weak evidence (due to risk of bias, very low sample
size and a wide confidence interval) of a reduction in the risk of
moderate to severe oral mucositis in favour of G-CSF: RR 0.33,
95% CI 0.12 to 0.95; 14 participants (Analysis 7.2).
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for haematological cancers
One study, at high risk of bias and analysing 121 participants
(Linch 1993), did not provide any details of how oral mucositis
was measured, so it is not clear what severity the information refers
to. There were no numerical results reported, only the statement:
“There was no difference in the frequency of stomatitis (defined as
a sore, infected or ulcerated mouth, lips or pharynx), the incidence
being between 29 and 33% in all groups” (Additional Table 3).
Interruptions to cancer treatment
Adults receiving radiotherapy to the head and neck
There was insufficient evidence, from one study at low risk of bias
(Su 2006), to determine whether or not G-CSF reduces the risk
of radiotherapy interruptions: RR 0.22, 95% CI 0.01 to 4.31; 40
participants (Analysis 7.4).
Normalcy of diet
Adults receiving radiotherapy to the head and neck
There was insufficient evidence, from one study at low risk of bias
(Su 2006), to determine whether or not G-CSF reduces the risk
of percutaneous endoscopic gastrostomy: RR 0.16, 95% CI 0.01
to 2.86; 40 participants (Analysis 7.5).
Adverse events
This outcome was difficult to summarise due to poor and incon-
sistent reporting, and we did not meta-analyse any data. However,
there do not appear to be any serious concerns regarding adverse
effects of G-CSF. We have tabulated relevant information in Ad-
ditional Table 4.
No studies assessed the outcomes ’oral pain’, ’quality of life’, ’num-
ber of days in hospital’, ’number of days of treatment with opioid
analgesics’ and ’number of days unable to take medicine orally’.
G-CSF (pegfilgrastim) versus G-CSF (filgrastim)
There was insufficient evidence, from one study at high risk of bias
and analysing 61 children receiving bone marrow/stem cell trans-
plantation after conditioning therapy for mixed cancers (Cesaro
2013), to determine whether pegfilgrastim or filgrastim perform
better in reducing the risk of any level of oral mucositis (RR 1.02,
95% CI 0.82 to 1.27; Analysis 8.1), moderate to severe oral mu-
cositis (RR 0.78, 95% CI 0.55 to 1.11; Analysis 8.2), or total par-
enteral nutrition (RR 1.00, 95% CI 0.94 to 1.06; Analysis 8.3).
Epidermal growth factor (EGF) versus placebo
Oral mucositis
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for haematological cancers
There was insufficient evidence, from one study at low risk of bias
and analysing 136 participants (Kim 2017), to determine whether
or not EGF reduces the risk of moderate to severe oral mucositis
(RR 1.06, 95% CI 0.78 to 1.43; Analysis 9.1), or severe oral
mucositis (RR 1.03, 95% CI 0.59 to 1.80; Analysis 9.2).
Adults receiving radiotherapy to the head and neck
with/without cisplatin
One study, at high risk of bias (Wu 2009), showed weak evidence
(due to risk of bias and low sample size) of a reduction in the risk
of moderate to severe oral mucositis in favour of EGF: RR 0.67,
95% CI 0.45 to 0.99; 103 participants (Analysis 9.1).
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Interruptions to cancer treatment
Adults receiving radiotherapy to the head and neck
with/without cisplatin
There was insufficient evidence, from one study at high risk of bias
(Wu 2009), to determine whether or not EGF reduces the risk of
having radiotherapy breaks longer than two days: RR 4.38, 95%
CI 0.25 to 75.44; 113 participants (Analysis 9.3).
Normalcy of diet
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for haematological cancers
There was insufficient evidence, from one study at low risk of bias
(Kim 2017), to determine whether or not EGF reduces the risk
of total parenteral nutrition: RR 1.03, 95% CI 0.55 to 1.94; 136
participants (Analysis 9.4).
Adverse events
There do not appear to be any serious concerns regarding adverse
effects of EGF. We have tabulated relevant information in Addi-
tional Table 5.
No studies assessed the outcomes ’oral pain’, ’quality of life’, ’num-
ber of days in hospital’, ’number of days of treatment with opioid
analgesics’ and ’number of days unable to take medicine orally’.
Intestinal trefoil factor (ITF) versus placebo
Oral mucositis
Adults receiving chemotherapy alone for colorectal cancer
One study, at unclear risk of bias and analysing 99 participants
(Peterson 2009), showed weak evidence (due to low sample size)
of a reduction in the risk of any level of oral mucositis (RR 0.52,
95% CI 0.35 to 0.79; Analysis 10.1), and moderate to severe oral
mucositis (RR 0.22, 95% CI 0.10 to 0.48; Analysis 10.2), both
in favour of ITF.
There was insufficient evidence, from the same study, to determine
whether or not EGF reduces the risk of severe oral mucositis: RR
1.52, 95% CI 0.06 to 36.39 (Analysis 10.3).
Adverse events
There do not appear to be any serious concerns regarding adverse
effects of ITF. We have tabulated relevant information in Addi-
tional Table 6.
No studies assessed the outcomes ’interruptions to cancer treat-
ment’, ’oral pain’, ’quality of life’, ’normalcy of diet’, ’number of
days in hospital’, ’number of days of treatment with opioid anal-
gesics’ and ’number of days unable to take medicine orally’.
Intestinal trefoil factor (ITF) dose comparison
There was insufficient evidence, from one study at unclear risk
of bias and analysing 66 adults receiving chemotherapy alone for
colorectal cancer (Peterson 2009), to determine whether a lower
dose (336 mg) or a higher dose (2688 mg) perform better in
reducing the risk of oral mucositis of any severity (Analysis 11.1;
Analysis 11.2; Analysis 11.3).
Erythropoietin versus placebo
Oral mucositis
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for haematological cancers
One study, at low risk of bias and analysing 80 participants (
Hosseinjani 2017), showedweak evidence (due to low sample size)
of a reduction in the risk of any level of oral mucositis (RR 0.35,
95% CI 0.21 to 0.60; Analysis 12.1), and moderate to severe oral
mucositis (RR 0.43, 95% CI 0.24 to 0.79; Analysis 12.2), both
in favour of erythropoietin.
The same study showed weak evidence (due to low sample size
and a wide confidence interval) that erythropoietin might reduce
the risk of severe oral mucositis, but there is also some possibility
of an increase in risk: RR 0.40, 95% CI 0.14 to 1.17 (Analysis
12.3).
Number of days in hospital
Adults receiving bone marrow/stem cell transplantation after
conditioning therapy for haematological cancers
There was insufficient evidence, from one study at low risk of bias
(Hosseinjani 2017), to determine whether or not erythropoietin
reduces the mean number of days in hospital: MD -2.95, 95% CI
-7.73 to 1.83; 80 participants (Analysis 12.4).
No studies assessed the outcomes ’interruptions to cancer treat-
ment’, ’oral pain’, ’quality of life’, ’normalcy of diet’, ’adverse
events’, ’number of days of treatment with opioid analgesics’ and
’number of days unable to take medicine orally’.
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Transforming growth factor (TGF) versus placebo
Oral mucositis
Adults receiving chemotherapy alone for colorectal cancer
There was insufficient evidence, from one study at high risk of
bias and analysing 13 participants (Antoun 2009), to determine
whether or not TGF reduces the risk of any level of oral mucositis:
RR 0.10, 95% CI 0.01 to 1.71 (Additional Table 7).
No studies assessed the outcomes ’interruptions to cancer treat-
ment’, ’oral pain’, ’quality of life’, ’normalcy of diet’, ’adverse
events’, ’number of days in hospital’, ’number of days of treat-
ment with opioid analgesics’ and ’number of days unable to take
medicine orally’.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
GM-CSF compared to placebo/no treatment for preventing oral mucositis in adults with cancer receiving treatment
Patient or population: adults∗∗ receiving treatment for cancer (see subgroup for treatment type)
Setting: hospital
Intervention: GM-CSF
Comparison: placebo/ no treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo/no
treatment
Risk with GM-CSF
Oral mucosit is (moder-
ate + severe)
BMT/ SCT af ter condit ioning for haematological
cancers
RR 0.94
(0.79 to 1.13)
109
(1 study)
⊕©©©
VERY LOW1
There is insuf f icient ev-
idence to determ ine a
benef it f or GM-CSF in
this populat ion
NNTB = 20 (95% CI 6
NNTB to 10 NNTH)
839 per 1000 789 per 1000
(663 to 948)
RT to head and neck RR 0.72
(0.49 to 1.06)
29
(1 study)
⊕©©©
VERY LOW2
There is insuf f icient ev-
idence to determ ine a
benef it f or GM-CSF in
this populat ion
NNTB = 4 (95% CI 3
NNTB to 14 NNTH)
929 per 1000 669 per 1000
(455 to 984)
Oral mucosit is (severe) BMT/ SCT af ter condit ioning for m ixed cancers RR 0.74
(0.33 to 1.67)
235
(3 studies)
⊕⊕©©
LOW3
There is insuf f icient ev-
idence to determ ine a
benef it f or GM-CSF in
this populat ion
NNTB = 12 (95% CI 5
NNTB to 5 NNTH)
347 per 1000 257 per 1000
(115 to 580)
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RT to head and neck RR 0.31
(0.01 to 7.09)
29
(1 study)
⊕©©©
VERY LOW4
There is insuf f icient ev-
idence to determ ine a
benef it f or GM-CSF in
this populat ion
NNTB = 21 (95% CI 15
NNTB to 3 NNTH)
71 per 1000 22 per 1000
(1 to 506)
CT alone for m ixed cancers RR 0.59
(0.05 to 7.11)
65
(2 studies)
⊕©©©
VERY LOW5
There is insuf f icient ev-
idence to determ ine a
benef it f or GM-CSF in
this populat ion
NNTB = 5 (95% CI 3
NNTB to 2 NNTH)
500 per 1000 295 per 1000
(25 to 1000)
Adverse events Adverse events that were attributed to the study drugs rather than the cancer therapy were typically bone pain, nausea, fever and headache. Events
were not reported as being serious. Some studies did not report adverse events and 1 even reported that there were none. However, report ing was
poor and inconsistent, meaning that it was not appropriate to meta-analyse data
∗The risk in the intervent ion group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its
95%CI).
∗∗There were no studies conducted on children.
∗∗∗The number of people that would need to receive GM-CSF in order to prevent 1 addit ional person f rom developing the outcome. Calculated as 1 divided by the absolute
risk reduct ion (which is the control arm event rate minus the experimental arm event rate). NNTH means the number of people that would need to receive GM-CSF to cause 1
addit ional person to develop the outcome. All decimal places have been rounded up to the nearest whole number (i.e. 6.1 = 7).
BMT: bone marrow transplantat ion; CI: conf idence interval; CT: chemotherapy; GM-CSF: granulocyte-macrophage colony-st imulat ing factor; NNTB: number needed to treat to
benef it∗∗∗; NNTH: number needed to treat to harm; RR: risk rat io; RT: radiotherapy; SCT: stem cell t ransplantat ion.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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1Downgraded by 2 levels for imprecision (single study with a small sample size and the conf idence interval includes a possible
increase in risk that is of a sim ilar magnitude to the possible reduct ion in risk); downgraded 1 further level for indirectness
(single study so not widely generalisable).
2Downgraded by 2 levels for imprecision (wide conf idence interval and very small sample size); downgraded by 1 further level
for high risk of performance bias; downgraded by 1 further level for indirectness (single study so not widely generalisable);
downgraded by 1 further level for publicat ion bias as there are 2 references in Studies await ing classif icat ion that would be
included in the RT to head and neck subgroup, but the data are not current ly available (Antonadou 1998; NCT00293462).
3Downgraded by 2 levels for imprecision (small sample size and the conf idence interval includes a possible increase in risk
that is of a sim ilar magnitude to the possible reduct ion in risk); downgraded by 1 further level for inconsistency (substant ial
heterogeneity: I2 = 50% to 90%, P < 0.1).
4Downgraded by 2 levels for imprecision (extremely wide conf idence interval incorporat ing both very large increase and
reduct ion in risk, very small sample size and very low event rate); downgraded by 1 further level for high risk of performance
bias; downgraded by 1 further level for indirectness (single study so not widely generalisable); downgraded by 1 further level
for publicat ion bias as there are 2 references in Studies await ing classif icat ion that would be included in the RT to head and
neck subgroup, but the data are not current ly available (Antonadou 1998; NCT00293462).
5Downgraded by 2 levels for imprecision (extremely wide conf idence interval incorporat ing both very large increase and
reduct ion in risk and very small sample size); downgraded by 1 further level for high risk of performance bias; downgraded by
1 further level for inconsistency (substant ial heterogeneity: I2 = 50% to 90%, P < 0.1).
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G-CSF compared to placebo/no treatment for preventing oral mucositis in patients with cancer receiving treatment
Patient or population: adults∗∗ receiving treatment for cancer (see subgroup for treatment type)
Setting: hospital
Intervention: G-CSF
Comparison: placebo/ no treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo/no
treatment
Risk with G-CSF
Oral mucosit is (moder-
ate + severe)
CT alone for breast cancer RR 0.33
(0.12 to 0.95)
14
(1 study)
⊕©©©
VERY LOW1
There is very weak evi-
dence that there might
be a benef it f or G-CSF
in this populat ion
NNTB = 2 (95% CI 2 to
20)
1000 per 1000 330 per 1000
(120 to 950)
Oral mucosit is (severe) RT to head and neck RR 0.37
(0.15 to 0.87)
54
(2 studies)
⊕⊕©©
LOW2
There is weak evidence
that there might be a
benef it f or G-CSF in this
populat ion
NNTB = 3 (95% CI 3 to
15)
519 per 1000 192 per 1000
(78 to 451)
Adverse events There was lim ited evidence of adverse events for G-CSF. 2 of the 6 studies did not report adverse events. There were low rates of m ild to moderate
events, the most common of which appeared to be bone pain. However, report ing was poor and inconsistent, meaning that it was not appropriate to
meta-analyse data
∗The risk in the intervent ion group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its
95%CI).
∗∗There were no studies conducted on children.
∗∗∗The number of people that would need to receive G-CSF in order to prevent 1 addit ional person f rom developing the outcome. Calculated as 1 divided by the absolute
risk reduct ion (which is the control arm event rate minus the experimental arm event rate). NNTH means the number of people that would need to receive G-CSF to cause 1
addit ional person to develop the outcome. All decimal places have been rounded up to the nearest whole number (i.e. 6.1 = 7).3
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CI: conf idence interval; CT: chemotherapy; G-CSF: granulocyte-colony st imulat ing factor; NNTB: number needed to treat to benef it∗∗∗; NNTH: number needed to treat to harm;
RR: risk rat io; RT: radiotherapy.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by 2 levels for imprecision (wide conf idence interval and very small sample size); downgraded by 1 further level
for high risk of performance bias; downgraded by 1 further level for indirectness (single study so not widely generalisable).
2Downgraded by 2 levels for imprecision (wide conf idence interval and very small sample size).
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D I S C U S S I O N
Summary of main results
Thirty-five studies met our eligibility criteria and were included in
this review. We used GRADE methodology to assess the quality
of the body of evidence for each of the main comparisons and
for the primary outcome of incidence and severity of oral mucosi-
tis (GRADE 2004). Most of the evidence we found was for ker-
atinocyte growth factor (KGF: Summary of findings for the main
comparison), granulocyte-macrophage colony-stimulating factor
(GM-CSF: Summary of findings 2), and granulocyte-colony stim-
ulating factor (G-CSF: Summary of findings 3).
Our main findings were as follows.
Keratinocyte growth factor (KGF)
Moderate to severe oral mucositis
• Adults receiving bone marrow/stem cell transplantation
after conditioning therapy for haematological cancer: might be a
reduction in risk (11% and ranging from 20% to 1%).
• Adults receiving radiotherapy to the head and neck with
cisplatin/fluorouracil (5FU): probably a reduction in risk (9%
and ranging from 17% to no reduction).
• Adults receiving chemotherapy alone for mixed cancers:
likely to be a reduction in risk (44% and ranging from 55% to
30%).
Severe oral mucositis
• Adults receiving bone marrow/stem cell transplantation
after conditioning therapy for haematological cancer: might be a
reduction in risk, but some possibility of an increase in risk (15%
reduction and ranging from 35% reduction to 11% increase).
• Adults receiving radiotherapy to the head and neck with
cisplatin/fluorouracil (5FU): very likely a reduction in risk (21%
and ranging from 31% to 10%).
• Adults receiving chemotherapy alone for mixed cancers:
might be a reduction in risk (60% and ranging from 86% to
35%).
Granulocyte-macrophage colony-stimulating factor
(GM-CSF)
Moderate to severe oral mucositis
• Adults receiving bone marrow/stem cell transplantation
after conditioning therapy for haematological cancer: insufficient
evidence of a benefit.
• Adults receiving radiotherapy to the head and neck:
insufficient evidence of a benefit.
Severe oral mucositis
• Adults receiving bone marrow/stem cell transplantation
after conditioning therapy for mixed cancers: insufficient
evidence of a benefit.
• Adults receiving radiotherapy to the head and neck:
insufficient evidence of a benefit.
• Adults receiving chemotherapy alone for mixed cancers:
insufficient evidence of a benefit.
Granulocyte-colony stimulating factor (G-CSF)
Moderate to severe oral mucositis
• Adults receiving chemotherapy alone for breast cancer: very
weak evidence of a possible reduction in risk (67% and ranging
from 88% to 5%).
Severe oral mucositis
• Adults receiving radiotherapy to the head and neck: weak
evidence of a possible reduction in risk (63% and ranging from
85% to 13%).
The remaining evidence for the primary outcome was from single-
study comparisons.
• Epidermal growth factor might reduce the risk of moderate
to severe oral mucositis in adults receiving radiotherapy to the
head and neck with or without cisplatin, but there was
insufficient evidence of a reduction in the risk of either moderate
to severe, or severe oral mucositis in adults receiving bone
marrow/stem cell transplantation after conditioning therapy for
haematological cancer.
• Intestinal trefoil factor might reduce the risk of moderate to
severe oral mucositis in adults receiving chemotherapy alone for
colorectal cancer.
• Erythropoietin might reduce the risk of moderate to severe
oral mucositis in adults receiving bone marrow/stem cell
transplantation after conditioning therapy for haematological
cancer.
There was mostly insufficient evidence of a benefit regarding the
secondary outcomes of this review. The interventions investigated
all appear to be relatively safe, with only mild to moderate adverse
effects reported.
Overall completeness and applicability of
evidence
The evidence we have presented in this review allows for some
conclusions to be made regarding the effects of KGF for prevent-
ing oral mucositis in adults receiving certain types of cancer treat-
ment. However, the evidence is lacking for other cytokines and
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growth factors, and for children. It is unfortunate that the two
studies we found on KGF versus placebo in children were unclear
in their reporting and we were unable to present any data. All
studies reported on our primary outcome, but the evidence for the
secondary outcomes of this review is lacking.
The evidence for KGF should have reasonable external validity as
most of the adult population were covered in terms of the types
of treatment people have for different types of cancer. The studies
were also carried out all over the world and often involvedmultiple
sites. One limitation, however, may be the fact that most studies
were done in middle-income and high-income countries, so may
be less generalisable to people in low-income countries.
Numerous studies reported on some of our secondary outcomes
but did not report the data in a suitable format for inclusion in our
meta-analyses e.g. as median with or without range, area under
the curve, or as mean (or a graph) but with no standard deviation/
standard error/P value. In such cases, themeta-analysis is biased by
missing information. However, the Cochrane risk of bias tool and
meta-analyses do not currently address this issue adequately. The
study may be assessed at high risk of selective outcome reporting,
but if the study is not included in the meta-analysis due to having
no data, then this is not reflected or accounted for. This highlights
the need for standardisation in both ’what to measure’ and ’how
to measure it’ in clinical trials in this area of research. Otherwise
there will continue to be research waste, with data that are not
able to be pooled in data syntheses. There are initiatives such as
COMET (Core Outcome Measures in Effectiveness Trials) and
COSMIN (COnsensus-based Standards for the selection of health
Measurement INstruments) that can help with these issues, and
future research in these areas would be beneficial.
During the systematic review process, we developed further con-
cerns regarding the usefulness of the secondary outcomes because
it was not clear whether or not they were due to oral mucositis.
Hospitalisation, the use of supplemental nutrition or opioid anal-
gesics, and interruptions to cancer treatment could all occur due
to reasons other than oral mucositis. Furthermore, it was not al-
ways clear if adverse effects were due to the interventions given to
prevent oral mucositis. These issues could be improved by clearer
and more explicit reporting.
Cost is an issue that we did not consider in this review, but it is
one that may affect whether or not the evidence can be applied in
some settings. Taking KGF as an example, cost per dose is high
but there is currently an absence of high quality health economic
evaluations, rendering decision making difficult.
Quality of the evidence
We included 35 randomised controlled trials (RCTs) analysing
3102 participants. Despite this large volume of research, we were
not able to make robust conclusions about the effects of most cy-
tokines and growth factors. The strongest body of evidence, both
in terms of volume and quality, was for the different populations
receiving KGF. We assessed the evidence for KGF in preventing
severe oral mucositis in adults receiving radiotherapy to the head
and neck with or without cisplatin or fluorouracil as high qual-
ity. In the same population, we downgraded the evidence for pre-
vention of moderate to severe oral mucositis by one level due to
inconsistency in the individual study results (heterogeneity), re-
sulting in moderate-quality evidence. In adults receiving chemo-
therapy alone for mixed cancers, we downgraded the evidence for
KGF in preventing moderate to severe oral mucositis once due to
publication bias, as we found an unpublished study that would be
included in the meta-analysis, resulting in moderate-quality evi-
dence (NCT00393822). In the same population, we downgraded
the evidence for prevention of severe oral mucositis by two levels:
one for publication bias and one for imprecision due to a small
sample size, low event rates and a wide confidence interval. This
resulted in low-quality evidence. In adults receiving bone marrow/
stem cell transplantation after conditioning therapy for haemato-
logical cancers, the evidence for KGF in preventing both moderate
to severe and severe oral mucositis was assessed as low quality. We
downgraded the evidence by two levels: one for heterogeneity and
one for publication bias, as there were two studies for which we
could not find published full reports (NCT02313792; Spielberger
2001). There were no concerns over risk of bias in the KGF studies
as they are often large multicentre trials which are carried out well,
mostly using placebos for blinding purposes, and with very low
attrition.
The evidence for GM-CSF and G-CSF was weaker, and conse-
quently was rated as being low or very low quality. The reasons for
downgrading were mostly due to imprecision because the volume
of evidence was much lower and the studies often recruited very
few participants, leading to very wide confidence intervals that
frequently included both the possibility of a decrease in risk and
an increase. Further reasons were risk of performance bias due to
lack of blinding in some of these studies, inconsistency, and also
because some of the evidence was from single studies. When a
body of evidence was from a single study, we automatically down-
graded a level. The reasoning behind this was because often, when
using GRADE methodology, bodies of evidence are downgraded
for inconsistency due to different effect estimates in the individual
studies. This inconsistency is not possible for a single-study body
of evidence and therefore not downgrading would falsely inflate
the rating of quality, whilst at the same time the larger body of
evidence is unfairly penalised, in comparison, due to having more
studies. In such cases, we downgraded the single-study evidence
due to indirectness as it may only be generalisable to the particular
population who took part in the study.
The remaining evidence for other interventions was from single-
study comparisons and therefore was all considered to be of low
to very low quality, mainly for indirectness (as described above)
and imprecision.
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Potential biases in the review process
Although systematic review methodology is designed to minimise
biases in the process, decisions are often made out of necessity or
for practical reasons, and this can introduce some potential bias.
Once we began to assess the literature identified by the searches, we
became concerned that we may have missed some relevant studies
because we had not included search terms for other conditions for
which cytokines and growth factors have been used tomanage (e.g.
diarrhoea, graft-versus-host disease, and neutropenia). In order
to assess the extent of this potential problem, a rough scoping
search was run including the search terms. The yield was very high
and a single review author assessed a sample of 500 records, but
no further studies were identified. Therefore, we decided not to
amend the search by adding the new search terms.We acknowledge
the possibility thatwe havemissed some studies that havemeasured
and reported onoralmucositis but notmentioned it in the abstract.
This could introduce bias if there are relevant data missing from
the review.
There were some studies that had multiple treatment arms with
different doses of the cytokine or growth factor. In all instances,
we combined the arms to make a pairwise comparison against the
control arm thus losing some possible subtleties of the data and
potentially biasing the results.
Agreements and disagreements with other
studies or reviews
The Mucositis Study Group (MSG) of the Multinational Associ-
ation of Supportive Care in Cancer/International Society of Oral
Oncology (MASCC/ISOO) is the leading international group in
this area of research. In 2013, they published a series of systematic
reviews on the different interventions for managing oralmucositis,
including one on cytokines and growth factors (Raber-Durlacher
2013). These reviews feed into the MASCC/ISOO Clinical Prac-
tice Guidelines for the Management of Mucositis Secondary to
Cancer Therapy (Lalla 2014). The MASCC/ISOO systematic re-
view is not limited to RCTs. The current guidance from this group
is as follows.
• Recommendations in favour of an intervention (i.e. strong
evidence supporting effectiveness): the panel recommends that
recombinant human keratinocyte growth factor-1 (KGF-1/
palifermin) be used to prevent oral mucositis (at a dose of 60 µg/
kg per day for three days prior to conditioning treatment and for
three days after transplant) in patients receiving high-dose
chemotherapy and total body irradiation, followed by autologous
stem cell transplantation, for a haematological malignancy (level
II evidence).
• Suggestions against an intervention (i.e. weaker evidence
indicating lack of effectiveness): the panel suggests that
granulocyte-macrophage colony-stimulating factor mouthwash
not be used to prevent oral mucositis in patients receiving high-
dose chemotherapy, for autologous or allogeneic stem cell
transplantation (level II evidence).
For our meta-analyses for KGF in the above mentioned popu-
lation, we combined studies of all types of KGF, both with au-
tologous and allogeneic transplants, and with total body irra-
diation (TBI), without TBI or a mixture of TBI/no TBI. The
MASCC/ISOO systematic review separated all of these factors.
However, looking at the individual studies in our meta-analyses,
the first recommendation appears to be a valid one. Furthermore,
the MASCC/ISOO systematic review states “Evidence on the ef-
ficacy of palifermin in autologous HSCT without TBI condition-
ing is conflicting...and these rather small studies did not allow a
guideline. In addition, no guideline could be provided for the use
of palifermin in the setting of allogeneic HSCT with or without
TBI.”Despite ourmeta-analyses including some further RCTs not
included in the other review, these statements also appear to be
valid.
The suggestion against GM-CSFmouthwash is also a valid one as,
although we did not separate studies by mode of administration,
it is clear that the two mouthwash studies in our analysis (Analysis
4.3) have conflicting results.However, based on one study onGM-
CSF given intravenously in this population (Nemunaitis 1995),
there is promising evidence of a benefit, but the MASCC/ISOO
systematic review considered this evidence alongside other studies
that we did not include, and concluded that there was no guideline
possible.
Our results are not in agreement with the following statements
from the MASCC/ISOO systematic review regarding other pop-
ulations receiving KGF.
• “No guideline could be provided for the use of palifermin
in the setting of CT for solid and hematological tumors...due to
insufficient evidence.”
• “In addition, no guideline could be provided for the use of
palifermin in H&N RT due to insufficient evidence.”
We present some moderate- to high-quality evidence of a benefit
for KGF in these populations, possibly warranting new guideline
statements in their next update. This evidence would equate to
level I evidence in the grading system used in the guidelines (“ev-
idence obtained from meta-analysis of multiple, well-designed,
controlled studies”). In another Cochrane Review on preventing
salivary gland dysfunction in patients receiving radiotherapy to
the head and neck, with or without chemotherapy, KGF did not
appear to have any detrimental effect on overall survival or pro-
gression-free survival (Riley 2017).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We are confident that keratinocyte growth factor (KGF) is bene-
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ficial in the prevention of oral mucositis in adults who are receiv-
ing: a) radiotherapy to the head and neck with cisplatin or flu-
orouracil; or b) chemotherapy alone for mixed solid and haema-
tological cancers. We are less confident about a benefit for KGF
in adults receiving bone marrow/stem cell transplant after con-
ditioning therapy for haematological cancers because of multiple
factors involved in that population, such as whether or not they
received total body irradiation (TBI) and whether the transplant
was autologous (the patients’ own cells) or allogeneic (cells from a
donor). KGF appears to be a relatively safe intervention.
Due to limited research, we are not confident that there are any
beneficial effects of other cytokines and growth factors. There is
currently insufficient evidence to draw any conclusions about the
use of cytokines and growth factors in children.
Implications for research
Despite a large volume of research, once studies are categorised
by cancer treatment type/population, there is very little we can
conclude regarding the effects of most cytokines and growth fac-
tors. It is clear that much more research is needed in this area,
especially as many of the interventions have shown promise in
some populations, yet we have not been able to make robust con-
clusions due to the limited volume/low sample sizes. Strong ev-
idence from randomised controlled trials (RCTs) using placebos
should be generated before head-to-head comparisons of different
interventions are undertaken. More RCTs of KGF are needed in
the population receiving bone marrow/stem cell transplant after
conditioning therapy so that in future updates we may be able to
include separate subgroups to account for differing factors such as
TBI/no TBI and autologous/allogeneic transplant. Further large
confirmatory RCTs of KGF would be beneficial in the other two
populations: a) radiotherapy to the head and neck with chemo-
therapy (and possibly without chemotherapy); and b) chemother-
apy alone for mixed cancers.
More research is needed on all other cytokines and growth factors
in the various populations, including in children. Placebo controls
should be used in the first instance to establish whether or not they
are effective, and only then should head-to-head comparisons of
active interventions be made.
Future RCTs should be adequately powered to detect a difference
if one actually exists and they should be reported according to
the CONSORT Statement (Consolidated Standards of Reporting
Trials). They should measure and report in full all the outcomes
listed in this review, most of which are recommended in the core
outcome set produced by Bellm et al (Bellm 2002). For our pri-
mary outcome of oral mucositis incidence, we urge trialists to use
a measurement tool such as the WHO (World Health Organiza-
tion) or NCI-NCT (National Cancer Institute common toxicity
criteria) scale (Appendix 9), to allow us to combine the data with
those already included in this review. Reporting the maximum
grade of oral mucositis experienced per participant would allow
us to assess the incidence of different severities, thus maximising
the usefulness of the data. It would also be useful if oral pain was
measured on a 0 to 10 scale and reported as an overall mean and
mean maximum score experienced per participant. Numbers in-
cluded in any analysis should always be reported and any contin-
uous data should be reported as means and standard deviations.
Furthermore, measurement of outcomes should be taken with ap-
propriate frequency so as to avoid any problems with ascertain-
ment bias.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Antoun 2009
Methods Trial design: parallel (2 arms)
Location: Institut Gustave Roussy, Villejuif, France
Number of centres: 1
Study duration: February 2005 to September 2006
Trials registry number: none/unknown
Participants Inclusion criteria: adults with metastatic colorectal adenocarcinoma (grade 3 to 4); life
expectancy greater than 3 months; receiving 5FU-based chemotherapy
Exclusion criteria: HIV; pregnant or lactating; unlikely to comply with interventions;
participation in another trial in the previous 12 months (unless regarding chemothera-
peutic protocols); undergone a total colectomy; state of subocclusion; chronic inflam-
matory diseases of the digestive tract; radiation enteropathy
Cancer type: metastatic colorectal adenocarcinoma (grade 3 to 4)
Cancer treatment: 5FU-based chemotherapy
Age at baseline (years): median 60 (not reported by group)
Gender: not reported
Number randomised: 22 (not reported by group)
Number evaluated: 13 (Group A: 9; Group B: 4)
Interventions Comparison: TGF-beta(2) versus placebo
GroupA: nutritional supplement of proteins, carbohydrates, fats, vitamins andminerals,
with TGF-beta(2) (2 ng/mg protein); formulas were in powder form, mixed with cool
previously boiled water at 0.23 g/mL (100 kcl/100 mL); during each cycle participants
received 750 mL to 1000 mL per day plus any other food desired; formula administered
for 2 days before, 2 days during, and 3 days after chemotherapy (7 days/cycle)
Group B: same as above without the TGF-beta(2)
Compliance: “Nine randomised patients who never ate the formula were excluded from
the study” (not reported by group)
Duration of treatment: “3 months (test or control formula), for a minimum of one and
a maximum of eight cycles of treatment”
Outcomes • Oral mucositis: WHO 0 to 4 scale (no details reported on who assessed this, or
when it was assessed; only reports incidence of any mucositis)
• Chemotherapy-induced diarrhoea (not an outcome of this review)
Notes Sample size calculation: not reported
Funding: “This study was funded by Nestec Ltd” - Nestlé (manufacturer of the inter-
vention)
Declarations/conflicts of interest: 6 of the 9 authors were either consultants (1) or
employees (5) of Nestlé
Data handling by review authors: reported in additional table
Other information of note: “Due to low accrual of patients (22 patients were enrolled
and randomised in 18 months), the study was prematurely stopped”
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Antoun 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly assigned”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “randomly assigned”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind” and “The test for-
mula differed only by containing an addi-
tional...”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of oral mucositis using this scale, re-
quiring the patient’s assessment of pain/
soreness and their ability to swallow but,
as the participants were unaware of their
group allocation, the assessment of oral
mucositis can be considered to be blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall attrition was 41% although it was
not reported by group
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Blazar 2006
Methods Trial design: parallel (7 arms) dose-ranging study
Location: Universities of Minnesota and Michigan, USA
Number of centres: 2
Study duration: not reported
Trials registry number: none/unknown
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Blazar 2006 (Continued)
Participants Inclusion criteria: aged 3 to 65 years; diagnosed with haematological malignancy (in-
cludingmyelodysplastic syndromes); ECOG score of 0 to 2; eligible for allogeneicHSCT
after conditioning treatment with chemotherapy with or without TBI
Exclusion criteria: received previous allogeneic HSCT; due to receive a T-cell-depleted
donor graft; active chronic skin disease; pre-existent inflammatory bowel disease; uncon-
trolled (antibiotic-resistant) bacterial infection; hepatitis; HIV
Cancer type: haematologic: ALL (Group A: 12%; Group B: 3%); AML (Group A: 35%;
Group B: 39%); CML (Group A: 10%; Group B: 26%); MDS (Group A: 9%; Group
B: 19%); NHL (Group A: 19%; Group B: 3%); Hodgkin’s (Group A: 1%; Group B:
0%); Other (Group A: 14%; Group B: 10%)
Cancer treatment: both centres had allogeneic HSCT on day 0 but differed in condi-
tioning regimen and GVHD prophylaxis as follows:
• Minnesota centre (n = 54): conditioning with cyclophosphamide (60 mg/kg per
day for 2 days) on days -7 and -6 and TBI (total dose 13.2 Gy, fractionated as 165 cGy
twice daily for 4 days) on days -4 to -1; GVHD prophylaxis with methotrexate (15 mg/
m², IV bolus on day +1, and 10 mg/m², IV bolus on days 3, 6, and 11) and
cyclosporine A (starting from day -3); Group A: 69%; Group B: 31%
• Michigan centre (n = 46): conditioning with busulfan (1 mg/kg per dose given 4
times daily for 4 days) on days -8 to -5 and cyclophosphamide (60 mg/kg per day for 2
days) on days -3 and -2; GVHD prophylaxis with methotrexate (15 mg/m², IV bolus
on day +1, and 10 mg/m², IV bolus on days 3, 6, and 11) and tacrolimus or
cyclosporine A (starting from day -3); Group A: 70%; Group B: 30%
Both centres received G-CSF (filgrastim) 5 µg/kg per day from 24 hours after HSCT
until neutrophil recovery
Age at baseline (years): Group A: median 46 (range 7 to 65); Group B: median 46
(range 7 to 63)
Gender: both groups 58% male
Number randomised: 100 (Group A: 69; Group B: 31)
Number evaluated: 96 (Group A: 65; Group B: 31)
Interventions Comparison: KGF (palifermin) versus placebo
(4 KGF arms and 3 placebo arms were each combined into a single arm)
Group A: KGF
• (n = 8): 40 µg/kg per day in 6 doses on days -11, -10, -9 and 0, 1, 2 (total dose =
240 µg/kg)
• (n = 10): 60 µg/kg per day in 6 doses on days -11, -10, -9 and 0, 1, 2 (total dose =
360 µg/kg)
• (n = 14): 60 µg/kg per day in 9 doses on days -11, -10, -9 and 0, 1, 2 and 7, 8, 9
(total dose = 540 µg/kg)
• (n = 37): 60 µg/kg per day in 12 doses on days -11, -10, -9 and 0, 1, 2 and 7, 8, 9
and 14, 15, 16 (total dose = 720 µg/kg)
Group B: placebo with matching schedule to either the 6, 9 or 12 dose regimen
Mode of administration not described but presumably IV as in other KGF studies
Compliance: Group A: 20 did not receive all study doses (17 of these were replaced to
allow a full assessment of safety); Group B: 2 did not receive all study doses (1 replaced)
Duration of treatment: varied from 13 days (6 doses) to 27 days (12 doses) - see above
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Blazar 2006 (Continued)
Outcomes • Oral mucositis: WHO 0 to 4 scale (measured 3 times per week during
hospitalisation by designated observers, maximum score reported)
• Adverse effects (assessed daily during study period using WHO and NCI-CTC
toxicities scale)
• Incidence and severity of acute GVHD (not an outcome of this review)
• Overall survival (not an outcome of this review)
• Incidence of transplantation-related toxicity (not an outcome of this review)
• Time to marrow engraftment (not an outcome of this review)
Notes Sample size calculation: not reported
Funding: government grants fromNIH and FDA, and also supported by Amgen (phar-
maceutical industry)
Declarations/conflicts of interest: not reported
Data handling by review authors: the data for incidence of mucositis were not re-
ported separately for each dose and therefore it was not possible to include head-to-
head comparisons of different dosages in this review; the data for incidence of mucositis
were presented in subgroups of those that did or did not receive the final methotrexate
infusion on day 11 but we used the overall data in our meta-analyses (the study authors
report that there was no difference between these subgroups)
Other information of note: the study authors report a greater decrease in incidence of
grade 3 to 4 (severe) oral mucositis due to palifermin in theMinnesota participants (who
received a more mucotoxic conditioning regimen) than in the Michigan participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients...were randomly assigned.
..”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “patients...were randomly assigned.
..”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of oral mucositis using this scale, re-
quiring the patient’s assessment of pain/
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Blazar 2006 (Continued)
soreness and their ability to swallow but,
as the participants were unaware of their
group allocation, the assessment of oral
mucositis can be considered to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Data for all patients randomly as-
signed and who received a transplant were
used in all other analyses (intent-to-treat)”
Comment: although 18 participants
(Group A: 17; Group B: 1) were replaced
to allow a full assessment of safety, it seems
that the originally randomised participants
were included in the analyses
Overall attrition was 4% (Group A: 6%;
Group B: 0%) for the oral mucositis inci-
dence outcome. The reasons were unclear
but this proportion of attrition is unlikely
to have biased the results
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Blijlevens 2013
Methods Trial design: parallel (3 arms)
Location: Europe (Italy, France, the Netherlands, Ireland, Germany, UK, Denmark,
Austria, Switzerland, Czech Republic, Sweden, Hungary, Belgium, Finland)
Number of centres: 39
Study duration: December 2006 to February 2009
Trials registry number: NCT00434161
Participants Inclusion criteria: aged between 18 and 70 years; due to receive high-dose melphalan;
ECOG score of 0 to 2 (or 3, if reason was due to multiple myeloma); at least 2 x 10
CD34+ cells per kg; corrected carbon monoxide diffusing capacity 50% or higher
of predicted; absolute neutrophil count at least 1.5 x 10 /L and platelets at least 100
x 10 /L; total bilirubin 2 mg/dL or lower; aspartate aminotransferase and/or alanine
aminotransferase 4 x institutional upper limit of normal or lower
Exclusion criteria: not reported
Cancer type: multiple myeloma
Cancer treatment: 1-day administration of high-dose melphalan (200 mg/m²) on day
-2, followed by auto-SCT on day 0
Age at baseline (years): Group A: median 55 (range 32 to 69); Group B: median 58
(range 40 to 68); Group C: median 58 (range 41 to 68)
Gender: Group A: 54% male; Group B: 55% male; Group C: 58% male
Number randomised: 281 (Group A: 109; Group B: 115; Group C: 57)
Number evaluated: 281 (Group A: 109; Group B: 115; Group C: 57)
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Blijlevens 2013 (Continued)
Interventions Comparison: KGF versus placebo
Group A: KGF (60 µg/kg) daily IV on days -6, -5, and -4, then placebo on days 0 (the
day of auto-SCT), 1, and 2 (total dose = 180 µg/kg)
Group B: KGF (60 µg/kg) daily IV on days -6, -5, -4, 0, 1, and 2 (total dose = 360 µg/
kg)
Group C: placebo daily IV on days -6, -5, -4, 0, 1, and 2
Compliance: Group A: 8% discontinued; Group B: 12% discontinued; Group C: 4%
discontinued; (point of discontinuation or number of treatments not stated for any
group)
Duration of treatment: 6 treatment days (over 9 days)
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed daily by nurses and physicians from
day -2 to day 32, maximum score reported) (duration of grade 2 to 4 and 3 to 4 oral
mucositis also measured but not outcomes of this review)
• Oral pain: OMDQ 5-point scale for mouth and throat soreness (higher = worse
pain) (assessed daily by participants from day -2 to day 32, data reported as AUC, not
used)
• Quality of life: EQ-5D 0 (worst imaginable health) to 10 (best imaginable health)
scale, incorporating mobility, self-care, usual activities, pain/discomfort and anxiety/
depression (assessed daily by participants from day -2 to day 32, mean reported only at
day 7 and with no SD, no usable data)
• Normalcy of diet (measured as incidence of TPN) (duration of TPN also
measured but not used for analysis in review)
• Adverse events (NCI-CTC version 3.0 toxicity scale)
• Number of days in hospital
• Number of days of treatment with opioid analgesics (incidence of opioid analgesic
use also measured and reported but not an outcome of this review)
• Febrile neutropenia (not an outcome of this review)
• Significant infections (not an outcome of this review)
• Anti-infective (IV) drug use (not an outcome of this review)
• Blood product use (not an outcome of this review)
• Nonopioid analgesic use (not an outcome of this review)
Notes Sample size calculation: 275 participants required at 95% power and 5% significance
to detect an odds ratio of at least 3.5 between placebo and KGF in grade 2 to 4 oral
mucositis
Funding: sponsored by Swedish Orphan Biovitrum (pharmaceutical industry); KGF
and placebo manufactured and packaged by Amgen (pharmaceutical industry)
Declarations/conflicts of interest: 2 authors were employees of the sponsors; the re-
maining authors declared no competing financial interests
Data handling by review authors: we combined the 2 KGF groups to make a single
pairwise comparison against placebo; we also made a separate comparison of the 2 KGF
regimens
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Blijlevens 2013 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed by
using an interactive-voice-response-system
before planned admission”
Comment: large multicentre trial using
high-tech randomisation method - likely to
be done properly
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed by
using an interactive-voice-response-system
before planned admission”
Comment: large multicentre trial using
high-tech randomisation method - likely to
be done properly
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
and “Study drug...packaged...in identical
vials”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of lower grades of oral mucositis us-
ing the WHO scale, requiring the patient’s
assessment of pain/soreness and their abil-
ity to swallow.Higher grades havemore ob-
jective elements so may not be affected by
potential lack of blinding of the assessor.
This would be the same for other subjective
and objective outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately (although quality of
life reported with no SD or P values, this
does not affect the risk of bias judgement
for other outcomes)
Other bias Low risk No other sources of bias are apparent
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Bradstock 2014
Methods Trial design: parallel (2 arms)
Location: Australia
Number of centres: 23
Study duration: recruitment from September 2006 to April 2010
Trials registry number: ACTRN012605000095662 (mentioned in trial report)
Participants Inclusion criteria: aged 15 to 60 years with newly diagnosed and previously untreated
(except for hydroxycarbamide for high presenting white blood cell count) acute myeloid
leukaemia - all subtypes except t(15;17) or variants, or core-binding factor AML (t(8;21)
or inv(16) or variants); ECOG score of 0 to 3; no history of cancer (other than basal
cell skin cancer or carcinoma of the cervix in situ, or other localised cancer treated by
surgical excision only more than 5 years earlier without evidence of recurrence in the
intervening period)
Exclusion criteria: not reported
Cancer type: acute myeloid leukaemia
Cancer treatment: induction chemotherapy consisting of: idarubicin 9 mg/m² daily IV
infusion on days 1 to 3; etoposide 75 mg/m² daily IV infusion on days 1 to 7; cytarabine
3 g/m² 12-hourly IV infusion on days 1, 3, 5, and 7
All participants received G-CSF (pegfilgrastim) 6 mg subcutaneously on day 8
Age at baseline (years): Group A: mean 46 (SD 12; range 17 to 60); Group B: mean
44 (SD 12; range 16 to 60)
Gender: Group A: 61% male; Group B: 67% male
Number randomised: 160 (Group A: 79; Group B: 81)
Number evaluated: 151 (Group A: 73; Group B: 78)
Interventions Comparison: KGF (palifermin) versus placebo
Group A: KGF (60 µg/kg) daily IV on days -3, -2, -1 prior to chemotherapy and for 3
days after completion of chemotherapy (total dose = 360 µg/kg)
Group B: same schedule with placebo
Compliance: received all 3 pre-chemotherapy doses: Group A: 97%; Group B: 100%;
received all 3 post-chemotherapy doses: Group A: 95%; Group B: 96%
Duration of treatment: 6 treatment days (over 14 days)
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed daily by investigators and specifically
trained site personnel from the first day of chemotherapy and until the earlier of the
date of discharge or day 28 after the start of chemotherapy, maximum score reported)
(duration of grade 3 to 4 oral mucositis also measured but not an outcome of this
review)
• Adverse events (NCI-CTC version 2.0 toxicity scale)
• Incidence of severe gastrointestinal toxicities related to the induction
chemotherapy (not an outcome of this review)
• Complete response to chemotherapy (not an outcome of this review)
Notes Sample size calculation: 128 per group required to detect a reduction in grade 3 to 4
mucositis from 22% to 10% at 70% power and 5% significance
Funding: “This study was funded in part from Project Grant 302133 from the National
Health and Medical Research Council of Australia” (government); KGF and placebo
provided by Amgen (pharmaceutical industry)
Declarations/conflicts of interest: “The authors have no conflicts of interest to declare”
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Data handling by review authors:N/A
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eligible patients were randomized
1:1 using a block randomization technique
and stratification by participating centre to
receive placebo or palifermin”
Comment: large multicentre trial using
block randomisation and stratification -
likely to be done properly
Allocation concealment (selection bias) Unclear risk Quote: “Eligible patients were randomized
1:1 using a block randomization technique
and stratification by participating centre to
receive placebo or palifermin”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “placebo-controlled” and “Both in-
vestigators and patients were blinded to the
randomization outcome”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “placebo-controlled” and “Both in-
vestigators and patients were blinded to the
randomization outcome”
Comment: investigators assessed oral mu-
cositis, which would have partly relied on
patient’s assessment of pain/soreness and
their ability to swallow; both investigators
and patients were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall attrition was 6% (Group A: 8%;
Group B: 4%) for the oral mucositis inci-
dence outcome. The reasons were similar
between groups and this proportion of at-
trition is unlikely to have biased the results
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
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Brizel 2008
Methods Trial design: parallel (2 arms)
Location: Australia, Canada and USA
Number of centres: 22
Study duration: September 1999 to May 2001
Trials registry number: none/unknown
Participants Inclusion criteria: adultswith newly diagnosed stage III/IVa or IVb squamous carcinoma
of the oral cavity, oropharynx, nasopharynx, hypopharynx, and larynx (or with unknown
primary and extensive neck disease) undergoing CRT intended to be curative; Karnofsky
performance score of 60 or higher; haemoglobin 10 g/dL or higher; white blood cell
count 3.5 x 10 /L or higher or absolute neutrophil count 1.5 x 10 /L or higher; platelet
count 100 x 10 /L or higher; serum bilirubin 1.5 mg/dL or lower; serum creatinine
lower than 2.0 mg/dL (plus a 24-hour urinary creatinine clearance 50 mL/min in those
aged 60 years or older)
Exclusion criteria: previous RT to the head and neck; previous surgery for the primary
tumour (not including biopsy); previousCT; allergy to Escherichia coli-derived products;
participation in any other investigational study within the 30 days prior to this study;
refusal to use adequate contraception during the study; pregnant or breastfeeding
Cancer type: head and neck: oral (Group A: 12%; Group B: 6%); oropharynx/nasophar-
ynx (Group A: 61%; Group B: 66%); hypopharynx/larynx (Group A: 27%; Group B:
28%)
Cancer treatment:
• Radiotherapy: standard (once daily 2-Gy fractions, 5 days per week; total 70 Gy
over 7 weeks) or hyperfractionated (twice daily 1.25-Gy fractions with 6-hour interval,
5 days per week with an 8 to 9 day break after 3 weeks; total 72 Gy over 6.5 weeks)
• Chemotherapy: cisplatin (20 mg/m²/day) as IV bolus injection and 5FU (1000
mg/m²/day) as continuous infusion on the first 4 days of the first and fifth weeks of
radiotherapy
Age at baseline (years): Group A: mean 54 (SD 10; range 25 to 80); Group B: mean
56 (SD 10; range 42 to 75)
Gender: Group A: 82% male; Group B: 84% male
Number randomised: 101 (Group A: 69; Group B: 32)
Number evaluated: 97 (Group A: 65; Group B: 32)
Interventions Comparison: KGF (palifermin) versus placebo
Group A:KGF 60 µg/kg once weekly by IV bolus injection starting on the Friday before
CRT began (on the following Monday), then each Friday after completion of RT for 7
weeks, and 2 more doses after completion of CRT i.e. 10 doses in total (total dose = 600
µg/kg)
Group B: same schedule with matching placebo
Compliance: 99 participants (Group A: 67; Group B: 32) received at least 1 dose of
their allocated intervention; 69 participants completed the full course (Group A: 47;
Group B: 22); mean number of doses (Group A: 8.4; Group B: 9.1)
Duration of treatment: 9 weeks (10 doses)
Outcomes • Oral mucositis: NCI-CTC (2.0) 0 to 4 scale (measured weekly by a radiation
oncologist for the first 12 weeks, reported as incidence of grade 2 to 4 i.e. moderate to
severe, and grade 3 to 4 i.e. severe) (duration, time to onset, and cumulative
radiotherapy dose at onset of grade 2+ and 3+ oral mucositis also measured but not
outcomes of this review)
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• Interruptions to cancer treatment (unscheduled radiotherapy breaks: reported as
any breaks and breaks longer than 4 days)
• Normalcy of diet (measured as incidence of supplemental nutrition by a
gastrostomy tube)
• Adverse effects (reports collected throughout the 20-week study)
• Opioid analgesic use (reported as incidence; number of days of treatment with
opioid analgesics is an outcome of this review and therefore we did not use these data)
• Dysphagia (not an outcome of this review)
• Xerostomia (not an outcome of this review)
• Antibiotic use (not an outcome of this review)
• Tumour response rate (not an outcome of this review)
• Progression-free and overall survival (assessed in a longer-term follow-up study)
(not an outcome of this review)
Notes Sample size calculation: based on a previous study, 99 participants required to detect
a 30% difference in the duration of grade 2 or higher oral mucositis with 80% power
provided that the mean duration in the placebo arm was 56 days
Funding: “Supported by Amgen Inc” (pharmaceutical industry)
Declarations/conflicts of interest: multiple and involving: employment or leadership
positions with the funders (Amgen); consultant or advisory roles with the funders and
other pharmaceutical companies; stock ownership with the funders; honoraria from the
funders and other pharmaceutical companies; research funding from the funders and
other pharmaceutical companies
Data handling by review authors: the data for incidence of mucositis were presented
in subgroups of those that received standard or hyperfractionated RT but we used the
overall data in our meta-analyses; for the interruptions to radiotherapy outcome, we used
the data for breaks longer than 4 days as these could be pooled with other studies in this
comparison
Other information of note: the study authors report a greater decrease in incidence
due to palifermin in the hyperfractionated subgroup than in the standard subgroup (see
figure 3A in the study report)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned..
.”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomly assigned..
.”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blinded” and “Palifermin.
..or matching placebo was administered by
intravenous bolus”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blinded” and “Palifermin.
..or matching placebo was administered by
intravenous bolus”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of oral mucositis using this scale, re-
quiring the patient’s assessment of pain/
soreness and their ability to swallow but,
as the participants were unaware of their
group allocation, the assessment of oral
mucositis can be considered to be blinded.
The other outcomes are objective and
therefore unlikely to be affected by any po-
tential lack of blinding of the outcome as-
sessor(s)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall attrition was 4% (Group A: 6%;
Group B: 0%) for the oral mucositis inci-
dence outcome. The reasons were unclear
but this proportion of attrition is unlikely
to have biased the results
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Cartee 1995
Methods Trial design: parallel (5 arms) dose-ranging study
Location: Duke University Medical Centre, Durham, North Carolina, USA
Number of centres: 1
Study duration: not reported
Trials registry number: none/unknown
Participants Inclusion criteria: premenopausal or perimenopausal patients with histologically con-
firmed metastatic breast cancer who had chemotherapy for inoperable or metastatic dis-
ease; performance status of 0 or 1 (CALGB criteria)
Exclusion criteria: metastatic disease involving the central nervous system; pregnant
Cancer type: stage IV breast
Cancer treatment: AFM regimen (21-day cycle): 5FU (500 mg/m²/day) continuous
infusion on days 1 to 5; adriamycin (25 mg/m²) IV bolus on days 3 to 5; methotrexate
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(250 mg/m²) IV on day 15 (if oral mucositis less than grade 3)
All participants received G-CSF (filgrastim) subcutaneously (5 µg/kg/day) on days 7 to
13 and from day 16 until resolution of neutropenia
Age at baseline (years): mean 44 (not reported by group)
Gender: 49 female; 1 male (not reported by group)
Number randomised: 50 (not reported by group)
Number evaluated: 45 (Group A: 36; Group B: 9)
Interventions Comparison: GM-CSF (molgramostim) versus placebo
Group A: GM-CSF
• (n = 9 analysed): 15 mL of mouthwash (0.01 µg/mL) gently swirled in the mouth
for 2 minutes before expectorating it; 4 times daily (after mealtimes, even if a meal was
not eaten, and at bedtime) after routine oral care procedures; no eating/drinking for 15
minutes after using mouthwash; beginning within 24 hours of the start of 5FU and
continued for the 21-day AFM cycle (total dose = 12.6 µg)
• (n = 9 analysed): same schedule with 0.1 µg/mL mouthwash (total dose = 126 µg)
• (n = 9 analysed): same schedule with 1 µg/mL mouthwash (total dose = 1260 µg)
• (n = 9 analysed): same schedule with 10 µg/mL mouthwash (total dose = 12,600
µg)
Group B: (n = 9 analysed) same schedule with matching placebo mouthwash
Compliance: (not reported by group) mouthwash therapy was discontinued if the par-
ticipant experienced oral mucositis of grade 3 or above; 30 participants took at least
80% of their prescribed doses; 11 participants discontinued mouthwash therapy within
3 days prior to day 15; 4 participants discontinued mouthwash therapy between day 15
and day 21
Duration of treatment: 21 days (first treatment cycle of AFM)
Outcomes • Oral mucositis: CALGB 0 to 4 scale (measured on days 1 to 5, 8 to 10, 15 and
22, reported as incidence of grade 3 to 4 i.e. severe) (duration of grade 3 to 4 oral
mucositis also measured but not an outcome of this review)
• Adverse effects (assessed during study period)
• Blood measurements (platelet, WBC, granulocyte, lymphocyte) (not an outcome
of this review)
• Myelosuppression (not an outcome of this review)
• GM-CSF plasma concentrations (not an outcome of this review)
Notes Sample size calculation: this was done but the numbers required are not reported
Funding: “...supported in part by National Cancer Institute (Bethesda, MD) grant
number PO1-47741-A4”
Declarations/conflicts of interest: not reported
Data handling by review authors:we combined the 4GM-CSF groups tomake a single
pairwise comparison against placebo and, in order to make a head-to-head comparison
of doses, we grouped the 2 lower doses (0.01 µg/mL and 0.1 µg/mL) together and
grouped the 2 higher doses (1 µg/mL and 10 µg/mL) together to make pairwise groups
for comparison
Other information of note: not reported
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomized by the
Duke Cancer Center Protocol Office ac-
cording to a block randomization scheme
and assigned a unique identifier number
which designated the GM-CSF dose level
to be received”
Comment: method of sequence generation
not fully described but was done by a dedi-
cated specialist centre sowas probably done
adequately
Allocation concealment (selection bias) Low risk Quote: “Patients were randomized by the
Duke Cancer Center Protocol Office” and
“The patient supply of mouthwash was
labelled to correspond with the assigned
identifier number and dispensed by the
Pharmacy. The patient assignment infor-
mation was maintained by the Pharmacy”
Comment: the entire randomisation pro-
cess was performed by third party so the
random sequence is unlikely to have been
manipulated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
and “The patient assignment information
was maintained by the Pharmacy”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of oral mucositis using this scale, re-
quiring the patient’s assessment of pain/
soreness and their ability to swallow but,
as the participants were unaware of their
group allocation, the assessment of oral
mucositis can be considered to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Overall attrition was 10%. Reasons for at-
trition fully reported. If all participants
would have developed severe oral mucositis
or dropped out due to severe oral mucositis
and were all from 1 particular group, this
would have biased the results. However, at-
trition was not reported by group, so it is
unclear
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Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Cesaro 2013
Methods Trial design: parallel (2 arms)
Location: Italy
Number of centres: 4
Study duration: May 2007 to June 2011
Trials registry number: EudraCT 2007-001430-14 (mentioned in trial report)
Participants Inclusion criteria: aged 0 to 17 years with leukaemia, lymphoma or solid tumour; due
to receive a first autologous PBSCT
Exclusion criteria: not reported
Cancer type: leukaemia/lymphoma (Group A: 22%; Group B: 17%); solid (Group
A: 78%; Group B: 83%) (neuroblastoma, Ewing sarcoma/peripheral neuroectodermal
tumour, medulloblastoma, Wilms tumour, central nervous system tumour)
Cancer treatment: all participants had autologous PBSCT on day 0 but differed in
conditioning regimen as follows:
• Chemotherapy: multiple regimens involving 1 to 4 chemotherapy drugs; the most
common regimen was busulfan 16 mg/kg with melphalan 140 mg/m² (Group A: 53%;
Group B: 37%)
• Radiotherapy: only 4 participants (2 in each arm) had TBI 12 Gy to 14.4 Gy
prior to their chemotherapy
Age at baseline (years): Group A: median 11.1 (range 1.7 to 17.4); Group B: median
11.9 (range 1.6 to 17.2)
Gender: Group A: 66% male; Group B: 59% male
Number randomised: 61 (Group A: 32; Group B: 29)
Number evaluated: 61 (Group A: 32; Group B: 29)
Interventions Comparison: G-CSF (pegfilgrastim) versus G-CSF (filgrastim)
Group A: pegfilgrastim single dose (100 µg/kg; maximum 6 mg) injected on day 3
Group B: filgrastim (5 µg/kg per day; maximum 300 µg per day) injected by 9 or more
doses starting on day 3 (total dose = at least 45 µg/kg)
Mode of administration not described but presumably subcutaneously as in other G-
CSF studies
Compliance: all participants received their allocated intervention with no discontinua-
tions
Duration of treatment: Group A: 1 day; Group B: 9 or more days
Outcomes • Oral mucositis: WHO 0 to 4 scale (reported as incidence of any mucositis and
grade 2 to 4 i.e. moderate to severe) (duration of any mucositis also measured but not
an outcome of this review)
• Normalcy of diet (measured as incidence of TPN) (duration of TPN also
measured but not used for analysis in review)
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• Adverse events
• Number of days in hospital (reported as median and range, unable to use data)
• Polymorphonuclear cell recovery (not an outcome of this review)
• Time to platelet engraftment (not an outcome of this review)
• Incidence of febrile neutropenia and proven infection (not an outcome of this
review)
• Duration of IV antibiotics (not an outcome of this review)
• Survival (not an outcome of this review)
Notes Sample size calculation: based on the noninferiority of pegfilgrastim versus filgrastim
in speeding the recovery of polymorphonuclear cells
Funding: “The authors have no support or funding to report”
Declarations/conflicts of interest: “The authors have declared that no competing in-
terests exist”
Data handling by review authors:N/A
Other information of note: G-CSF administration only began after the chemotherapy
and PBSCT were completed, by which point oral mucositis may have already begun to
develop
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A computer-generated randomisa-
tion list was drawn up at Data Office Cen-
tre of AIEOP in Bologna, Italy, by a statisti-
cian not involved in patient management”
Comment: adequate method used
Allocation concealment (selection bias) Low risk Quote: “The list was stored by sequentially
numbered sealed envelopes that was con-
cealed to investigators until the completion
of recruitment. The local investigator ...as-
signed each eligible patient to randomiza-
tion list by phoning to AIEOPData Office
Centre”
Comment: ideal method of concealment
used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment regimens were different so
blinding not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It would be possible to blind the outcome
assessor for oral mucositis, but it was not
mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
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Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Chi 1995
Methods Trial design: cross-over (2 arms)
Location: Cancer Centre and Department of Otolaryngology, Veterans General Hospi-
tal, Taiwan, Republic of China
Number of centres: 1
Study duration: not reported
Trials registry number: none/unknown
Participants Inclusion criteria: diagnosed stage IV SCC of head and neck, previously untreated or
locally recurrent after previous surgery or radiotherapy or both; ECOG score of 2 or
above; adequate bone marrow, liver and renal function
Exclusion criteria: concurrent medical illness; local radiotherapy to oropharynx region
in the previous 3 months
Cancer type: head and neck: nasopharyngeal (Group A: 44%; Group B: 27%); tongue
(Group A: 22%; Group B: 36%); hypopharynx (Group A: 11%; Group B: 18%); buccal
(Group A: 11%; Group B: 9%); tonsillar (Group A: 11%; Group B: 9%)
Cancer treatment: PFL regimen (21-day cycle): cisplatin (20 mg/m²/day), 5FU (800
mg/m²/day) and leucovorin (90 mg/m²/day) IV for days 1 to 4; cycle repeated every 3
weeks (study consisted of 2 cycles)
Age at baseline (years): Group A: median 44 (range 36 to 62); Group B: median 49
(range 40 to 66)
Gender: Group A: 89% male; Group B: 91% male
Number randomised: 20 (Group A: 9; Group B: 11) - figures for first cycle
Number evaluated: 20 (Group A: 9; Group B: 11)
Interventions Comparison: GM-CSF versus no treatment
Group A: GM-CSF (4 µg/kg) subcutaneously from day 5 to 14 (total dose = 40 µg)
Group B: no treatment
Compliance: not reported
Duration of treatment: 10 days (days 5 to 14 of 21-day cycle)
Outcomes • Oral mucositis: RTOG 0 to 4 scale (measured on days 5 to 21 by both physician’s
objective gross score and participant’s subjective functional score, reported as area
under the curve and also in the text as incidence of severe gross mucositis i.e. grade 3 to
4) (duration of grade 2 to 4 and 3 to 4 oral mucositis also measured but not an
outcome of this review)
• Adverse effects (assessed across both cycles)
Notes Sample size calculation: not reported
Funding: “..supported in part by Department of Health, Taiwan, Republic of China,
research grant no. DOH 83-HR-202” and “GM-CSF (supplied by Schering Plough
Corp, Kenilworth, NJ)” (pharmaceutical industry)
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Declarations/conflicts of interest: not reported
Data handling by review authors: as stated in the methods section, we would only
include first-period data from cross-over studies due to potential for period effects (which
were reported in this study). The only usable data in this study were reported in the text
as incidence of severe gross mucositis for the first cycle
Other information of note: the authors report a significant period effect of GM-CSF
(P < 0.01), whereby the benefits continued into the second cycle
GM-CSF administration only began after the 4-day chemotherapy was completed, by
which point oral mucositis may have already begun to develop
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomized to re-
ceive GM-CSF or no therapy”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomized to re-
ceive GM-CSF or no therapy”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comparison with no treatment so blinding
not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It would be possible to blind the outcome
assessor, as the datawe usedwere assessed by
a physician using an objective scale. How-
ever, it was not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants appear to be
included in the analyses
Selective reporting (reporting bias) Low risk Although most of the data were not usable
in this review, this does not seem to be due
to selective reporting
Other bias Low risk No other sources of bias are apparent
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Methods Trial design: parallel (2 arms)
Location: USA
Number of centres: 14
Study duration: recruitment from May 1988 to November 1989
Trials registry number: none/unknown
Participants Inclusion criteria: newly diagnosed small-cell lung cancer meeting standard criteria for
end-organ function; ECOG score of 0 to 2
Exclusion criteria: previous radiotherapy; other serious medical illnesses precluding
participation
Cancer type: small-cell lung cancer
Cancer treatment: CAE regimen (21-day cycle): cyclophosphamide (1000 mg/m²) and
doxorubicin (50 mg/m²) on day 1; etoposide (120 mg/m²) on days 1 to 3; all by IV;
repeated for up to 6 cycles
Age at baseline (years): Group A: mean 61 (SD 10; range 31 to 78); Group B: mean
62 (SD 8; range 31 to 80)
Gender: Group A: 65% male; Group B: 63% male
Number randomised: 211 (Group A: 101; Group B: 110)
Number evaluated: 195 (Group A: 93; Group B: 102) - figures for first cycle
Interventions Comparison: G-CSF (r-metHuG-CSF) (filgrastim) versus placebo
Group A: G-CSF (230 µg/m²) self-administered subcutaneously on days 4 to 17 (total
dose = 3220 µg/m²)
Group B: as above but with placebo
G-CSF stopped if postnadir neutrophil count exceeded 10 x 10 /L after day 12; par-
ticipants kept receiving their allocated intervention until they experienced fever with
neutropenia, then they received unblinded G-CSF (230 µg/m²) in subsequent cycles;
participants in the G-CSF group who experienced fever with neutropenia were allowed
25% reduction in chemotherapy dosages in subsequent cycles
Compliance: not reported
Duration of treatment: 14 days during a 21-day cycle
Outcomes • Oral mucositis: WHO 0 to 4 scale (measured weekly, reported as incidence of any
mucositis) (duration and time to onset of oral mucositis also measured but not an
outcome of this review)
• Adverse effects (assessed over the 6 cycles)
• Number of days in hospital (reported graphically in secondary trial report with no
SD or P value, no usable data)
• Incidence, duration and severity of fever with neutropenia (not an outcome of
this review)
• Incidence and duration of antibiotic use (not an outcome of this review)
Notes Sample size calculation: based on a difference of 20% in the incidence of fever with
neutropenia over the 6 cycles
Funding: “The study was designed, coordinated, and analyzed in conjunction with
Amgen, the supplier of the G-CSF”
Declarations/conflicts of interest: not reported but some authors were employed by
Amgen (pharmaceutical industry)
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Data handling by review authors: for oral mucositis, we only used the data from the
first cycle due to the reasons listed above (under ’Interventions’)
Other information of note: G-CSF administration only began after the 3-day che-
motherapy was completed, by which point oral mucositis may have already begun to
develop
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomly as-
signed to chemotherapy followed by study
drug (either placebo or G-CSF)”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “The patients were randomly as-
signed to chemotherapy followed by study
drug (either placebo or G-CSF)”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Placebo was supplied in matching
vials for double blinding”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Placebo was supplied in matching
vials for double blinding”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of oral mucositis using this scale, re-
quiring the patient’s assessment of pain/
soreness and their ability to swallow but,
as the participants were unaware of their
group allocation, the assessment of oral
mucositis can be considered to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall attrition was 8% (Group A: 8%;
Group B: 7%) for the oral mucositis inci-
dence outcome. The reasons were reported
and similar between groups, and this pro-
portion of attrition is unlikely to have bi-
ased the results
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
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Crawford 1999 (Continued)
Other bias Low risk No other sources of bias are apparent
Dazzi 2003
Methods Trial design: parallel (2 arms)
Location: Ravenna, Italy
Number of centres: 1
Study duration: recruitment from July 1997 to February 2002
Trials registry number: none/unknown
Participants Inclusion criteria: 14 years of age or older; hospitalised for high-dose chemotherapy
with autologous PBSCT
Exclusion criteria: not reported
Cancer type: breast (Group A: 17.5%; Group B: 27.5%); Ewing’s sarcoma (Group A:
41.5%; Group B: 28.5%); osteosarcoma (Group A: 13%; Group B: 14%); NHL (Group
A: 15%; Group B: 11.5%); germ cell tumours (Group A: 11%; Group B: 16%); small-
cell lung (Group A: 2%; Group B: 0%); soft tissue sarcoma (Group A: 0%; Group B: 2.
5%)
Cancer treatment: high-dose chemotherapy with autologous PBSCT; chemotherapy
regimens were categorised into high risk and low risk and this was used as a stratifi-
cation factor for randomisation, therefore high- and low-risk participants were equally
distributed across groups
All participants received subcutaneous G-CSF (300 µg/day) until haematopoietic recon-
stitution
Age at baseline (years): Group A: median 29 (range 15 to 57); Group B: median 29
(range 17 to 61)
Gender: Group A: 59% male; Group B: 55% male
Number randomised: 90 (Group A: 46; Group B: 44)
Number evaluated: 90 (Group A: 46; Group B: 44)
Interventions Comparison: GM-CSF versus placebo
Group A: GM-CSF mouthwash 150 µg/day in 100 cm³ of sterile water taken in 4
doses per day; mouthrinsing performed for 1 minute each time; treatment started on the
day after the completion of chemotherapy and continued until bone marrow recovery
(absolute neutrophil count > 500/mm³) or resolution of mucositis if still persistent after
bone marrow recovery (total dose = variable)
Group B: as above but with placebo (sterile water)
All participants received 0.2% oral chlorhexidine and amphotericin B
Compliance: all but 7 participants regularly completed mouthwashes: 1 participant in
the placebo group had none due to persistent vomiting; 6 (4 in placebo group and 2 in
GM-CSF group) started treatment but interrupted it early due to nausea and vomiting
Duration of treatment: variable and dependent on bone marrow recovery/resolution of
mucositis
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Outcomes • Oral mucositis: NCI-CTC 0 to 4 scale (measured daily by the physicians,
reported as incidence of mucositis and incidence of grade 3 to 4 i.e. severe) (duration of
grade 3 to 4 oral mucositis also measured but not an outcome of this review)
• Oral pain: 0 to 10 VAS (self-evaluated daily, reported as mean worst score
experienced)
• Number of days of treatment with opioid analgesics (also reported as incidence;
we did not use these data)
Notes Sample size calculation: 90 participants required to detect 25% minimal difference in
the rate of severe mucositis at 90% power and 5% significance
Funding: no external funding (from correspondence with authors)
Declarations/conflicts of interest: not reported
Data handling by review authors: the data for incidence of mucositis were presented
in subgroups of those at low or high risk of mucositis but we used the overall data in our
meta-analyses
Other information of note: there does not appear to be any difference in risk of any or
severe mucositis between the low- and high-risk subgroups
GM-CSF administration only began after the chemotherapy was completed, by which
point oral mucositis may have already begun to develop
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from correspondence with authors:
“The randomization list was centralized”
Comment: centralised randomisation
method - likely to be done properly
Allocation concealment (selection bias) Low risk Quote from correspondence with authors:
“The randomization list was centralized”
Comment: centralised randomisation
method - likely to be done properly
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, random-
ized, placebo-controlled study” and “The
color, odor, texture and taste of both solu-
tions were virtually identical”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, randomized,
placebo-controlled study”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
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Dazzi 2003 (Continued)
ment of oral mucositis using this scale, re-
quiring the patient’s assessment of pain/
soreness and their ability to swallow but,
as the participants were unaware of their
group allocation, the assessment of oral
mucositis can be considered to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Fink 2011
Methods Trial design: parallel (2 arms)
Location: Department of Hematology and Oncology, University Hospital Freiburg,
Germany
Number of centres: 1
Study duration: March 2006 to December 2010
Trials registry number: EudraCT 2008-001833-87; DRKS00000043
Participants Inclusion criteria: adults aged 18 to 75 years with either: high-grade non-Hodgkin’s
lymphoma with high-risk syndrome (> 2 risk factors according to age-adapted IPI =
international prognostic index) in the first complete remission; Hodgkin’s lymphoma
in the first recurrence; recurrence of follicular lymphoma; primary therapy of a coat-
cell lymphoma (MCL) in stage II-IV; due to receive BEAM chemotherapy followed by
autologous PBSCT; Karnofsky performance score more than 60%; life expectancy more
than 3 months
Exclusion criteria: previous therapy using palifermin; severe concomitant diseases with
organ failure; pregnancy, lactation, positive pregnancy test; hypersensitivity to 1 of the
trial drugs; severe psychiatric illness; HIV disease or immunologic deficiency; known
central nervous system involvement
Cancer type: haematologic: diffuse large-cell lymphoma (Group A: 33%; Group B:
42%); B-cell type acute lymphocytic leukaemia (Group A: 10%; Group B: 6%); T-
cell non-Hodgkin’s lymphoma (Group A: 13%; Group B: 11%); follicular/mantle cell
lymphoma (Group A: 27%; Group B: 28%); Hodgkin’s lymphoma (Group A: 17%;
Group B: 14%)
Cancer treatment: prior to receiving autologous PBSCT on day 0, participants received
BEAMconditioning regimen fromday -8 to -2: carmustine (BCNU) 300mg/m²; etopo-
side 800 mg/m²; cytosine arabinoside 1600 mg/m²; melphalan 140 mg/m²
Age at baseline (years): (ITT population) Group A: median 50 (range 22 to 71); Group
B: median 55 (range 22 to 73)
Gender: (ITT population) Group A: 57% male; Group B: 61% male
Number randomised: 73 (Group A: 37; Group B: 36)
Number evaluated: ITT: 66 (Group A: 30; Group B: 36); PP: 54 (Group A: 22; Group
B: 32)
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Interventions Comparison: KGF (palifermin) plus best supportive care versus best supportive care
alone
Group A: KGF (60 µg/kg) by IV daily for 3 days (days -10, -9, -8) prior to conditioning
regimen and autologous PBSCT and then for 3 days after (days 0, 1, 2) (total dose =
360 µg/kg)
Group B: best supportive care (“effective oral hygiene like teeth brushing, oral rinsing”)
beginning on day -8 (the day of hospital admission for BEAM conditioning)
Compliance: Group A: 7/37 withdrew before therapy started, 3/37 had a different
conditioning regimen to that specified in the study protocol (unclear if they still received
KGF), 5/37 either had no KGF or did not receive all doses; Group B: 4/36 had a different
conditioning regimen to that specified in the study protocol (unclear if they still received
control intervention)
Duration of treatment: 6 treatment days (over 13 days)
Outcomes • Oral mucositis: WHO 0 to 4 scale (measured daily during hospital stay by trained
nurses, study assistant, or treating physician, maximum score reported) (duration of
oral mucositis also measured but not an outcome of this review)
• Normalcy of diet (measured as incidence of TPN)
• Adverse events
• Number of days in hospital (medians reported, unable to use data)
• Number of days of treatment with opioid analgesics (medians reported, unable to
use data)
• Survival (not an outcome of this review)
• Febrile neutropenia (not an outcome of this review)
Notes Sample size calculation: 76 participants required to detect 30% difference in the rate
of severe mucositis at 80% power and 5% significance
Funding: Amgen (pharmaceutical industry)
Declarations/conflicts of interest: not reported
Data handling by review authors: data for ITT population used
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly assigned”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “randomly assigned”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The randomization result was
known to the patient as well as to the prac-
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titioners before the start of therapy”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The randomization result was
known to the patient as well as to the prac-
titioners before the start of therapy”
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall attrition was 10% (Group A: 19%;
Group B: 0%) for the ITT population. All
7 participants died before therapy started.
Although this reason is not related to the
outcomes, the balance created by randomi-
sation may have been lost
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Freytes 2004
Methods Trial design: parallel (3 arms)
Location: USA
Number of centres: 8
Study duration: not reported
Trials registry number: none/unknown
Participants Inclusion criteria: aged 18 years or older; due to receive autologous HSCT with a
conditioning regimen with a high propensity for producing mucositis (typically 50%
incidence of NCI-CTC grade 3 or 4 when receiving standard mucositis management)
; Karnofsky performance score of 70%; free of acute or significant chronic dental or
periodontal disease at baseline examination
Exclusion criteria: previous HSCT; visible oral ulcerations at screening; pregnant or
breastfeeding; childbearing potential or not using adequate contraception; history of
allergy to Escherichia coli-derived products; posterior subcapsular cataract identified at
screening; history of thyroid disease prior to receiving chemotherapy (except for hypothy-
roidism adequately controlled with replacement therapy); history or clinical evidence of
active significant acute or chronic diseases that may affect evaluation or interpretation of
the effects of the study medication on mucositis; following medications: interleukin 11,
topical steroids, sucralfate, hydrogen peroxide, pilocarpine, misoprostol, oral chlorhexi-
dine rinses, or any agent that would affect the assessment of changes in the appearance
of mucositis during the study
Cancer type: lymphoma (Group A: 64%; Group B: 71%; Group C: 57%); other hae-
matologic malignancy (Group A: 36%; Group B: 29%; Group C: 43%)
Cancer treatment: prior to receiving autologous HSCT, participants received the fol-
lowing conditioning regimens:
• CBV (cyclophosphamide, etoposide, and carmustine) (Group A: 50%; Group B:
64%; Group C: 43%)
• melphalan monotherapy (Group A: 7%; Group B: 21%; Group C: 14%)
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• melphalan combination (Group A: 21%; Group B: 14%; Group C: 28%)
• cyclophosphamide + TBI (total body irradiation) (Group A: 7%; Group B: 0%;
Group C: 14%)
• thiotepa + TBI (Group A: 7%; Group B: 0%; Group C: 0%)
• cyclophosphamide + busulfan (Group A: 7%; Group B: 0%; Group C: 0%)
Age at baseline (years):Group A: mean 54 (SD 10); Group B: mean 47 (SD 10); Group
C: mean 51 (SD 15)
Gender: Group A: 79% male; Group B: 64% male; Group C: 79% male
Number randomised: 42 (Group A: 14; Group B: 14; Group C: 14)
Number evaluated: 42 (Group A: 14; Group B: 14; Group C: 14)
Interventions Comparison: KGF-2 (repifermin) versus placebo
Group A: KGF-2 (25 µg/kg) by IV daily for 3 days prior to conditioning regimen and
autologous HSCT and then for 10 days after (total dose = 325 µg/kg)
Group B: KGF-2 (50 µg/kg) as above (total dose = 650 µg/kg)
Group C: placebo as above
Compliance: not reported
Duration of treatment: 13 treatment days (over a longer period dependent on condi-
tioning regimen)
Outcomes • Oral mucositis: NCI-CTC 0 to 4 scale (incidence of grade 2, 3 or 4, assessed prior
to conditioning regimen, on day of HSCT, then 3 times per week until resolution of
mucositis)
• Oral mucositis: OMAS 0 to 45 scale (reported as mean worst score and mean 3
worst scores, NCI-CTC data used for analysis)
• Oral and oropharyngeal pain: 0 (no pain) to 10 (worse pain) scale (assessed on
days reported above, reported as mean worst score experienced)
• Normalcy of diet: ability to eat 1 to 4 score, where 1 = normal, 2 = only soft
solids, 3 = only liquids, 4 = no solids or liquids (assessed on days reported above,
reported as mean worst score)
• Adverse events (assessed from the start of the intervention until 28 days after the
final dose, reported as events with a statistically significant difference between groups
or that occurred in at least 50% of participants in any group and differed between
groups by at least 10%)
• Number of days of treatment with opioid analgesics (assessed as reported for oral
mucositis outcome, reported as mean number of days due to mucositis pain, and mean
number of days due to all pain; we used the former although acknowledge other studies
typically do not specify whether or not they are reporting usage due to mucositis pain)
• Pain on swallowing (not an outcome of this review)
• Laboratory parameters (not outcomes of this review)
• Immunogenicity (not an outcome of this review)
• Electrocardiogram abnormalities, chest x-ray assessments and ophthalmologic
examinations (not outcomes of this review)
Notes Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
Data handling by review authors: we combined the 2 KGF-2 groups to make a single
pairwise comparison against placebo and we also made a comparison of the 2 different
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KGF-2 dosages against each other
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from correspondence with authors:
“Themethod to implement the random al-
location was by central telephone”
Comment: centralised randomisation
method - likely to be done properly
Allocation concealment (selection bias) Low risk Quote from correspondence with authors:
“Themethod to implement the random al-
location was by central telephone”
Comment: centralised randomisation
method - likely to be done properly
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blinded, placebo-
controlled”
Comment: the use of a placebo and iden-
tical schedule of treatment for all 3 arms
should have ensured that blinding was suc-
cessful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blinded, placebo-
controlled”
Comment: it is not clear who was blinded.
There are subjective elements to the as-
sessment of oral mucositis using the NCI-
CTC scale, requiring the patient’s assess-
ment of pain/soreness and their ability to
swallow but, as the participants were un-
aware of their group allocation, the assess-
ment of oral mucositis can be considered
to be blinded. This would be the same for
other subjective outcomes. The objective
outcomes are unlikely to be affected by any
potential lack of blinding of the outcome
assessor(s)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
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Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Gholizadeh 2016
Methods Trial design: parallel (2 arms)
Location: Iran
Number of centres: not reported
Study duration: not reported
Trials registry number: IRCT2013021812510N1 (mentioned in trial report)
Participants Inclusion criteria: previously untreated acute lymphoblastic leukaemia patients; aged
between 5 and 18 years
Exclusion criteria: any other systemic disease; presence of oral mucositis or other oral
lesions prior to chemotherapy; history of dermatology or respiratory hypersensitivity;
acute lymphoblastic leukaemia recurrence
Cancer type: acute lymphoblastic leukaemia (ALL)
Cancer treatment: induction chemotherapy protocol consisted of standard risk B-pre-
cursor ALL (COG)/dexamethasone, vincristine, L-asparaginase, intrathecal (methotrex-
ate + ara-C + hydrocortisone). The intensification protocol was dexamethasone, vin-
cristine, L-asparaginase/ dexamethasone, cyclophosphamide/6-thioguanine + cytarabine
+ intrathecal methotrexate
Age at baseline (years): Group A: mean 8.8 (SD 2.5); Group B: mean 8.4 (SD 2.2);
overall range: 5 to 18
Gender: Group A: 49% male; Group B: 49% male
Number randomised: 90 (Group A: 45; Group B: 45)
Number evaluated: 90 (Group A: 45; Group B: 45)
Interventions Comparison: KGF (palifermin) versus chlorhexidine
Group A: KGF (60 µg/kg) by IV bolus daily for 3 days prior to chemotherapy regimen
and then for 3 days after (total dose = 360 µg/kg)
Group B: chlorhexidine (concentration not reported) mouthwash used for 1 minute
once daily for 3 days prior to chemotherapy regimen and then for 3 days after
Compliance: not reported
Duration of treatment: 6 treatment days (over an unspecified longer period)
Outcomes • Oral mucositis: WHO 0 to 4 scale (measured after 1 and 2 weeks and reported
separately for each time point)
• Adverse events
Notes Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: “There is no conflict of interest in relation to this
study”
Data handling by review authors: we report the data at 2 weeks as they represent the
maximum oral mucositis score experienced better than those at 1 week
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Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The patients were randomly as-
signed to the palifermin or control group
by using the table of random numbers”
Comment: adequate method used
Allocation concealment (selection bias) Unclear risk Quote: “The patients were randomly as-
signed to the palifermin or control group
by using the table of random numbers”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comparison with chlorhexidine so blind-
ing not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Each patient was evaluated for oral
lesions one and two weeks after the chemo-
therapy completion by the same specialist
who was blind to the type of treatment”
and “This limited use of chlorhexidine was
to prevent the adverse effects like tooth dis-
coloration and temporally taste changes”
Comment: grade 1 on this scale would
require the unblinded participant’s assess-
ment of soreness but other aspects of the
scale are more objective and were assessed
by a blinded assessor. Also, blinding may
not have been broken by staining/dis-
colouration due to limited use of chlorhex-
idine
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
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Methods Trial design: parallel (2 arms)
Location: Australia, Canada, and Europe (Austria, France, Germany, Italy, Spain, UK)
Number of centres: 38
Study duration: recruitment from January 2005 to August 2007
Trials registry number: NCT00131638; 2004-002016-28 (EudraCT number)
Participants Inclusion criteria:more than 18 years old; resected for pathohistologically documented
high-risk stage 2 to 4B SCC of the oral cavity, oropharynx, hypopharynx, or larynx;
ECOG score of 0 to 2; at least 2 of 9 areas of the oral or oropharyngeal mucosa due to
receive at least 50 Gy RT
Exclusion criteria: tumours of the lips, paranasal sinuses, salivary glands, or unknown
primary site;metastatic disease; history of chronic pancreatitis or acute pancreatitiswithin
the last year; prior RT to the head and neck region or prior chemotherapy; previous
treatment on this study or with other KGFs
Cancer type: head and neck: oropharynx (Group A: 47%; Group B: 48%); oral cavity
(Group A: 32%; Group B: 27%); larynx (Group A: 11%; Group B: 15%); hypopharynx
(Group A: 10%; Group B: 10%); other (Group A: 1%; Group B: 1%)
Cancer treatment: after R0 or R1 resection:
• radiotherapy: standard fractionation of once daily 2-Gy fractions, 5 days per
week; total 60 Gy (for R0 resection) over 6 weeks, or 66 Gy (for R1 resection) over 7
weeks, both with allowable range of ± 15%
• chemotherapy: cisplatin (100 mg/m²) by IV after appropriate hydration on days 1
and 22 (for R0 resection), or days 1, 22 and 43 (for R1 resection)
Age at baseline (years): Group A: mean 56 (SD 8); Group B: mean 57 (SD 9)
Gender: Group A: 85% male; Group B: 80% male
Number randomised: 186 (Group A: 92; Group B: 94)
Number evaluated: 186 (Group A: 92; Group B: 94)
Interventions Comparison: KGF (palifermin) versus placebo
Group A: KGF (120 µg/kg) 3 days prior to start of, and then once per week during
radiochemotherapy, i.e. 7 doses for those with R0 resection, 8 doses for those with R1
resection (total dose = 840 µg/kg or 960 µg/kg respectively)
Group B: same schedule with placebo
Mode of administration not described but presumably IV as in other KGF studies
Compliance: 78% of participants in KGF group completed all planned doses compared
to 86% in placebo group
Duration of treatment: 7 or 8 treatment days (over 7 or 8 weeks), depending on R0 or
R1 resection respectively
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed twice weekly by trained evaluators
during radiochemotherapy and then until either mucositis had reduced to grade 2 or
lower or week 15, whichever occurred first, maximum score reported) (duration and
time to onset of grade 3 to 4 oral mucositis also measured but not outcomes of this
review)
• Interruptions to cancer treatment: incidence of 5 or more missed consecutive RT
fractions; incidence of chemotherapy delays/discontinuations
• Oral pain: OMWQ-HN 0 (no soreness) to 4 (extreme soreness) scale for mouth
and throat soreness
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• Normalcy of diet (measured as incidence of supplemental feeding by TPN, PEG,
nasogastric tube, or IV hydration) (broken down by overall supplemental feeding and
also where due to oral mucositis; we used the latter although acknowledge other studies
do not specify reason for supplemental feeding)
• Adverse events: reported as those with a difference in incidence of at least 5%
between arms
• Use of opioid analgesics (total dose reported but not an outcome of this review)
• Xerostomia (not an outcome of this review)
• Weight change (not an outcome of this review)
• Laboratory assessments (not an outcome of this review)
• Survival (not an outcome of this review)
Notes Sample size calculation: assuming 60% of placebo group would develop grade 3 to 4
mucositis, 90 per group required to detect a reduction of at least 25% at 90% power
and 5% significance
Funding: “This study was supported by Amgen” (Amgen also named as sponsor on trials
registry - pharmaceutical industry)
Declarations/conflicts of interest: some authors had both employment or leadership
positions and stock ownership within Amgen
Data handling by review authors:N/A
Other information of note: study originally randomised participants to 3 arms (180 µg/
kg once per week for 7 weeks, 180 µg/kg once per week for 4 weeks followed by placebo
for the next 3 doses, or placebo throughout) but, after 1 serious adverse event of respi-
ratory insufficiency reported in 1 of the first 10 participants, the data monitoring com-
mittee decided to restart the study using 120 µg/kg doses, excluding the 17 randomised
participants from the efficacy assessments. The arm with KGF for 4 weeks followed by
placebo was stopped due to slow recruitment, after enrolment of 38 participants, and
the results analysed in a separate appendix
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random assignment was made by
a centralized interactive voice response sys-
tem”
Comment: large multicentre trial using
high-tech randomisation method - likely to
be done properly
Allocation concealment (selection bias) Low risk Quote: “Random assignment was made by
a centralized interactive voice response sys-
tem”
Comment: large multicentre trial using
high-tech randomisation method - likely to
be done properly
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, randomized,
placebo-controlled”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, randomized,
placebo-controlled”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of lower grades of oral mucositis us-
ing the WHO scale, requiring the patient’s
assessment of pain/soreness and their abil-
ity to swallow.Higher grades havemore ob-
jective elements so may not be affected by
potential lack of blinding of the assessor.
This would be the same for other subjective
and objective outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Hosseinjani 2017
Methods Trial design: parallel (2 arms)
Location: Tehran University of Medical Sciences, Tehran, Iran
Number of centres: 1
Study duration: February 2014 to March 2015
Trials registry number: IRCT2015042518842N8 (mentioned in trial report)
Participants Inclusion criteria: aged 18 years or older with non-Hodgkin’s lymphoma, Hodgkin’s
disease or multiple myeloma; due to receive autologous HSCT; adequate cardiac, pul-
monary, renal and hepatic function
Exclusion criteria:Karnofsky performance score less than 70%; participation in another
study using an unlicensed product
Cancer type: haematologic: non-Hodgkin’s lymphoma (Group A: 25%; Group B: 25%)
; Hodgkin’s disease (Group A: 23%; Group B: 23%); multiple myeloma (Group A: 53%;
Group B: 53%)
Cancer treatment: prior to receiving autologous HSCT, participants received the fol-
lowing conditioning regimens:
• Hodgkin’s/non-Hodgkin’s: high-dose combination chemotherapy (carboplatin
750 mg/m² IV daily for 2 days, etoposide 300 mg/m² IV daily for 2 days, cytarabine
300mg/m²/dose IV 2 doses in each day for 2 days, and melphalan 140 mg/m² IV for 1
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day)
• Multiple myeloma: high-dose melphalan (100 mg/m² IV daily for 2 days)
Age at baseline (years): Group A: mean 43 (SD 14); Group B: mean 45 (SD 16)
Gender: Group A: 55% male; Group B: 48% male
Number randomised: 80 (Group A: 40; Group B: 40)
Number evaluated: 80 (Group A: 40; Group B: 40)
Interventions Comparison: Erythropoietin (recombinant human) versus placebo
Group A: 50 IU/mL erythropoietin mouthwash in aqueous vehicle (sodium benzoate,
sodium citrate, citric acid, sodium hydroxide, sugar and distilled water) supplied in glass
bottle stored at 4°C, 15 mL 4 times daily, starting from the first day of conditioning che-
motherapy until 14 days after HSCT or until discharge from hospital (i.e. neutrophil re-
covery), whichever occurred first, oral intake not permitted for 1 hour following mouth-
washing
Group B: same schedule with placebo (aqueous vehicle-only)
All participants received oral hygiene care in addition to 20 drops of nystatin every
3 hours, mouthwashes containing 10 mL chlorhexidine 0.02% plus 10 mL diluted
povidone iodine every 3 hours
Compliance: “However, it was a limitation of our study that EPO mouthwash admin-
istration might be affected by patients’ low compliance” (no data reported)
Duration of treatment: variable and dependent on neutrophil recovery
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed daily by single trained pharmacist
starting from the first day of conditioning chemotherapy and then until either 21 days
after HSCT or mucositis had resolved, whichever occurred first, maximum score
reported) (duration and time to onset reported but not outcomes of this review)
• Number of days in hospital
• Use of opioid analgesics (incidence reported but not an outcome of this review)
• Blood measurements (not an outcome of this review)
• Incidence and duration of fever (not an outcome of this review)
Notes Sample size calculation: 40 per group required assuming a 30% decrease in incidence
of grade 2 to 4 mucositis at 5% significance and 80% power
Funding: “There was no applicable funding source for the clinical trial”
Declarations/conflicts of interest: “The authors have no conflict of interests to report”
Data handling by review authors: there is a discrepancy in the incidence of grade 2
to 4 mucositis between Figure 2 and Table 2 (the latter has 1 extra event per group).
However, this does not change the effect estimate. We have used the data in Table 2 as
it reports numbers of participants along with percentages
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly allocated.
..in a blocked randomization schedule”
and “Both patient randomization and drug
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preparation were performed in the phar-
maceutical laboratory of PharmacyDepart-
ment”
Comment: method of random sequence
generation not described but done by uni-
versity hospital pharmacy and therefore
probably done adequately
Allocation concealment (selection bias) Low risk Quote: “Both patient randomization and
drug preparation were performed in the
pharmaceutical laboratory of Pharmacy
Department”
Comment:
not explicitly described but pharmacy-con-
trolled randomisation should have ensured
concealment of the random sequence from
those recruiting participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, random-
ized, placebo-controlled” and “The study
participants, the attending physician and
the outcome assessor were all blind to the
treatment assignment” and “There were no
differences in colour, flavour, taste or con-
tainer of the study drug and the placebo”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind,
randomized, placebo-controlled” and “The
study participants, the attending physician
and the outcome assessor were all blind to
the treatment assignment”
Comment: all parties were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
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Methods Trial design: parallel (2 arms)
Location: USA (16 sites) and Australia (4 sites)
Number of centres: 20
Study duration: December 2005 to November 2008
Trials registry number: NCT00189488 (mentions obsolete number in trial report:
NCT00964899)
Participants Inclusion criteria: aged 18 years or older with haematologic malignancy (including
myelodysplastic syndromes) and due to receive allogeneic SCT (marrow or PBPC) after
a conditioning regimen; Karnofsky performance score of 70% or more; related donor or
HLA-matched unrelated donor identical at 6/6 HLA-A, -B and -DRB1 loci (molecular
typing of class I and class II for unrelated donors)
Exclusion criteria: other malignancies; prior SCT; previous use of KGF; active infection
or oral mucositis; congestive heart failure (NYHA class III or IV); use of a T-cell depleted
graft for GVHD prophylaxis; inadequate renal, liver or pulmonary function; pregnant
or breastfeeding; refusal to use adequate contraception during study; participation in
another investigational device or drug trial in previous 30 days
Cancer type:haematologic: leukaemia (GroupA: 71%;GroupB: 79%);myelodysplastic
syndrome (Group A: 16%; Group B: 12%); non-Hodgkin’s lymphoma (Group A: 12%;
Group B: 8%); multiple myeloma (Group A: 0%; Group B: 1%); Hodgkin’s disease
(Group A: 1%; Group B: 0%)
Cancer treatment: prior to receiving allogeneic SCT on day 0, participants received 1
of the following conditioning regimens from day -11 to -2:
• cyclophosphamide plus TBI with or without etoposide
• TBI plus etoposide
• melphalan plus TBI > 11 Gy
• busulfan plus cyclophosphamide
• busulfan plus melphalan (fully ablative doses)
• fludarabine plus melphalan (fully ablative doses)
Participants received methotrexate (with a calcineurin inhibitor - either cyclosporine or
tacrolimus) for GVHD prophylaxis on days 1, 3 and 6 (planned), and on day 11 (if
toxicity allowed) at doses of 15 mg/m², 10 mg/m², 10 mg/m² and 10 mg/m² respectively
Age at baseline (years): Group A: median 42 (range 18 to 62); Group B: median 44
(range 18 to 64)
Gender: Group A: 52% male; Group B: 63% male
Number randomised: 155 (Group A: 77; Group B: 78)
Number evaluated: 155 (Group A: 77; Group B: 78)
Interventions Comparison: KGF (palifermin) versus placebo
Group A: KGF (60 µg/kg) by IV bolus daily for 3 days prior to start of conditioning
therapy, then a single 180 µg/kg dose after conditioning, but often 1 or 2 days before
SCT (total dose = 360 µg/kg)
Group B: same schedule with placebo
Compliance: received at least 1 dose: Group A: 99%; Group B: 96%; received all doses:
Group A: 92%; Group B: 88%
Duration of treatment: 4 treatment days (over roughly 14 days)
Outcomes • Oral mucositis: WHO 0 to 4 scale (reported as incidence of grade 2 to 4 i.e.
moderate to severe, and grade 3 to 4 i.e. severe, assessed daily by trained evaluators
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from day -11 (first day of conditioning) and then until hospital discharge or day 28,
whichever occurred first) (duration also measured but not an outcome of this review)
• Normalcy of diet (measured as incidence of TPN)
• Adverse events
• Use of opioid analgesics (incidence reported but not an outcome of this review)
• Incidence and severity of acute GVHD (not an outcome of this review)
Notes Sample size calculation: based on GVHD (not met due to early stopping)
Funding: “This study was supported by research funding from Amgen Inc. Jonathan
Latham of PharmaScribe, LLC received funding from Amgen Inc. to provide assistance
with the preparation of themanuscript. XuesongGuan of Amgen Inc. provided assistance
with statistical analyses” (pharmaceutical industry)
Declarations/conflicts of interest: some authors were employees and stockholders of
Amgen and some received compensation from Amgen for consultation
Data handling by review authors:N/A
Other information of note: planned sample size was 200 participants but the study was
stopped due to slow recruitment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were randomly assigned.
..”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “Subjects were randomly assigned.
..”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
Comment: it is not clear who was blinded
but grades 2 to 4 on the WHO scale are
sufficiently objective and unlikely to be af-
fected by any lack of blinding of the asses-
sors
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Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Katano 1995
Methods Trial design: parallel (2 arms)
Location: Saga Medical School, Saga, Japan
Number of centres: 1
Study duration: not reported
Trials registry number: none/unknown
Participants Inclusion criteria: breast cancer patients
Exclusion criteria: not reported
Cancer type: breast: primary advanced (Group A: 2; Group B: 5); inflammatory (Group
A: 4; Group B: 1); recurrent (Group A: 1; Group B: 1)
Cancer treatment: preoperative IA high-dose adriamycin (10 mg to 40 mg every 2 to 3
days to a total dose of 70 mg to 170 mg)
Age at baseline (years): Group A: mean 53 (SD 11; range 38 to 69); Group B: mean
52 (SD 10; range 45 to 69)
Gender: all female
Number randomised: 14 (Group A: 7; Group B: 7)
Number evaluated: 14 (Group A: 7; Group B: 7)
Interventions Comparison: G-CSF versus no treatment
Group A: G-CSF (125 µg) by daily subcutaneous injection until leukocyte counts >
8000/mm³; timing in relation to chemotherapy not specifically reported, but the group
was further divided into 2 subgroups where one (n = 4) received G-CSF during/as an
adjunct to the chemotherapy, and the other (n = 3) received G-CSF afterwards (after the
leukocyte counts were likely to drop below 2000/mm³)
Group B: no treatment
Compliance: not reported
Duration of treatment: variable and dependent on leukocyte recovery (to > 8000/mm³)
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed once 1 to 7 days prior to
chemotherapy and then every day afterwards by a single experienced examiner,
reported as incidence of grade 2 to 4) (duration of grade 2 to 4 also measured but not
an outcome of this review)
• Blood measurements (not an outcome of this review)
• Alopecia (not an outcome of this review)
• Adult respiratory distress syndrome (not an outcome of this review)
• Fever (not an outcome of this review)
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Notes Sample size calculation: not reported
Funding: “G-CSF (Neutrogin) was provided by Chugai Pharmaceutical”
Declarations/conflicts of interest: not reported
Data handling by review authors: the data for incidence of mucositis were presented
in subgroups of those receiving G-CSF during or after chemotherapy but we used the
overall data in our meta-analyses
Other information of note: both cases of mucositis were in the subgroup who received
G-CSF after chemotherapy. Oral mucositis may have already begun to develop in this
subgroup
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized into two groups”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “randomized into two groups”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comparison with no treatment so blinding
not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It would be possible to blind the outcome
assessor, as the data we used were assessed
by an examiner looking for erythema and
ulcers. However, it was not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
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Methods Trial design: parallel (2 arms)
Location: Seoul National University Hospital, Seoul, South Korea
Number of centres: 1
Study duration: recruitment from March 2009 to August 2014
Trials registry number: NCT00845819 (mentioned in trial report)
Participants Inclusion criteria: aged 18 years or older with haematologic malignancy; due to receive
intensive chemotherapy followed by autologous or allogeneic HSCT; normal oral cavity
(grade 0 mucositis); ECOG score of 0 to 2
Exclusion criteria: received chemotherapy, radiotherapy or surgery within previous 3
weeks; history of allergy to the intervention or similar drugs; participation in other
clinical trials within the previous 4 weeks with the potential to affect study results
Cancer type: haematologic: multiple myeloma (Group A: 57%; Group B: 55%); lym-
phoma (Group A: 36%; Group B: 38%); other (Group A: 7%; Group B: 7%)
Cancer treatment: prior to receiving autologous (Group A: 96%; Group B: 96%) or
allogeneic HSCT, participants received the following conditioning regimens:
• high-dose melphalan (Group A: 57%; Group B: 57%)
• mitoxantrone-etoposide-cytarabine-melphalan (Group A: 15%; Group B: 23%)
• busulfan-etoposide-cytarabine-melphalan (Group A: 19%; Group B: 16%)
• other (Group A: 9%; Group B: 4%)
Age at baseline (years): Group A: median 53 (range 18 to 65); Group B: median 51
(range 19 to 65)
Gender: Group A: 49% male; Group B: 54% male
Number randomised: 138 (Group A: 69; Group B: 69)
Number evaluated: 136 (Group A: 67; Group B: 69)
Interventions Comparison: EGF (recombinant human) versus placebo
Group A: EGF (50 µg/mL) daily by oral spray, applied twice daily, sprayed (6 sprays
per application) over the entire oral mucosa and then swallowed, no oral intake for 30
minutes afterwards; starting on first day of conditioning therapy and continuing until
absolute neutrophil count recovered more than 1000 µL for 3 days and mucositis had
resolved
Group B: placebo as above
Compliance: median patient compliance rate: Group A: 93% (range 35% to 100%);
Group B: 92% (range 18% to 100%)
Duration of treatment: variable and dependent on neutrophil recovery/resolution of
mucositis
Outcomes • Oral mucositis: NCI-CTC (version 3.0) 0 to 4 scale (assessed daily during study
period by researchers, reported as incidence of grade 2 to 4 i.e. moderate to severe, and
grade 3 to 4 i.e. severe) (duration and time to onset reported but not outcomes of this
review)
• Oral pain: mouth and throat soreness 0 to 10 scale (reported as AUC median/
range and only for those who had grade 2 to 4 mucositis - data not usable)
• Quality of life: modified OMDQ (reported as AUC median/range and only for
those who had grade 2 to 4 mucositis - data not usable)
• Normalcy of diet (use of total parenteral nutrition)
• Adverse events (NCI CTC version 3.0)
• Number of days in hospital (listed as an outcome but not reported anywhere in
the results - data not usable)
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• Number of days of treatment with opioid analgesics (reported as median/range
and only for those who had grade 2 to 4 mucositis - data not usable)
• Incidence of febrile neutropenia (not an outcome of this review)
• Blood infections (not an outcome of this review)
• Antibiotic use (not an outcome of this review)
• Clinical laboratory measurements (not outcomes of this review)
Notes Sample size calculation: 62 participants per group required to detect 27% difference
in incidence of grade 2 to 4 mucositis with 80% power and 5% significance
Funding: multiple government grants; Daewoong Pharmaceutical Company (Seoul,
Korea) only supplied interventions but provided no further funding and had no involve-
ment with data collection, analysis or manuscript writing
Declarations/conflicts of interest: none apparent
Data handling by review authors:N/A
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned.
..using a computer-generated randomiza-
tion protocol, by the Medical Research
Collaborating Center, Seoul National Uni-
versity Hospital”
Comment: adequate method used
Allocation concealment (selection bias) Low risk Quote: “Patients were randomly assigned.
..using a computer-generated randomiza-
tion protocol, by the Medical Research
Collaborating Center, Seoul National Uni-
versity Hospital”
Comment: although concealment not ex-
plicitly mentioned, use of centralised/third
party randomisation - likely to be done
properly
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “placebo-controlled, double-blind”
and “clinicians, patients, and investigators
responsible for assessing outcomes and an-
alyzing data were masked to treatment as-
signments”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “placebo-controlled, double-blind”
and “clinicians, patients, and investigators
responsible for assessing outcomes and an-
alyzing data were masked to treatment as-
84Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kim 2017 (Continued)
signments”
Comment: all parties were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 2 of 138 randomised participants
were not included in the analysis
Selective reporting (reporting bias) Low risk Although most of the data were not usable
in this review, this does not seem to be due
to selective reporting
Other bias Low risk No other sources of bias are apparent
Le 2011
Methods Trial design: parallel (2 arms)
Location: Canada, USA and Europe (Hungary, Poland, Austria, Germany, Italy, Czech
Republic)
Number of centres: 46
Study duration: recruitment started August 2005, 4-month follow-up finished Septem-
ber 2007
Trials registry number: NCT00101582; 2005-000213-35 (EudraCT number)
Participants Inclusion criteria: newly diagnosed, unresected stage 3 to 4B SCC of the oral cavity,
oropharynx, nasopharynx, hypopharynx, or larynx; no evidence of secondary malig-
nancy; at least 2 of 9 areas of the oral or oropharyngeal mucosa due to receive more than
50 Gy RT
Exclusion criteria: not reported
Cancer type: head and neck: oropharynx (Group A: 59%; Group B: 54%); oral cavity
(Group A: 5%; Group B: 10%); larynx (Group A: 17%; Group B: 10%); hypopharynx
(Group A: 15%; Group B: 23%); nasopharynx (Group A: 4%; Group B: 3%)
Cancer treatment:
• Radiotherapy: standard fractionation of once daily 2-Gy fractions, 5 days per
week; total 70 Gy over 7 weeks
• Chemotherapy: cisplatin (100 mg/m²) by IV infusion on days 1, 22 and 43
Age at baseline (years): Group A: mean 56 (SD 9); Group B: mean 55 (SD 8)
Gender: Group A: 84% male; Group B: 85% male
Number randomised: 188 (Group A: 94; Group B: 94)
Number evaluated: 188 (Group A: 94; Group B: 94)
Interventions Comparison: KGF (palifermin) versus placebo
Group A: KGF (180 µg/kg) by IV bolus over 30 to 60 seconds, 3 days prior to start of,
and then once per week during radiochemotherapy, i.e. 8 doses (total dose = 1440 µg/
kg)
Group B: same schedule with placebo
Compliance: 93% (SD 19%) of planned KGF doses were administered compared to
96% (SD 14%) in placebo group
Duration of treatment: 8 treatment days (over 8 weeks)
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Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed twice weekly by trained evaluators
during radiochemotherapy and then until either mucositis had reduced to grade 2 or
lower or week 15, whichever occurred first, maximum score reported) (duration and
time to onset of grade 3 to 4 oral mucositis also measured but not outcomes of this
review)
• Interruptions to cancer treatment: incidence of 5 or more missed consecutive RT
fractions; incidence of chemotherapy delays/discontinuations
• Oral pain: OMWQ-HN 0 (no soreness) to 4 (extreme soreness) scale for mouth
and throat soreness (assessed twice weekly by trained evaluators during
radiochemotherapy)
• Normalcy of diet (measured as incidence of supplemental feeding by TPN, PEG,
nasogastric tube, or IV hydration) (duration of supplemental feeding also reported but
not used for analysis)
• Adverse events: NCI-CTC (version 3.0) reported separately for those related to
study drugs
• Use of opioid analgesics (total dose reported but not an outcome of this review)
• Xerostomia (not an outcome of this review)
• Survival (not an outcome of this review)
• Laboratory assessments (not an outcome of this review)
• Antipalifermin antibodies (not an outcome of this review)
Notes Sample size calculation: assuming 60% of placebo group would develop grade 3 to 4
mucositis, 90 per group required to detect a reduction of at least 25% at 90% power
and 5% significance
Funding: “Supported by Amgen” (Swedish Orphan Biovitrum named as sponsor on
trials registry, Amgen named as collaborator - both pharmaceutical industry)
Declarations/conflicts of interest: some authors had both employment or leadership
positions and stock ownership within Amgen; some authors had received research fund-
ing from Amgen
Data handling by review authors:N/A
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A centralized randomization sys-
tem assigned patients to either palifermin
or placebo in a 1:1 ratio”
Comment: large multicentre trial using
centralised randomisation method - likely
to be done properly
Allocation concealment (selection bias) Low risk Quote: “A centralized randomization sys-
tem assigned patients to either palifermin
or placebo in a 1:1 ratio”
Comment: large multicentre trial using
centralised randomisation method - likely
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to be done properly
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “placebo-controlled, double-blind”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “placebo-controlled, double-blind”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of lower grades of oral mucositis us-
ing the WHO scale, requiring the patient’s
assessment of pain/soreness and their abil-
ity to swallow.Higher grades havemore ob-
jective elements so may not be affected by
potential lack of blinding of the assessor.
This would be the same for other subjective
and objective outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Linch 1993
Methods Trial design: parallel (5 arms)
Location: UK
Number of centres: 12
Study duration: recruitment from August 1989 to July 1990
Trials registry number: none/unknown
Participants Inclusion criteria: adults due to receive BMT after conditioning
Exclusion criteria: myeloid malignancies
Cancer type: mixed haematologic and solid (not reported by group): Hodgkin’s disease
(29%); non-Hodgkin’s lymphoma (33%); multiple myeloma (Group A: 20%); ALL
(15%); solid (3%)
Cancer treatment: prior to receiving BMT (autologous 84%; allogeneic 16%), partici-
pants received a conditioning regimen which consisted of chemotherapy only (71%) or
with TBI (29%)
Age at baseline (years): median 36 (range 17 to 64) (not reported by group)
Gender: 69% male (not reported by group)
Number randomised: 121 (Group A: 96; Group B: 25); Group A represents 4 arms
with different dosages
Number evaluated: 121 (Group A: 96; Group B: 25)
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Interventions Comparison: G-CSF versus placebo
GroupA:G-CSF (2 µg/kg, 5 µg/kg, 10 µg/kg or 15 µg/kg) by 30-minute IV daily starting
from the day after BMT transplant and continuing until neutrophil count was > 1.0 x 10
/L for 3 consecutive days or until day 28, whichever occurred first
Group B: as above but with placebo
Compliance: not reported
Duration of treatment: variable and dependent on neutrophil recovery
Outcomes • Oral mucositis: unspecified scale (frequency of measurement not mentioned, no
usable data)
• Adverse events
• Number of days in hospital (median reported, no usable data)
• Neutropenia-related outcomes (not outcomes of this review)
• Antibiotic use (not an outcome of this review)
• Fever (not an outcome of this review)
• Sepsis (not an outcome of this review)
• Blood product use (not an outcome of this review)
Notes Sample size calculation: not reported
Funding: “Financial support for this trial was provided by Chugai Rhone Poulene”
(pharmaceutical industry)
Declarations/conflicts of interest: 1 author was employed by the funders
Data handling by review authors: oral mucositis reported narratively in additional
table
Other information of note: G-CSF administration only began after the conditioning
and BMT transplant were completed, by which point oral mucositis may have already
begun to develop (although time scale of conditioning/BMT transplant not reported)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised...in
blocks of five by a computer-generated ran-
domisation schedule”
Comment: adequate method used
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomised...in
blocks of five by a computer-generated ran-
domisation schedule”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “single blind...vehicle-controlled”
Comment: the use of a placebo (the ’vehi-
cle’) should have ensured that blinding was
successful
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “single blind...vehicle-controlled”
Comment: the quote implies that outcome
assessment was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) High risk Oralmucositis notmentioned in themeth-
ods section as 1 of the study end points. It
is only mentioned in the results narratively
as there being no difference between any
group, but with no data or P value
Other bias Low risk No other sources of bias are apparent
Lucchese 2016a
Methods Trial design: parallel (2 arms)
Location: Vita-Salute San Raffaele University Hospital, Milan, Italy
Number of centres: 1
Study duration: conducted from April 2009 to January 2015
Trials registry number: none/unknown
Participants Inclusion criteria: children aged 7 years or older with B-cell lineage acute lymphoblas-
tic leukaemia; scheduled to receive autologous HSCT after a conditioning regimen;
Karnofsky performance score of 70 or more; were to have at least 1.5 x 10 CD34+ cells
reinfused per kilogram available for transplant; adequate cardiac, pulmonary, renal and
hepatic function
Exclusion criteria: not reported
Cancer type: B-cell lineage acute lymphoblastic leukaemia
Cancer treatment: prior to receiving autologous HSCT (on day 0), participants received
a conditioning regimen which consisted of TBI delivered in 8 fractions over 3 days (-3
to -1) with at least 6 hours between fractions, followed by chemotherapy on day -1 (type
and dose of radiotherapy and chemotherapy not reported)
Age at baseline (years): Group A: median 11 (range 7 to 16); Group B: median 11
(range 7 to 16)
Gender: Group A: 52% male; Group B: 44% male
Number randomised: 60 (Group A: 30; Group B: 30)
Number evaluated: 54 (Group A: 27; Group B: 27)
Interventions Comparison: KGF (palifermin) versus placebo
Group A: KGF (60 µg/kg) by IV, on days -6 (3 days prior to start of conditioning
regimen), -5 and -4, and on days 0 (the day of HSCT), 1, and 2 after transplant (total
dose = 360 µg/kg)
Group B: same schedule with placebo
Compliance: not reported
Duration of treatment: 6 treatment days (over 9 days)
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Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed daily by same clinician from day -7 to
day 28, or until severe mucositis had reduced to grade 0, 1, or 2, data in text and figure
2 do not agree with data in table 3) (duration of grade 2 to 4 and 3 to 4 oral mucositis
also measured but not an outcome of this review)
• Oral pain: OMDQ 5-point scale for mouth and throat soreness (higher = worse
pain) (assessed daily by participant, reported as AUC, not used)
• Normalcy of diet (methods states incidence of supplemental feeding by TPN but
only duration is reported, yet text states enteral and table states parenteral, not used for
analysis) (patient-reported difficulty eating and drinking also assessed daily, both using
OMDQ 0 (no difficulty) to 5 (unable to do) scale, but the means are reported as whole
numbers, data not used)
• Adverse events: NCI-CTC (version 4.0)
• Opioid analgesic use (reported as quantity per day; number of days of treatment
with opioid analgesics is an outcome of this review but only medians were reported,
and therefore we did not use these data)
• GVHD incidence and severity (not an outcome of this review)
• Fever with neutropenia (not an outcome of this review)
• HSV incidence (not an outcome of this review)
• Candidiasis incidence (not an outcome of this review)
• Superinfections incidence (not an outcome of this review)
• Blood measurements (not an outcome of this review)
Notes Sample size calculation: numbers required not reported but was estimated at 80%
power and 5% significance
Funding: “This work was performed with Departmental funding only”
Declarations/conflicts of interest: the authors report that they have no conflict of
interest (supplemental material on journal website)
Data handling by review authors:we emailed the lead author June 2017 for clarification
of the oral mucositis data but, until we receive a response, we are unable to use those
data
Other information of note: unclear definitions of ulcerative (should be grade 2 to 4)
and severe (should be grade 3 to 4): “...ulcerative OM (WHO grades
3 and 4), incidence and duration of severe OM (WHO grades 3 and 4)...”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A centralized randomization sys-
tem assigned patients either to palifermin
or conventional treatment in a 1:1 ratio.....
.The statistician gave randomization list to
the pharmacy, so the patient and the clini-
cal research team (who assessed outcomes)
were blinded to the study treatment”
Comment: randomisation ’system’ used
and done by a statistician, likely to be done
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properly
Allocation concealment (selection bias) Low risk Quote: “A centralized randomization sys-
tem assigned patients either to palifermin
or conventional treatment in a 1:1 ratio.....
.The statistician gave randomization list to
the pharmacy, so the patient and the clini-
cal research team (who assessed outcomes)
were blinded to the study treatment”
Comment: centralised randomisation with
pharmacy assigning participants to groups
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
and “The statistician gave randomization
list to the pharmacy, so the patient and the
clinical research team (who assessed out-
comes) were blinded to the study treat-
ment. The pharmacy provided the research
team with the blinded study medication”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The statistician gave randomiza-
tion list to the pharmacy, so the patient
and the clinical research team (who assessed
outcomes) were blinded to the study treat-
ment. The pharmacy provided the research
team with the blinded study medication”
Comment: outcome assessors were clearly
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall attrition was same in both groups
(10%) with the same reason given
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
91Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lucchese 2016b
Methods Trial design: parallel (2 arms)
Location: Vita-Salute San Raffaele University Hospital, Milan, Italy
Number of centres: 1
Study duration: conducted from April 2010 to January 2014
Trials registry number: none/unknown
Participants Inclusion criteria: children aged 9 to 15 years with B-cell lineage acute lymphoblastic
leukaemia; scheduled to receive allogeneic HSCT after a conditioning regimen
Exclusion criteria: not reported
Cancer type: B-cell lineage acute lymphoblastic leukaemia
Cancer treatment: prior to receiving allogeneic HSCT, participants received a condi-
tioning regimen of a total of 12 Gy TBI delivered in 8 fractions of 1.5 Gy twice daily
over 4 days
Age at baseline (years): Group A: median 12 (range 8 to 15); Group B: median 12
(range 8 to 15)
Gender: Group A: 50% male; Group B: 55% male
Number randomised: 46 (Group A: 24; Group B: 22)
Number evaluated: 46 (Group A: 24; Group B: 22)
Interventions Comparison: KGF (palifermin) versus placebo
Group A: KGF (60 µg/kg) by IV, for 3 days prior to start of conditioning regimen and
for 3 days after completion (total dose = 360 µg/kg)
Group B: same schedule with placebo
Compliance: not reported
Duration of treatment: 6 treatment days (over unclear period of time - not fully de-
scribed)
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed by the clinical research team at
baseline, days 1, 2, 3 (it is not clear when this is in relation to the cancer treatment or
study treatment) and at the end of the cycle - “All of these results were confirmed at the
last follow-up (60 days)” - it is not clear how they have been confirmed if, for example,
OM has resolved by 60 days; it is not clear whether or not there were multiple cycles,
incidence of each grade does not add up or make sense or match the data in table 3)
(duration of grade 2 to 4 and 3 to 4 oral mucositis also measured but not an outcome
of this review)
• Normalcy of diet (duration of supplemental feeding by TPN, not used for
analysis) (patient-reported difficulty eating and drinking assessed using OMDQ 0 (no
difficulty) to 5 (unable to do) scale, but the means are reported as whole numbers, data
not used)
• Adverse events
• Opioid analgesic use (number of days of treatment with opioid analgesics
(morphine) reported but unclear if mean/median and no SD or P value reported;
unable to use data; also reported as quantity per day but not an outcome of this review)
Notes Sample size calculation: not reported
Funding: “This work has been performed with departmental funding only”
Declarations/conflicts of interest: “The authors certify that there is no conflict of inter-
est with any financial organization regarding the material discussed in the manuscript”
Data handling by review authors:we emailed the lead author June 2017 for clarification
of the oral mucositis data but, until we receive a response, we are unable to use those
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data
Other information of note: “Patients who had severe (grade 3 or 4) OMduring blinded
cycles received open-label palifermin at the same dosages as in the other group. The
research team assessed patients for OM at baseline before the cycle; at days 1, 2, 3 and
at the end of the transplant cycle.” - nowhere else in the report suggests that there were
multiple cycles of treatment; unclear definitions of ulcerative mucositis i.e. described
correctly in one section as grades 2 to 4, but described in another section as grades 1 to
4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “No stratification was performed
and two distinct computer-generated a ran-
domization lists. The statistician gave both
randomization lists to the pharmacy, so
the patient and the clinical research team
(who assessed outcomes) were blinded to
the study treatment”
Comment: adequate method done by a
statistician (although it is unclear why there
were 2 lists)
Allocation concealment (selection bias) Low risk Quote: “No stratification was performed
and two distinct computer-generated a ran-
domization lists. The statistician gave both
randomization lists to the pharmacy, so
the patient and the clinical research team
(who assessed outcomes) were blinded to
the study treatment”
Comment: randomisation ’system’ used
and done by a statistician, likely to be done
properly
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
and “The statistician gave both randomiza-
tion lists to the pharmacy, so the patient
and the clinical research team (who assessed
outcomes) were blinded to the study treat-
ment. The pharmacy provided the research
team with the blinded study medication”
Comment: the use of a placebo should have
ensured that blinding was successful
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The statistician gave both ran-
domization lists to the pharmacy, so the pa-
tient and the clinical research team (who as-
sessed outcomes) were blinded to the study
treatment. The pharmacy provided the re-
search team with the blinded study medi-
cation”
Comment: outcome assessors were clearly
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Makkonen 2000
Methods Trial design: parallel (2 arms)
Location: Turku University Central Hospital and Helsinki University Central Hospital,
Finland
Number of centres: 2
Study duration: recruitment from November 1994 to August 1996
Trials registry number: none/unknown
Participants Inclusion criteria: scheduled to receive total target dose of at least 56 Gy to the oropha-
ryngeal mucosa
Exclusion criteria: prior chemotherapy or radiotherapy; concurrent use of anticholin-
ergic drugs; autoimmune thrombocytopenic purpura; WHO performance status higher
than 2
Cancer type: head and neck: mobile tongue (Group A: 30%; Group B: 20%); oral cavity,
other (Group A: 40%; Group B: 25%); oropharynx (Group A: 20%; Group B: 15%);
nasopharynx (Group A: 5%; Group B: 10%); supraglottic larynx (Group A: 5%; Group
B: 15%); hypopharynx (Group A: 0%; Group B: 15%)
Cancer treatment:
• conventional radiotherapy (Group A: 50%; Group B: 50%): 1.9 Gy to 2 Gy daily
fractions, 5 fractions per week
• hyperfractionated radiotherapy (Group A: 50%; Group B: 50%): 1.6 Gy fractions
twice per day with minimum 6 hours between fractions, to a total dose of 38.4 Gy;
planned break of 9 to 12 days during which the mucosa healed in order to allow
further doses to a total of 56 Gy to 73 Gy; overall treatment time was 5 to 6 weeks
Total target dose: Group A: median 65 Gy (range 56 to 68); Group B: median 66 Gy
(range 58 to 73); oral surgery prior to RT: Group A: 20%; Group B: 30%; oral surgery
after radiotherapy: 23 (not reported by group)
Age at baseline (years): Group A: mean 63 (SD 10; range 47 to 87); Group B: mean
59 (SD 13; range 33 to 79)
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Gender: Group A: 60% male; Group B: 55% male
Number randomised: 40 (Group A: 20; Group B: 20)
Number evaluated: unclear; results presented as percentages
Interventions Comparison: GM-CSF (molgramostim) plus sucralfate versus sucralfate alone
Both groups rinsed mouth with sucralfate (1 g) suspension for 1 minute before swal-
lowing, 6 times per day, starting after 1 week of RT and continued until the end of RT
(including weekends and planned/unplanned treatment breaks). Both groups advised to
rinse their mouths with saline solution in between the sucralfate rinses if required
Group A: after cumulative radiation dose of 10 Gy, GM-CSF (150 µg to 300 µg -
dependent on body weight) by daily subcutaneous injection until the last day of RT; not
given over weekends or during planned/unplanned treatment breaks; mean total dose =
3398 µg (range 300 µg to 7200 µg)
Group B: no other treatment
Oral pain was treated with anti-inflammatory analgesics and with local anaesthetic
mouthwashes (lidocaine hydrochloride, Xylocain 0.5%)
Compliance: not reported
Duration of treatment: variable and dependent on duration of RT
Outcomes • Oral mucositis: 0 to 2 scale where 0 = no mucositis, 1 = erythema and edema
without ulcers but food intake/use of dental prosthesis was not affected, and 2 = one or
more ulcers or bleeding or food intake/use of dental prosthesis was affected (assessed
weekly during RT and 1 and 6 months after completion of RT, reported at start of RT
and weekly for 4 weeks after; no usable data)
• Interruptions to cancer treatment (only 2 due to mucositis but not reported by
group; data not usable)
• Oral pain: 0 to 10 VAS and also 1 to 4 scale where 1 = no pain, 2 = mild, 3 =
moderate, and 4 = severe (assessed daily at midday during RT) (data not usable - 1 to 4
scale reported as “no difference” and VAS reported on a graph with no SD or P values)
• Adverse events (due to GM-CSF, sucralfate, or both)
• Saliva flow rates (not an outcome of this review)
• Salivary lactoferrin (not an outcome of this review)
• Blood measurements (not an outcome of this review)
• Body weight (not an outcome of this review)
• Overall survival (not an outcome of this review)
Notes Sample size calculation: not reported
Funding: GM-CSF and sucralfate were both provided by pharmaceutical industry
(Schering-Plough Corporation and Orion-Farmos Pharmaceuticals respectively)
Declarations/conflicts of interest: not reported
Data handling by review authors: no usable data
Other information of note: GM-CSF administration began after cumulative radiation
dose of 10 Gy, by which point oral mucositis may have already begun to develop
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “assignment to the treatment
groups was carried out via a phone call
to the randomization center located at the
Finnish Cancer Registry, Helsinki”
Comment: use of a specialist randomisa-
tion centre
Allocation concealment (selection bias) Low risk Quote: “assignment to the treatment
groups was carried out via a phone call
to the randomization center located at the
Finnish Cancer Registry, Helsinki”
Comment: third party/remote randomisa-
tion would have ensured concealment of
the random sequence from those recruiting
participants
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not possible as no placebo was
used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It would be possible to blind the outcome
assessor for oral mucositis as the scale was
fairly objective, but it was not mentioned.
It would not be possible to blind oral pain
assessment as this was done by the partic-
ipant who was not blinded (however, we
could not use the pain data so there was no
bias for this outcome)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is not clear how many participants were
included in the analyses
Selective reporting (reporting bias) High risk Poor reporting of oral mucositis and oral
pain
Other bias Low risk No other sources of bias are apparent
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Methods Trial design: parallel (2 arms)
Location: Royal Marsden Hospital, London, UK
Number of centres: 1
Study duration: recruitment from September 1997 to October 2000
Trials registry number: NCT00004256
Participants Inclusion criteria: histologically proven T1 N0 or T2 N0 glottic carcinoma; due to
receive RT with a 16-fraction 3-week regimen; WHO performance status 0 or 1
Exclusion criteria: renal or hepatic impairment; serious infections requiring antibiotics;
taking corticosteroids or likely to require them; known allergy to GM-CSF
Cancer type: laryngeal
Cancer treatment: accelerated radiotherapy: once-daily fractions of 3.125 Gy, to a total
dose of 50 Gy in 16 fractions over 21 days
Age at baseline (years): Group A: median 60 (range 48 to 79); Group B: median 65
(range 32 to 70)
Gender: Group A: 93% male; Group B: 86% male
Number randomised: 29 (Group A: 15; Group B: 14)
Number evaluated: 29 (Group A: 15; Group B: 14)
Interventions Comparison: GM-CSF (molgramostim) versus no treatment
Group A: GM-CSF (150 µg) by daily subcutaneous injection, starting on day 14 of RT
and continuing for 14 days i.e. for the last week of RT and for 1 week after completion
of RT (total dose = 2100 µg)
Group B: no treatment
Compliance: 2 participants did not complete their course of GM-CSF
Duration of treatment: 14 days
Outcomes • Oral mucositis: RTOG 0 to 4 scale (measured weekly by 1 of 2 independent
observers using physician’s objective criteria (see Appendix 9), reported graphically over
time and by maximum score experienced in the text) (time to mucositis healing also
measured but not an outcome of this review)
• Normalcy of diet: use of feeding tubes
• Adverse events
• Analgesic use (“No differences were detected in...analgesic usage” - we do not
know if this is number of days or whether or not opioids)
• Dysphagia and odynophagia (not outcomes of this review)
• Candida infection (not an outcome of this review)
• Laryngeal edema (not an outcome of this review)
• Moist or dry desquamation (not an outcome of this review)
• Weight change (not an outcome of this review)
• Skin erythema (not an outcome of this review)
Notes Sample size calculation: 17 per group needed at 90% power and 5% significance to
detect reduction from an anticipated 60% incidence of severe mucositis to 10%
Funding: not reported
Declarations/conflicts of interest: not reported
Data handling by review authors:N/A
Other information of note: imbalance in stage distribution, with more T2 patients in
the GM-CSF group. Consequently more of this group were treated with larger fields
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GM-CSF administration only began after 14 days of radiotherapy, by which point oral
mucositis may have already begun to develop
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “were randomly assigned to the ac-
tive or control arms”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “were randomly assigned to the ac-
tive or control arms”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not possible as no placebo was
used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “At each visit one of two indepen-
dent observers, blinded to group allocation,
scored mucositis...”
Comment: a physician’s objective version
of the RTOG scale was used. Use of feeding
tube is also an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Analgesic use reported as “No differences”
with no data, however mucositis fully re-
ported
Other bias Low risk No other sources of bias are apparent
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Methods Trial design: parallel (7 arms)
Location: USA
Number of centres: 10
Study duration: not reported
Trials registry number: none/unknown
Participants Inclusion criteria: 18 years or older; metastatic colon or rectal adenocarcinoma; sched-
uled to receive palliative 5FU and leucovorin chemotherapy; ECOG performance status
0 to 2 (ambulatory at least 50% of waking hours); life expectancy of at least 4 months;
free of lesions and no recent history (within 30 days before baseline examination) of oral
ulceration, herpes simplex, oral candidiasis, severe gingivitis, or the presence of active or
chronic mucositis, xerostomia, or diarrhoea; absolute neutrophil count ≥ 1.5 x 109/L;
platelet count ≥ 100 x 109/L; serum creatinine ≤ 2.0 mg/dL; serum bilirubin ≤ 2.0
mg/dL; serum aspartate amino transferase less than 5 times the upper limit of normal;
absence of other serious concurrent medical illness
Exclusion criteria: received chemotherapy, radiotherapy, or other investigational drugs
within 4weeks of enrolment (6weeks for chemotherapywithmitomycin or nitrosoureas);
any unresolved adverse event from previous therapy; major surgery within 2 weeks before
study entry; history of insulin-dependent diabetes mellitus; pregnant or breastfeeding;
of child-bearing potential and not using adequate contraceptive precautions; previous
hypersensitivity reaction to leucovorin calcium or Escherichia coli-derived material
Cancer type: metastatic colorectal
Cancer treatment: (palliative) leucovorin 20 mg/m² by rapid IV injection, followed
immediately by 5FU 425 mg/m² by rapid IV injection for 5 consecutive days on days 4
to 8 of each 28-day cycle
Age at baseline (years): Group A: mean 62 (SD 10; range 44 to 84); Group B: mean
66 (SD 13; range 41 to 86)
Gender: Group A: 57% male; Group B: 59% male
Number randomised: 81 (Group A: 54; Group B: 27)
Number evaluated: 81 (Group A: 54; Group B: 27)
Interventions Comparison: KGF (recombinant human) versus placebo
Group A: KGF
• (n = 7): 1 µg/kg per day by IV bolus on days 1 to 3 (total dose = 3 µg/kg)
• (n = 8): 10 µg/kg as above (total dose = 30 µg/kg)
• (n = 10): 20 µg/kg as above (total dose = 60 µg/kg)
• (n = 11): 40 µg/kg as above (total dose = 120 µg/kg)
• (n = 8): 60 µg/kg as above (total dose = 180 µg/kg)
• (n = 10): 80 µg/kg as above (total dose = 240 µg/kg)
Group B: placebo as above
Compliance: 3 participants stopped KGF treatment due to adverse reactions involving
the skin (1 in 60 and 2 in 80 µg/kg group)
Duration of treatment: 3 days
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed on days 1, 4, 8, 15 and 28, reported
as incidence of grade 2 to 4; first cycle data only) (duration of mucositis also measured
but not an outcome of this review)
• Oral pain: self-assessed daily questionnaire including mouth and throat pain
assessed on both a 5-point ordinal scale (reported graphically, no usable data) and a 0
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to 10 VAS (reported as AUC, not used)
• Adverse events: WHO 0 to 4 scale (reported as events of any grade that differed
by at least 10% between any KGF group and placebo; events were not reported if they
occurred in less than 10% of KGF group; also reported as incidence of grade 3 to 4
events)
• Blood measurements (not an outcome of this review)
Notes Sample size calculation: not reported
Funding: “Supported by a grant from Amgen, Inc” (pharmaceutical industry)
Declarations/conflicts of interest: not reported
Data handling by review authors: we combined the 6 KGF groups to make a single
pairwise comparison against placebo; in order to make a head-to-head comparison of
doses we grouped the 3 lower doses (1 µg/kg, 10 µg/kg and 20 µg/kg) together and
grouped the 3 higher doses (40 µg/kg, 60 µg/kg and 80 µg/kg) together to make pairwise
groups for comparison
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “This study was a multicenter,
randomized, double-blinded, placebo-con-
trolled, phase I study”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “This study was a multicenter,
randomized, double-blinded, placebo-con-
trolled, phase I study”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blinded, placebo-
controlled”
Comment: the use of a placebo should have
ensured that blinding was successful; inci-
dence of adverse events does not appear to
differ enough between groups to cause un-
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blinded, placebo-
controlled”
Comment: it is not clear who was blinded
but the outcome is grade 2 to 4WHO-scale
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mucositis and it is unlikely that this would
be affected by any lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Nemunaitis 1995
Methods Trial design: parallel (2 arms)
Location: USA and Canada
Number of centres: 7
Study duration: 1 November 1990 to 1 July 1993
Trials registry number: none/unknown
Participants Inclusion criteria: any age; undergoing allogeneic BMT (from HLA-identical sibling)
for haematological malignancy
Exclusion criteria: due to receive methotrexate as part of GVHD prophylaxis; chronic
lymphocytic leukaemia; chronic myelogenous leukaemia in blast crisis; acute lym-
phoblastic leukaemia or acute myelogenous leukaemia with failure at first induction or
progressed beyond a second relapse; previously received cytokines; HIV; life expectancy
less than 7 days
Cancer type: haematologic malignancy: lymphoid malignancy (Group A: 21%; Group
B: 16%); acute myeloid malignancy (Group A: 34%; Group B: 27%); chronic myeloid
malignancy (Group A: 32%; Group B: 30%); multiple myeloma (Group A: 6%; Group
B: 5%); myelodysplastic syndrome (Group A: 6%; Group B: 11%); aplastic anaemia
(Group A: 2%; Group B: 11%)
Cancer treatment: prior to receiving allogeneic BMT (fromHLA-identical sibling), par-
ticipants received the following conditioning regimens: busulfan and cyclophosphamide
with TBI (Group A: 9%; Group B: 16%) or without TBI (Group A: 32%; Group B:
34%); busulfan, cyclophosphamide, cytosine arabinoside, and methotrexate with TBI
(Group A: 23%; Group B: 13%) or without TBI (Group A: 8%; Group B: 11%); cyclo-
phosphamide and steroid with TBI (Group A: 0%; Group B: 2%); cyclophosphamide,
cytosine arabinoside, and steroid with TBI (Group A: 23%; Group B: 18%); etoposide
with TBI (Group A: 0%; Group B: 2%); etoposide, cytosine arabinoside, and cyclo-
phosphamide with TBI (Group A: 2%; Group B: 0%); etoposide, cytosine arabinoside,
cyclophosphamide, and asparaginase with TBI (Group A: 0%; Group B: 2%); etoposide,
methotrexate, cytosine arabinoside, and steroid with TBI (Group A: 4%; Group B: 4%)
All participants received cyclosporine and methylprednisolone for GVHD prophylaxis
Age at baseline (years): Group A: mean 32; Group B: mean 34
Gender: Group A: 60% male; Group B: 54% male
Number randomised: 109 (Group A: 53; Group B: 56)
Number evaluated: 109 (Group A: 53; Group B: 56)
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Interventions Comparison: GM-CSF (yeast-derived recombinant human) versus placebo
Group A: GM-CSF (250 µg/m²) by 4-hour IV infusion starting on day 0 (the day of
BMT) to day 20 (total dose = 5250 µg/m²)
Group B: as above with placebo
Compliance: Group A: 13 participants (25%) stopped their intervention early: 11 due
to adverse events (1 rash, 7 bone pain, 2 acute dyspnoea, 1 seizure); 2 (with no apparent
toxicity) due to participant or physician request; Group B: 9 participants (16%) stopped
their intervention early: 6 due to adverse events (2 rash, 2 bone pain, 1 elevated liver
enzymes, 1 infections); 2 (on day 19) due to miscalculation of the number of days to
receive the intervention; 1 (on day 9) due to severe mucositis and veno-occlusive disease
of the liver
Duration of treatment: 21 days
Outcomes • Oral mucositis: assessment methods are not clear but reported on 0 to 4 scale
which is probably WHO (assessment frequency and duration also unclear, reported in
text as incidence of grade 2 to 4 and grade 3 to 4)
• Adverse events: 0 to 4 scale which is probably WHO (reported as incidence of any
grade of event and incidence of grade 3 to 4 events with a greater than 10% frequency)
• Number of days in hospital (reported as median values; unable to use data)
• GVHD incidence and severity (not an outcome of this review)
• Veno-occlusive disease of the liver (not an outcome of this review)
• Blood measurements (not an outcome of this review)
• Infection: bacterial, fungal and viral (not an outcome of this review)
• Duration of IV antibiotics (not an outcome of this review)
• Fever (not an outcome of this review)
• Survival: overall, disease-free, relapse (not an outcome of this review)
Notes Sample size calculation: not reported
Funding: “..product provided by Immunex” (pharmaceutical). Also mention of “spon-
soring company” which is likely to be Immunex
Declarations/conflicts of interest: not reported but 4 authors employed by Immunex
Data handling by review authors:N/A
Other information of note:GM-CSF administration only began after the conditioning
regimen, by which point oral mucositis may have already begun to develop
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Assignment to treatmentwasmade
via a randomization schema prepared by
Almedica Corporation”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Low risk Quote: “Blinded numbered vials contain-
ing placebo or rhGM-CSF were provided
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to each participating centre. The pharma-
cists, principal investigators, patients, sup-
port care personnel and sponsoring com-
pany were blinded to the study medication
for the entire course of the study”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind placebo-controlled”
and “The pharmacists, principal investiga-
tors, patients, support care personnel and
sponsoring company were blinded to the
study medication for the entire course of
the study”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind placebo-controlled”
and “The pharmacists, principal investiga-
tors, patients, support care personnel and
sponsoring company were blinded to the
study medication for the entire course of
the study”
Comment: everyone involved in the study
was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk 5 participants in the placebo group received
cytokines off study during the first 42 days
after BMT but unlikely to bias the results
in a meaningful way
Peterson 2009
Methods Trial design: parallel (3 arms)
Location: Russia
Number of centres: 9
Study duration: recruitment from August 2006 to May 2007
Trials registry number: none/unknown
Participants Inclusion criteria: 18 years or older with colorectal cancer (stage I to IV); undergoing
chemotherapy as primary cancer therapy; experienced WHO grade 2 or higher oral
mucositis during first cycle of chemotherapy, but recovered prior to enrolment (i.e. grade
0); ECOG score of 0 to 2
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Exclusion criteria: pregnant (or risk of pregnancy) or lactating; scheduled to receive RT
to the head and neck; received other investigational drugs within 14 days of the start
of the study; evidence of alcohol and drug abuse; pre-existing conditions such as active
fungal or herpetic infection
Cancer type: colorectal (stage I to IV)
Cancer treatment: all participants received 5FU (97% with leucovorin) but 1 received
capecitabine; 6 participants (3 in low-dose ITF, 3 in placebo) also received oxaliplatin;
doses or regimens comparable between groups
Age at baseline (years): Group A: median 62 ; Group B: median 56 ; Group C: median
59
Gender: Group A: 42% male; Group B: 33% male; Group C: 48% male
Number randomised: 99 (Group A: 33; Group B: 33; Group C: 33)
Number evaluated: 99 (Group A: 33; Group B: 33; Group C: 33)
Interventions Comparison: ITF (recombinant human) versus placebo
Group A: ITF (10 mg/mL) oral spray, 300 µL (3 sprays) to the oral mucosa 8 times
daily, starting on the first day (day 1) of the second chemotherapy cycle for total 14 days
(total dose = 336 mg)
Group B: ITF (80 mg/mL) oral spray as above (total dose = 2688 mg)
Group C: placebo oral spray as above
Compliance: patient-reported compliance was 97%
Duration of treatment: 14 days
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed on days 0, 1, 3, 5, 7, 10, 12, 14, and
21 ± 2, maximum score reported) (duration of mucositis also measured but not an
outcome of this review)
• Oral mucositis: OMAS 0 to 45 scale (assessed on days reported above; WHO data
used for analysis)
• Adverse events (assessed on days reported above)
• Patient daily self-assessment: including discolouration, mouth and throat pain,
preference for solid/semi-solid food, analgesic use, and dysphagia (no usable data for
the outcomes relevant to this review)
Notes Sample size calculation: based on previous study, 80% power to detect 40% difference
in incidence of WHO grade 2 or above
Funding: The GI Company (pharmaceutical)
Declarations/conflicts of interest: some authors had roles with the funding pharma-
ceutical company (and other companies) both compensated and uncompensated
Data handling by review authors: we combined the 2 ITF groups to make a single
pairwise comparison against placebo; we also made a separate comparison of the 2 ITF
dosages
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomly as-
signed”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “The patients were randomly as-
signed”
Comment: insufficient information to de-
termine whether or not the random se-
quence was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of oral mucositis using this scale, re-
quiring the patient’s assessment of pain/
soreness and their ability to swallow but,
as the participants were unaware of their
group allocation, the assessment of oral
mucositis can be considered to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Rosen 2006
Methods Trial design: parallel (2 arms)
Location: USA and Australia
Number of centres: 15
Study duration: not reported
Trials registry number: none/unknown
Participants Inclusion criteria: 18 years or older with advanced (Duke’s D) colon or rectal adenocar-
cinoma; scheduled to receive bolus 5FU and low-dose leucovorin (Mayo regimen) as first-
line or subsequent therapy; normal oral cavity examination (no ulceration, herpes sim-
plex, candidiasis, or severe gingivitis); ECOG score of 0 to 2; life expectancy of 4 months
or more; absolute neutrophil count of 1.5 x 10 /L or higher; platelet count of 100 x 10
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/L or higher; normal renal and hepatic function
Exclusion criteria: previous radiotherapy or chemotherapy within 4 weeks or major
surgery within 2 weeks of study day 1; insulin-dependant diabetes; known allergy to
leucovorin; known hypersensitivity to Escherichia coli-derived material
Cancer type: advanced colorectal (Duke’s D)
Cancer treatment: low-dose leucovorin (20 mg/m²) by IV immediately followed by
5FU (425 mg/m²) by rapid IV once daily for 5 consecutive days on days 4 to 8 of each
28-day cycle; 2 cycles (5FU dose could be decreased by 20% during cycle 2 if moderately
severe toxicities occurred in cycle 1)
Age at baseline (years): Group A: mean 65 (SD 11.2); Group B: mean 65 (SD 11.1)
Gender: Group A: 57% male; Group B: 72% male
Number randomised: 65 (not reported by group)
Number evaluated: 64 (Group A: 28; Group B: 36)
Interventions Comparison: KGF (palifermin) versus placebo
Group A: KGF (40 µg/kg) by IV for 3 consecutive days (days 1 to 3 of each 28-day
cycle) before the start of chemotherapy (total dose = 120 µg/kg)
Group B: as above with placebo
Compliance: not reported (only reports “palifermin was generally well tolerated”)
Duration of treatment: 3 days
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed on days 0, 1, 4, 8, 12, 15, and 28,
maximum score reported)
• Oral pain: patient daily self-assessment using OMDQ 5-point scale for mouth
and throat soreness (higher = worse pain, reported as AUC, not used)
• Adverse events
• Diarrhoea (related to the cancer therapy - not an outcome of this review)
• Laboratory assessments (not an outcome of this review)
• Neutropenia (not an outcome of this review)
• Antibody assessments (not an outcome of this review)
• Survival (not an outcome of this review)
Notes Sample size calculation: not reported
Funding: “Supported by Amgen Inc” (pharmaceutical industry)
Declarations/conflicts of interest: all authorswere linked to the funding pharmaceutical
company in terms of employment, consultancy, stock ownership, honoraria, and receipt
of research funding
Data handling by review authors: data were reported separately for the chemotherapy
cycles 1 and 2 - we used the data for cycle 1
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned
(by center and prior chemotherapy)”
Comment: insufficient information to de-
termine method of random sequence gen-
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eration
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomly assigned
(by center and prior chemotherapy)”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of oral mucositis using this scale, re-
quiring the patient’s assessment of pain/
soreness and their ability to swallow but,
as the participants were unaware of their
group allocation, the assessment of oral
mucositis can be considered to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 randomised participant was not in-
cluded in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Saarilahti 2002
Methods Trial design: parallel (2 arms)
Location: Helsinki University Central Hospital, Finland
Number of centres: 1
Study duration: recruitment from October 1999 to April 2001
Trials registry number: none/unknown
Participants Inclusion criteria: undergone radical surgery for head and neck cancer and scheduled to
receive postoperative RT to a total dose of 50 Gy or more to the oral and oropharyngeal
mucosa
Exclusion criteria: prior chemotherapy or RT; chronic autoimmune or inflammatory
disease; WHO performance score > 2
Cancer type: head and neck: mobile tongue (Group A: 33%; Group B: 37%); floor of
mouth (Group A: 19%; Group B: 16%); tonsil (Group A: 29%; Group B: 32%); oral
cavity other (Group A: 19%; Group B: 16%)
Cancer treatment: mean time from radical surgery to start of RT: Group A: 39 days
(range 20 to 73); Group B: 38 days (range 20 to 56); conventionally fractionated RT to
a total dose of 50 Gy to 60 Gy in 2-Gy daily fractions, 5 times weekly (on weekdays) for
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5 to 6 weeks, to the primary site and locoregional lymph nodes
Age at baseline (years): Group A: median 56 (range 43 to 87); Group B: median 60
(range 24 to 72)
Gender: Group A: 57% male; Group B: 79% male
Number randomised: 40 (Group A: 21; Group B: 19)
Number evaluated: 40 (Group A: 21; Group B: 19)
Interventions Comparison: GM-CSF versus sucralfate
Group A: starting after a cumulative RT dose of 10 Gy (after 1 week of RT); mouth
was cleaned with water, then GM-CSF (37.5 µg per 25 mL rinse) mouthwash rinsed
around the mouth for 3 minutes then swallowed, 4 times daily after meals, on RT-days
(weekdays), until the end of RT (total dose dependent on duration of RT)
Group B: as above but with sucralfate (1 g per 25 mL rinse) (total dose dependent on
duration of RT)
Compliance: not reported (only reports “both mouthwashes were well tolerated, and
none of the patients reported any adverse effects related to the mouthwashes”)
Duration of treatment: 4 to 5 weeks (dependent on duration of RT)
Outcomes • Oral mucositis: RTOG 0 to 4 scale (assessed before RT, weekly during RT, and at
1, 2, and 4 weeks after RT, reported graphically as mean score over time but authors
provided maximum incidence data on request)
• Interruptions to cancer treatment (RT interruptions due to OM)
• Oral pain: 0 (no pain) to 10 (worse pain) VAS (assessed as reported above,
reported graphically as mean score over time - no mean maximum score and no SDs,
unable to use data)
• Normalcy of diet: use of PEG feeding tube
• Adverse events
• Incidence of hospitalisation (number of days in hospital is an outcome of this
review and therefore we did not use these data)
• Opioid analgesic use (reported as incidence; number of days of treatment with
opioid analgesics is an outcome of this review and therefore we did not use these data)
• Laboratory parameters (not outcomes of this review)
• Use of antimycotic agents (not an outcome of this review)
• Use of antibiotics (not an outcome of this review)
• Weight loss (not outcomes of this review)
Notes Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
Data handling by review authors: we used oral mucositis incidence (maximum score
experienced per patient) data provided by the authors; all participants experienced mu-
cositis (grade 1 or above) as they had already received a week of RT before the interven-
tion started, therefore we felt an analysis of incidence of any grade of mucositis should
not be included
Other information of note:GM-CSF/sucralfate administration only began after 1 week
of RT, by which point oral mucositis may have already begun to develop
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was done using
computer-generated random digits”
Comment: adequate method used
Allocation concealment (selection bias) Low risk Quote: “they were assigned to a treatment
group by way of a telephone call to the ran-
domization office”
Comment: third party/remote randomisa-
tion would have ensured concealment of
the random sequence from those recruiting
participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind” and “Both solutions
looked alike, and neither the investigators
nor the patients were aware of the contents
of the solutions given. The drug vials were
marked with a study code that prevented
identification of the allocation group”
Comment: adequate methods to ensure
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blinded, placebo-
controlled”
Comment: nobody involved in the study
was aware of group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Schneider 1999
Methods Trial design: parallel (2 arms)
Location: USA
Number of centres: not reported
Study duration: recruitment from January 1995 to April 1996
Trials registry number: none/unknown
Participants Inclusion criteria: 18 years or older with histologically proven head and neck ma-
lignancy; mucosa of the oropharynx and/or oral cavity to be included in RT portal;
Karnofsky performance score of 60 or more; no known hypersensitivity to E coli-derived
109Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Schneider 1999 (Continued)
proteins; haemoglobin and platelet counts 100 x 10 /L or higher; absolute neutrophil
count higher than 1.5 x 10 /L; normal blood pressure; agreement to bring dentition to
acceptable level prior to RT (teeth with periapical abscesses or severe periodontal disease
extracted, followed by a 10-day healing period allowance)
Exclusion criteria: lactating/pregnant/females not taking effective form of contracep-
tion; scheduled to receive chemotherapy or radiosensitising drugs during the planned
RT; history of myeloid malignancy; underlying collagen vascular disease; active rheuma-
toid arthritis
Cancer type:head and neck: nasopharynx (GroupA: 0;GroupB: 1); oropharynx (Group
A: 2; Group B: 1); tongue (Group A: 2; Group B: 1); larynx (Group A: 2; Group B: 1);
other/unknown (Group A: 2; Group B: 2)
Cancer treatment: radiotherapy in 1.8Gy to 2Gy standard daily fractions fromMonday
to Friday, to total dose 50 Gy or more
Age at baseline (years): not reported
Gender: Group A: 100% male; Group B: 83% male
Number randomised: 14 (Group A: 8; Group B: 6)
Number evaluated: 14 (Group A: 8; Group B: 6)
Interventions Comparison: G-CSF (r-metHuG-CSF) (filgrastim) versus placebo
Group A: G-CSF (starting at 3 µg/kg and titrated to keep neutrophil count between
10 x 10 /L and 30 x 10 /L) by daily subcutaneous injection, starting on the first day
of RT (weekdays), until the end of RT (total dose dependent on duration of RT and
neutrophil counts)
Group B: placebo as above
Compliance: not reported (only reports “Filgrastim was well tolerated”)
Duration of treatment: variable and dependent on duration of RT
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed on weekly by single examiner,
reported as incidence of any mucositis and grade 3 or higher)
• Oral mucositis: Hickey 0 to 3 scale (not used)
• Interruptions to cancer treatment (delays or dose reductions, no usable data)
• Weight change (not an outcome of this review)
• Blood measurements (not an outcome of this review)
Notes Sample size calculation: 54 required to detect 30% decrease in incidence of grade 2 or
3 mucositis at 80% power at the 5% significance level
Funding: “Financial support was provided through a grant from Amgen Inc” (pharma-
ceutical industry)
Declarations/conflicts of interest: not reported
Data handling by review authors: interruptions to cancer treatment outcome only
reported narratively
Other information of note: study was stopped after an interim analysis. Authors state
that “owing to administrative obstacles, completion of the trial is not possible”, rather
than due to previously stated early stopping rules
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “The patients were randomized
equally between the two treatment groups”
and “The study material and randomiza-
tion list were held by the UCLA Pharmacy
for the duration of the study”
Comment: method of random sequence
generation not described but done by
UCLA Pharmacy and therefore probably
done adequately
Allocation concealment (selection bias) Low risk Quote: “Amgen Inc...prepared and pack-
aged all drug and placebo in identical con-
tainers, with the only designator being the
randomization number. The study mate-
rial and randomization list were held by the
UCLA Pharmacy for the duration of the
study”
Comment: pharmacy-controlled randomi-
sation would have ensured concealment of
the random sequence from those recruiting
participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
and “Amgen Inc...prepared and packaged
all drug and placebo in identical contain-
ers, with the only designator being the ran-
domization number”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
and “A single examiner...who was blinded
to the patients’ randomization status...
scored mucositis on a weekly basis”
Comment: both participants and outcome
assessor were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk Although the study reports an interim anal-
ysis only, the study was stopped due to ad-
ministrative reasons and is unlikely to in-
troduce bias
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Methods Trial design: parallel (2 arms)
Location: USA
Number of centres: 13
Study duration: recruitment from March 2001 to October 2002
Trials registry number: NCT00041665
Participants Inclusion criteria: 18 years or older; Karnofsky performance score of 70 or more;
scheduled to undergo autologous HSCT after conditioning regimen of fractionated TBI
plus etoposide and cyclophosphamide for haematological cancers; adequate cardiac, pul-
monary, renal, and hepatic function
Exclusion criteria: not reported
Cancer type: haematologic: NHL (Group A: 68%; Group B: 65%); Hodgkins (Group
A: 20%; Group B: 22%); multiple myeloma (Group A: 10%; Group B: 8%); leukaemia
(Group A: 2%; Group B: 5%)
Cancer treatment: prior to autologous HSCT, participants received the following con-
ditioning regimen:
• Radiotherapy: prior to chemotherapy, TBI of total 12 Gy in 6, 8, or 10 fractions
over 3 or 4 days, with at least 6 hours between fractions
• Chemotherapy: IV etoposide (60 mg/kg) the day after the last RT fraction (4 days
before HSCT) and cyclophosphamide (100 mg/kg) 2 days later (2 days before HSCT)
All participants receivedG-CSF (filgrastim) 5 µg/kg per day fromHSCTuntil neutrophil
recovery
Age at baseline (years): Group A: median 48 (range 18 to 69); Group B: median 49
(range 19 to 68)
Gender: Group A: 56% male; Group B: 68% male
Number randomised: 214 (Group A: 107; Group B: 107)
Number evaluated: 212 (Group A: 106; Group B: 106)
Interventions Comparison: KGF (palifermin) versus placebo
Group A: KGF (60 µg/kg) by IV for 3 consecutive days starting 3 days before RT,
followed by 3 more doses after HSCT starting on the day of HSCT (total dose = 360
µg/kg)
Group B: placebo as above
Compliance: 212 participants received at least 1 dose of their allocated intervention and
205 participants (Group A: 103; Group B: 102) “completed the study” (it is not clear
whether or not this means that they received all doses)
Duration of treatment: 6 treatment days over 13 to 14 days
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed daily by trained assessors starting 8
days before HSCT and for 28 days after HSCT or until severe mucositis had returned
to grade 0 to 2, maximum score reported) (duration of grade 3 to 4 oral mucositis also
measured but not an outcome of this review)
• Oral mucositis: RTOG 0 to 4 scale (assessed as above but only used for reporting
duration of severe mucositis)
• Oral mucositis: WCCNR 0 to 3 scale (assessed as above but only used for
reporting duration of severe mucositis)
• Oral pain: patient daily self-assessment (day -12 to 28) using OMDQ 5-point
scale for mouth and throat soreness (higher = worse pain, reported as AUC, not used)
• Quality of life: physical, functional, emotional, and social/family well-being
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domains of the FACT general questionnaire (days -12, -1, 7, 10, 14, and 28, reported
as AUC, not used)
• Normalcy of diet (measured as incidence of TPN)
• Adverse events: 1 (mild) to 5 (fatal) scale
• Number of days of treatment with opioid analgesics (reported as median and
range, unable to use data)
• Dysphagia (not an outcome of this review)
• Febrile neutropenia (not an outcome of this review)
• Infections (not an outcome of this review)
• Survival (not an outcome of this review)
• Laboratory results (not an outcome of this review)
Notes Sample size calculation: 210 participants required to detect a mean difference in dura-
tion of severe oral mucositis of at least 3 days (SD 6.6) at 90% power and 5% significance
Funding: “Funded by Amgen” (pharmaceutical industry)
Declarations/conflicts of interest: the majority of authors were linked to the funding
pharmaceutical company in terms of employment, consulting fees, lecture fees, receipt
of research funding, and ownership of equity
Data handling by review authors:N/A
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly assigned
in a 1:1 ratio”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “patients were randomly assigned
in a 1:1 ratio”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “placebo-controlled, double-blind”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “placebo-controlled, double-blind”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of lower grades of oral mucositis us-
ing the WHO scale, requiring the patient’s
assessment of pain/soreness and their abil-
ity to swallow.Higher grades havemore ob-
jective elements so may not be affected by
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potential lack of blinding of the assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 2 randomised participants (1 per
group) were not included in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Su 2006
Methods Trial design: parallel (2 arms)
Location: USA
Number of centres: 1
Study duration: recruitment from January 1992 to December 1996
Trials registry number: none/unknown
Participants Inclusion criteria: 18 years or older with histologically proven AJCC stage II to IV
squamous cell carcinoma of the head and neck; undergone gross complete resection with
negative pathological surgical margins and medically fit to begin RT within 8 weeks
of surgery; Karnofsky performance score of 80% or more; adequate haematologic and
serum metabolic laboratory indices
Exclusion criteria: nasopharyngeal cancer; concurrent active malignancy other than lo-
calised; nonmelanoma skin cancer; previous RT to head and neck; previous chemother-
apy; positive serum β-human chorionic gonadotropin in women of procreative poten-
tial; need for tube feeding at the start of RT
Cancer type: stage II to IV squamous cell carcinoma of the head and neck: hypopharynx
(Group A: 11%; Group B: 5%); larynx (Group A: 16%; Group B: 23%); oral cavity
(GroupA: 26%;GroupB: 27%); oropharynx (GroupA: 21%;GroupB: 32%); unknown
primary (Group A: 26%; Group B: 14%)
Cancer treatment: postoperative external beam RT in once-daily fractions of 1.8 Gy,
5 days per week, to total dose of 63 Gy at primary site and involved neck (54 Gy to
regional lymphatics at risk for subclinical metastasis; spinal cord dose limited to 45 Gy)
Age at baseline (years): Group A: median 67 (interquartile range 59 to 75); Group B:
median 61 (interquartile range 54 to 67)
Gender: Group A: 79% male; Group B: 73% male
Number randomised: 41 (Group A: 19; Group B: 22)
Number evaluated: 40 (Group A: 19; Group B: 21)
Interventions Comparison: G-CSF versus placebo
Group A: G-CSF (3 µg/kg) by daily subcutaneous injection, 7 days per week, starting
3 days before the start of RT and continued to end of RT (total dose = dependent on
duration of RT)
Group B: placebo as above
Compliance: not reported
Duration of treatment: variable and dependent on duration of RT
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Outcomes • Oral mucositis: unknown 0 to 3 scale, where 0 = none, 1 = erythema, 2 = patchy
mucositis, and 3 = confluent mucositis (assessed twice weekly by the treating radiation
oncologist, maximum score reported)
• Interruptions to cancer treatment: RT interruptions
• Normalcy of diet (use of PEG feeding tube, as defined by 10% or higher weight
loss from pre-RT baseline)
• Adverse events (NCI-CTC)
• Blood measurements (not an outcome of this review)
• Survival (not an outcome of this review)
Notes Sample size calculation: planned sample sample size was 66 per group to detect absolute
difference of 20% in PEG tube use (from 10% in one group to 30% in the other) at
80% power and 5% significance
Funding: “This study was supported by NIH grant #CA69913” (government)
Declarations/conflicts of interest: “Nobenefits in any formhave beenorwill be received
from a commercial party related directly or indirectly to the subject of this article”
Data handling by review authors: although the scale for assessing oral mucositis does
not completelymatch the 0 to 4 scales (such asWHO, etc), it was possible to dichotomise
it for use in the ’any mucositis’ meta-analysis, and we also used grade 3 (confluent
mucositis) as incidence of severe mucositis
Other information of note: planned to enrol 132 participants but stopped due to slow
recruitment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomized...by
randomly permuted blocks...A randomiza-
tion list was prepared by the Memorial
Sloan-Kettering Cancer Center Biostatis-
tics Service and held by the pharmacy”
Comment: specialist centre used
Allocation concealment (selection bias) Low risk Quote: “A randomization list was prepared
by the Memorial Sloan-Kettering Cancer
Center Biostatistics Service and held by the
pharmacy. Investigators did not have ac-
cess to this list, ensuring that allocation
could not be predicted before registration
or changed afterwards”
Comment: central/remote randomisation
would have ensured concealment of the
random sequence from those recruiting
participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
and “All patients and treating physicians
were blinded to treatment group assign-
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ment”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
and “All patients and treating physicians
were blinded to treatment group assign-
ment”
Comment: the treating physician was the
outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 randomised participant was not in-
cluded in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
Vadhan-Raj 2010
Methods Trial design: parallel (2 arms)
Location: University of Texas MD Anderson Cancer Center, USA
Number of centres: 1
Study duration: recruitment from December 2005 to February 2008; last follow-up in
May 2008
Trials registry number: NCT00267046 (mentioned in trial report)
Participants Inclusion criteria: aged 15 to 65 years with sarcoma; due to start chemotherapy at the
centre; Karnofsky performance score of 80% or more; adequate bone marrow, renal, and
hepatic function
Exclusion criteria: history of pelvic RT; clinically significant cardiac disease; undergone
surgery within the previous 2 weeks
Cancer type: sarcoma
Cancer treatment: doxorubicin (total dosage 90 mg/m²) administered by continuous
IV infusion over 72 hours, and ifosfamide (total dosage 10 g/m²) administered by 3-
hour IV infusion for 4 days; participants with osteosarcoma (Group A: 2; Group B: 1)
received the same dosage of doxorubicin but with intra-arterial cisplatin (120 mg/m²); all
participants received G-CSF (pegfilgrastim) the day after chemotherapy; cycle repeated
every 21 days; planned 6 cycles
Age at baseline (years): Group A: median 42 (range 17 to 63); Group B: median 39
(range 15 to 64)
Gender: Group A: 53% male; Group B: 50% male
Number randomised: 48 (Group A: 32; Group B: 16)
Number evaluated: 48 (Group A: 32; Group B: 16)
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Interventions Comparison: KGF (palifermin) versus placebo
Group A: KGF (180 µg/kg) by IV as single dose 3 days before the start of each chemo-
therapy cycle
Group B: placebo as above
Compliance: the proportion of participants that completed all 6 blinded cycles (i.e. they
took their allocated intervention) was higher in Group A (63%) than Group B (31%)
Duration of treatment: 1 day per 3-week cycle; planned total 6 days of intervention
over 18 weeks
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed for each cycle before chemotherapy,
days 10, 12, 14 and at the end of the cycle, reported as incidence of grade 2 to 4 and
grade 3 to 4, reported separately for blinded phase (first 2 cycles) and then the open-
label phase) (duration of mucositis also measured but not an outcome of this review)
• Oral pain: 0 to 10 (10 being worst) scale (assessed by questionnaire for each cycle
before chemotherapy, days 10, 12, 14 and at the end of the cycle, reported for blinded
phase, reported as median maximum score; unable to use data)
• Quality of life: 1 to 7 (7 being worst) scale (assessed by questionnaire for each
cycle before chemotherapy, days 10, 12, 14 and at the end of the cycle, reported for
blinded phase, reported as median maximum score; unable to use data)
• Normalcy of diet: eating and drinking assessed separately on 0 to 4 (4 being most
difficult) scales (assessed by questionnaire for each cycle before chemotherapy, days 10,
12, 14 and at the end of the cycle, reported for blinded phase, reported as median
maximum score; unable to use data)
• Adverse events
• Opioid analgesic use (reported as quantity per cycle; number of days of treatment
with opioid analgesics is an outcome of this review and therefore we did not use these
data)
• Multiple patient-reported outcomes (overall health, sleeping, dysphagia, talking,
brushing teeth, throat pain, rectal soreness) (not outcomes of this review)
• Blood and laboratory measurements (not outcomes of this review)
• Weight loss (not an outcome of this review)
• Survival (not an outcome of this review)
Notes Sample size calculation: 48 participants required to detect absolute difference of 50%
(from 26% in Group A to 76% in Group B) in grade 2 to 4 mucositis at 88% power
and 5% significance
Funding: “Amgen provided the palifermin and partial funding for the study” (pharma-
ceutical industry)
Declarations/conflicts of interest: principal investigator is a member of the Amgen
board
Data handling by review authors: we only report data from the first 2 cycles (blinded
phase) as very few participants received placebo in the remaining cycles
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Vadhan-Raj 2010 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Two distinct computer-generated
randomization lists were prepared by the
University of TexasM.D. AndersonCancer
Center, Department of Biostatistics, one
for the 20 patients who consented to phar-
macokinetic sampling and the other for the
28 patients who did not. For the pharma-
cokinetics cohort, the treatment allocation
ratio was 4 patients receiving palifermin to
1 receiving placebo, in blocks of 5; for the
other cohort, the ratio was 4 patients re-
ceiving palifermin to 3 receiving placebo,
in blocks of 14”
Comment: adequate method used
Allocation concealment (selection bias) Low risk Quote: “The statisticianprovided both ran-
domization lists to the pharmacy, so the pa-
tient and the clinical research team (who as-
sessed outcomes) were blinded to the study
treatment. At patient enrolment, the re-
search team notified the pharmacy, which
assigned the patient the next sequential slot
and treatment from the appropriate ran-
domization list on the basis of whether he
or she had consented to pharmacokinetic
sampling. The pharmacy provided the re-
search teamwith the blinded studymedica-
tion. Upon completion of the study, phar-
macy provided the statistician with the 2
randomization lists, including individual
patient treatment assignments, for analy-
sis”
Comment: pharmacy-controlled randomi-
sation would have ensured concealment of
the random sequence from those recruiting
participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
and “the patient and the clinical re-
search team (who assessed outcomes) were
blinded to the study treatment” and
“Blinding might not have been maintained
because of adverse effects of palifermin”
Comment: some personnel may not have
been blinded due to increased adverse ef-
fects, although adverse effects from palifer-
min may have been difficult to isolate from
adverse effects of cancer treatment
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
and “the patient and the clinical re-
search team (who assessed outcomes) were
blinded to the study treatment” and
“Blinding might not have been maintained
because of adverse effects of palifermin” and
“patients were assessed at each cycle by both
research and clinical teams, including those
without direct knowledge of the protocol”
Comment: it seems unlikely that lack of
blinding would affect outcomes as the
higher grades of oral mucositis assessed in
this study are more objective; also, some
were assessed by personnel without knowl-
edge of the protocol
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
van der Lelie 2001
Methods Trial design: parallel (2 arms)
Location: the Netherlands
Number of centres: 1
Study duration: recruitment from May 1997 to August 1999
Trials registry number: none/unknown
Participants Inclusion criteria: malignant disease and due to have myeloablative treatment followed
by autologous or allogeneic BMT or PBSCT
Exclusion criteria: not reported
Cancer type: haematologic: lymphoma (Group A: 28%; Group B: 50%); acute
leukaemia (Group A: 28%; Group B: 28%); CML (Group A: 22%; Group B: 6%);
multiple myeloma (Group A: 22%; Group B: 17%)
Cancer treatment: prior to autologous or allogeneic BMT or PBSCT, participants re-
ceived the following conditioning regimens:
• BEAM (Group A: 28%; Group B: 44%): carmustine (BCNU) 300 mg/m² on day
-6; etoposide (VP16) and cytosine arabinoside (Ara-C) 200 mg/m² of each on days -5,
-4, -3, -2; melphalan 140 mg/m² on day -1
• CYTBI (Group A: 56%; Group B: 44%): cyclophosphamide 60 mg/kg on days -5
and -4; TBI 4.5 Gy on days -2 and -1
• BUCY (Group A: 17%; Group B: 11%): busulfan 4 mg/kg on days -7, -6, -5, -4;
cyclophosphamide 60 mg/kg on days -3 and -2
Lymphoma patients received BEAM; other patients received CYTBI or BUCY; nearly
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van der Lelie 2001 (Continued)
all participants received autologous or allogeneic PBSCT
Age at baseline (years): Group A: median 47 (range 25 to 63); Group B: median 48
(range 18 to 62)
Gender: Group A: 61% male; Group B: 39% male
Number randomised: 36 (Group A: 18; Group B: 18)
Number evaluated: 36 (Group A: 18; Group B: 18)
Interventions Comparison: GM-CSF versus placebo
Group A:GM-CSF (300 µg daily dose) gel, 5 mL twice daily (early in the morning and
before going to sleep) kept in the mouth for as long as possible and then swallowed; no
oral intake for 1 hour afterwards; starting on day 1 (the day after the day of transplant)
and continued until neutrophil recovery (typically up to 14 days after transplant)
Group B: placebo as above
All participants followed hospital’s standard protocol formouth care: toothbrushing after
meals, rinsing with 0.9% saline, and if there was inflammation, 0.12% chlorhexidine
rinse 6 times daily
Compliance: 8 participants (Group A: 4; Group B: 4) did not complete the study; they
all cited the main reason being nausea and the taste of the gel
Duration of treatment: variable and dependent on neutrophil recovery
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed daily by dentists, reported in text as
incidence of grade 3 to 4)
• Oral mucositis: 8 (all 8 sites normal) to 24 (all 8 sites severely affected) oral
assessment score (assessed daily by dentists, reported graphically as median score over
14 days, unable to use data)
• Oral pain: 0 (no pain) to 100 (worst pain) VAS (assessed daily by participant,
reported graphically as median score over 14 days, unable to use data)
• Normalcy of diet: incidence of total parenteral nutrition (started when patients
were unable to eat for longer than 3 days)
• Number of days in hospital (reported as median, unable to use data)
• Opioid analgesic use (reported as incidence; number of days of treatment with
opioid analgesics is an outcome of this review and therefore we did not use these data)
• Blood measurements (not an outcome of this review)
• Fever (not an outcome of this review)
• Infection (not an outcome of this review)
• Antibiotic use (not an outcome of this review)
Notes Sample size calculation: not reported (“GM-CSF was supplied by the sponsor for 18
patients so that 36 patients could be included in the study. This should be enough to
demonstrate a clinically significant difference”)
Funding: “We thank Novartis and Schering-Plough for supplying the GM-CSF” (phar-
maceutical industry)
Declarations/conflicts of interest: not reported
Data handling by review authors:N/A
Other information of note:GM-CSF administration only began after the conditioning
treatment had been completed, by which point oral mucositis may have already begun
to develop
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the patients were randomized to
receive GM-CSF or placebo”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “the patients were randomized to
receive GM-CSF or placebo”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind placebo-controlled”
and “There was no difference in taste or
appearance between the placebo and the
GM-CSF”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind placebo-controlled”
and “There was no difference in taste or
appearance between the placebo and the
GM-CSF”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of lower grades of oral mucositis us-
ing the WHO scale, requiring the patient’s
assessment of pain/soreness and their abil-
ity to swallow.Higher grades havemore ob-
jective elements so may not be affected by
potential lack of blinding of the assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) Low risk Data for outcomes of this review were re-
ported appropriately
Other bias Low risk No other sources of bias are apparent
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Wu 2009
Methods Trial design: parallel (4 arms)
Location: South Korea
Number of centres: 6
Study duration: recruitment from January to August 2007
Trials registry number: none/unknown
Participants Inclusion criteria: 18 years or older with histological evidence of head and neck cancer;
due to receive at least 5 weeks of primary RT, primary chemoradiotherapy, or postopera-
tive RT; agreement to have complete medical history and physical examination; ECOG
score of 0 to 2; white blood counts 3 x 10³/L or higher; platelet counts 100 x 10³/L or
higher
Exclusion criteria: oral ulcers; herpes simplex virus; severe periodontal disease; serum
creatine levels greater than 2 mg/dL; ALT/AST values greater than 200 IU/L; cytotoxic
chemotherapy or RT within 3 weeks of the start of the study; systemic or topical corti-
costeroids within 30 days of the start of the study; participated in another clinical study
within 30 days of the start of the study
Cancer type: head and neck: nasopharynx (Group A: 36%; Group B: 32%); orophar-
ynx (Group A: 24%; Group B: 25%); oral cavity (Group A: 19%; Group B: 25%);
hypopharynx (Group A: 2%; Group B: 4%); other (Group A: 19%; Group B: 14%)
Cancer treatment:
• Radiotherapy: conventional fractionation once daily in 2 (± 0.25) Gy fractions, 5
times per week, for at least 5 weeks
• Chemotherapy: concurrent cisplatin was allowed (just over 50% per group
received this)
Age at baseline (years): Group A: median 56 (range 18 to 75); Group B: median 51
(range 18 to 77)
Gender: Group A: 69% male; Group B: 57% male
Number randomised: 113 (Group A: 85; Group B: 28)
Number evaluated: 103 (Group A: 76; Group B: 27) for incidence of moderate to severe
mucositis; 94 (Group A: 70; Group B: 24) for incidence of severe mucositis
Interventions Comparison: EGF (recombinant human) versus placebo
Group A: EGF
• (n = 29): 10 µg daily by oral spray, applied twice daily, sprayed over the entire oral
mucosa and then swallowed, no oral intake for 30 minutes afterwards; starting on first
day of RT and continuing for 5 weeks
• (n = 29): 50 µg daily as above
• (n = 27): 100 µg daily as above
Group B: placebo as above
All participants gargled with chlorhexidine to maintain oral hygiene
Compliance: not reported
Duration of treatment: 5 weeks
Outcomes • Oral mucositis: RTOG 0 to 4 scale (assessed weekly by radiation oncologists,
reported as incidence of grade 2 to 4 and grade 3 to 4 at week 4 or 5; unclear reporting
for grade 3 to 4, unable to use data) (time to develop mucositis also assessed but not an
outcome of this review)
• WHO oral toxicity grade (assessed weekly, not clear whether this is the WHO 0
to 4 scale for oral mucositis, no data reported)
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• Interruptions to cancer treatment (incidence of 3 or more consecutive days of
interruption to RT)
• Oral pain (assessed weekly, no description of scale used, no data reported)
• Averse events (no data reported; narrative only)
• Opioid analgesic use (assessed weekly, not clear if duration, quantity or incidence
of use was assessed, no data reported)
• Weight (not an outcome of this review)
• Laboratory measurements (not an outcome of this review)
Notes Sample size calculation: allowing for 10% attrition, 26 participants per group required
Funding: “This study was supported by a grant from the National R&D Program for
Cancer Central, Ministry of Health, Welfare and Family Affairs, Republic of Korea
(0620270)” (government) and “The EGF and placebo treatments were supplied free of
charge” (presumably pharmaceutical industry)
Declarations/conflicts of interest: not reported
Data handling by review authors: we combined the 3 EGF groups to make a single
pairwise comparison against placebo; no formal statistical analysis was undertaken for
the different EGF dosages
Other information of note: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “We assigned patients randomly to
4 arms”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Quote: “We assigned patients randomly to
4 arms”
Comment: insufficient information to de-
termine method of random sequence gen-
eration
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
and “Three concentrations of EGF and a
placebo containing the drug delivery vehi-
cle were manufactured, packaged, and sup-
plied in a double-blind fashion”
Comment: the use of a placebo should have
ensured that blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled”
Comment: it is not clear who was blinded.
There are subjective elements to the assess-
ment of most grades of oral mucositis using
the RTOG scale, requiring the patient’s as-
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sessment of pain. Grade 4 is more objective
so may not be affected by potential lack of
blinding of the assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall attrition was 9% (Group A: 11%;
Group B: 4%). Slight differential be-
tween groups but the reasons were reported
and mostly unrelated to interventions/out-
comes. Unlikely to have biased the results
Selective reporting (reporting bias) High risk Several outcomes were assessed but not
properly reported (“No secondary end-
point showed any difference between the
placebo and study groups”)
Other bias Low risk No other sources of bias are apparent
5FU = fluorouracil; AJCC = American Joint Committee on Cancer; ALL = acute lymphoblastic leukaemia; allogeneic = cells from
donor; AML = acute myelogenous leukaemia; AUC = area under the curve; autologous = patients’ own cells; BMT = bone marrow
transplantation; CALGB = Cancer and Leukaemia Group B; cGy = centigray; CML = chronic myelogenous leukaemia; CRT =
chemoradiotherapy; CT = chemotherapy; ECOG = Eastern Co-operative Oncology Group; EGF = epidermal growth factor; EQ-
5D = European Quality Of Life Utility Scale; FACT = Functional Assessment of Cancer Therapy; FDA = US Food and Drug
Administration; G-CSF = granulocyte-colony stimulating factor; GM-CSF = granulocyte-macrophage colony-stimulating factor;
GVHD = graft-versus-host disease; Gy = gray; HLA = human leukocyte antigen; HSCT = haematopoietic stem cell transplantation;
IA = intra-arterial; ITF = intestinal trefoil factor; ITT = intention-to-treat; IV = intravenous; KGF = keratinocyte growth factor;MDS
= myelodysplastic syndrome; N/A = not applicable; NCI-CTC = National Cancer Institute common toxicity criteria; NHL = non-
Hodgkin’s lymphoma; NIH =National Institutes of Health; OMAS = oral mucositis assessment scale; OMDQ = oral mucositis daily
questionnaire; OMWQ-HN = Oral Mucositis Weely Questionnaire - Head and Neck cancer; PBPC = peripheral blood progenitor
cell; PBSCT = peripheral blood stem cell transplantation; PEG = percutaneous endoscopic gastrostomy; PP = per protocol; RT =
radiotherapy; RTOG = Radiation Therapy Oncology Group; SCC = squamous cell carcinoma; SCT = stem cell transplantation; SD
= standard deviation; SMD = standardised mean difference; TBI = total-body irradiation; TGF = transforming growth factor; TPN
= total parenteral nutrition; VAS = visual analogue scale; WBC = white blood cell; WHO =World Health Organization; WCCNR
= Western Consortium for Cancer Nursing Research.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Antin 2002 Recombinant human interleukin-11 versus placebo. Study stopped early due to adverse event triggering preset
stopping rule - data only for 10 patients in rhIL group and 3 placebo
de Koning 2007 TGF-beta(2) versus placebo. Cross-over study with no first period data reported (see Types of studies)
Foncuberta 2001 TGF-beta(3) versus placebo. Participants assigned sequentially, not randomised
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Gebbia 1994 G-CSF versus thymopentin versus G-CSF plus thymopentin versus placebo. Oral mucositis not mentioned
(unknown if measured)
Gladkov 2013 G-CSF (lipegfilgrastim) versus G-CSF (pegfilgrastim). Oral mucositis not mentioned (unknown if measured).
Insufficient information (abstract)
Gordon 1993 GM-CSF versus no treatment. Unclear if randomised or not. Only 13 participants. Insufficient information
(abstract)
Horsley 2007 KGF (palifermin) versus standard care. No random allocation
Hunter 2009 ATL-104 versus placebo. Not RCT - this study combines patients who were in cohorts with increasing doses of
mouthrinse to assess safety, with an RCT
Ifrah 1999 GM-CSF versus placebo. Primary outcome was survival/cure, with mucositis as a toxicity. Unclear if mucositis
was oral or gastrointestinal
Iwase 1997 G-CSF versus no treatment. No mention of randomisation and no description of when intervention given in
relation to cancer treatment
Jones 1996 GM-CSF versus placebo. Unclear if mucositis was oral or gastrointestinal
Karthaus 1998 G-CSF versus placebo. Only 8 patients, 32 chemotherapy cycles and results presented assuming independent
Kubo 2016 G-CSF (pegfilgrastim) versus G-CSF (filgrastim). Incidence of stomatitis reported in adverse events table
Trials registry number: JapicCTI-111394
Lee 2016 G-CSF (pegteograstim) versus G-CSF (pegfilgrastim). Incidence of stomatitis reported in adverse events table
Trials registry number: NCT01328938
Legros 1997 GM-CSF versus placebo. Unclear if mucositis was oral or gastrointestinal
Limaye 2013 AG013 versus placebo. AG013 is composed of recombinant Lactococcus lactis engineered to secrete human Trefoil
Factor 1. Randomised at first but participants not developing oral mucositis in chemotherapy cycle 1 were
excluded from the next phase where oral mucositis was measured, so randomisation was lost
Trials registry number: NCT00938080
Nabholtz 2002 G-CSF (leridistim) versus G-CSF (filgrastim). Incidence of stomatitis reported in adverse events table
NCT00360971 KGF (palifermin) versus placebo. Study terminated at 21 participants (298 planned) due to positive preliminary
results from other palifermin studies
NCT00626639 KGF (palifermin) versus placebo. Study terminated at 5 participants due to departure of principal investigator
and slow enrolment
Pettengell 1992 G-CSF versus no treatment. Unclear if mucositis was oral or gastrointestinal
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Ryu 2007 GM-CSF versus placebo. Some participants (6%) had oral mucositis at baseline
Trials registry number: NCT00008398
Throuvalas 1995 GM-CSF versus no treatment. Probably not RCT - described as comparative study. Only 10 participants. Insuf-
ficient information (abstract)
Tsurusawa 2016 G-CSF versus no treatment. Incidence of stomatitis reported in adverse events table
Trials registry number: UMIN ID: 000000675
Vitale 2014 KGF (palifermin) versus no treatment. From full text it is not RCT - retrospective and allocation of KGF/no
KGF based on doctor’s decision
G-CSF = granulocyte-colony stimulating factor; GM-CSF = granulocyte-macrophage colony-stimulating factor; KGF = keratinocyte
growth factor; RCT = randomised controlled trial; rhIL = recombinant human interleukin; TGF = transforming growth factor.
Characteristics of studies awaiting assessment [ordered by study ID]
ACTRN12606000083594
Methods Multicentre, double-blind, randomised placebo-controlled trial
Participants 18 years or older with lymphoma and due to undergo high-dose BEAM chemotherapy and autologous stem cell
transplantation as inpatient
Interventions Whey growth factor extract at 13.5 mg/mL in sterile saline versus placebo (sterile saline)
Outcomes • Oral mucositis: WHO 0 to 4 scale
• Normalcy of diet: incidence of enteral/parenteral feeding
• Duration of opiate analgesics
• Quality of life: OMDQ
• Adverse events
Notes Funding: commercial sector/industry (TGR Biosciences, Australia)
Contact: correspondence with pharmaceutical company suggests no benefit
Antonadou 1998
Methods Multicentre, randomised controlled trial (no placebo)
Participants Head and neck cancer; receiving continuous course of radiotherapy for 6 to 7 weeks
Interventions GM-CSF (subcutaneous) versus no treatment
Outcomes Signs and symptoms of oral mucositis: erythema, pain and dysphagia each measured on 0 to 3 scale
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Notes Abstract only (we were unable to link this abstract to a full-text report)
Some P values suggest benefit for GM-CSF at some time points
Quote: “GM-CSF reduces the incidence and severity of radiation mucositis and allows the completion of the XRT
treatment without protraction”
Elsaid 2001
Methods Randomised controlled trial (no placebo)
Participants Anaemic participants with head and neck cancer receiving radiotherapy once daily (1.8 Gy or 2 Gy) to doses of 66
Gy to 70 Gy
Interventions Recombinant human erythropoietin versus no treatment
Outcomes Incidence of grade 3 mucositis and dermatitis
Notes Abstract only (we were unable to link this abstract to a full-text report)
Higher rate of mucositis in the no-treatment group (5.9% versus 0%)
Grzegorczyk 2006
Methods Randomised placebo-controlled trial
Participants Adults (aged 19 to 68 years) undergoing haematopoietic stem cell transplantation
Interventions G-CSF versus placebo
Outcomes • Oral mucositis: WHO 0 to 4 scale
• Oral pain: 0 to 10 VAS
• Neutrophil counts
Notes Translation provided insufficient information. Discrepancy between graph legends and descriptions
Unable to contact author
Koga 2015
Methods Randomised controlled trial (no placebo)
Participants Children with B-cell non-Hodgkin’s lymphoma (B-NHL) receiving chemotherapy
Interventions G-CSF versus no treatment
Outcomes • Oral mucositis (no further details)
• Duration of hospitalisation
• Incidence of febrile neutropenia
• Infections
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• Time to neutrophil recovery
• Costs
Notes Abstract only (we were unable to link this abstract to a full-text report)
Quote: “G-CSF+ patients showed a positive impact on the meantime to neutrophil recovery and hospital stay, but
they had no impact in incidences of febrile neutropenia, infections, stomatitis, and total cost”
NCT00293462
Methods Double-blind, randomised placebo-controlled trial (1 of the 3 arms is a cross-over)
Participants 18 years or older with head and neck cancer due to receive conventional or hyperfractionated radiotherapy or intensity-
modulated radiotherapy (IMRT) with or without concurrent chemotherapy
Interventions GM-CSF mouthwash versus salt and soda mouthwash versus both (cross-over arm)
Outcomes • Oral mucositis: scale/s unclear
• Quality of life: 0 to 10 scale
• Oral pain: 0 to 10 scale
• Functional status by Karnofsky performance status scale
Notes Trials registry number: NCT00293462
Funding: University of California, San Francisco; National Cancer Institute (NCI)
NCT00393822
Methods Double-blind, randomised placebo-controlled trial
Participants 18 years or older with resected colon cancer (American Joint Committee on Cancer Stage 2B or 3) and due to receive
5-FU and leucovorin
Interventions KGF versus placebo
Outcomes • Oral mucositis: WHO 0 to 4 scale - incidence and duration of moderate to severe (grade 2 to 4)
• Interruptions to cancer treatment
• Mouth and throat pain
• Adverse events
• Survival
• Changes in laboratory values
• Serum anti-KGF antibody formation
Notes Trials registry number: NCT00393822
Funding: Amgen (pharmaceutical industry)
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NCT02303197
Methods Randomised controlled trial (no placebo)
Participants Adults (aged 18 to 75 years) with head and neck cancer due to receive radiotherapy
Interventions Recombinant human EGF versus Chining
Outcomes • Oral mucositis: RTOG 0 to 4 scale
• Oral pain: VAS
• Quality of life: EORTC QLQ-H&N35
• Weight change
• Safety (blood/urine/kidney/liver/electrocardiogram)
Notes Trials registry number: NCT02303197
Funding: Tianjin Medical University Cancer Institute and Hospital
NCT02313792
Methods Double-blind, randomised placebo-controlled trial
Participants 16 years or older due to receive preparative cancer treatment regimen followed by autologous or allogeneic HSCT
(cancer type not reported)
Interventions KGF versus placebo
Outcomes • Oral mucositis: incidence and duration of severe (scale not reported)
• Oral pain: VAS
• Use of opioid analgesics
• Quality of life (scale not reported)
• Cost-effectiveness
Notes Trials registry number: NCT02313792
Funding: The Catholic University of Korea; Collaborator: “BLNH” (probably pharmaceutical industry)
Patte 2002
Methods Randomised controlled trial (no placebo)
Participants Children with non-Hodgkin’s lymphoma due to receive 2 courses of COPAD induction chemotherapy
Interventions G-CSF versus no treatment
Outcomes • Mucositis (unclear if oral or gastrointestinal): 0 to 4 scale - incidence of severe (grade 3 to 4)
• Duration of hospitalisation
• Febrile neutropenia
• Severe infections
• Blood measurements
• Use of IV antifungals or antibiotics
• Survival
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Notes Quote: “The incidence of grade 3 and 4 mucositis was similar in both arms”
Contact: emailed corresponding author July 2017 to clarify if mucositis is oral or gastrointestinal
Schuster 2007a
Methods Multicentre, double-blind, randomised placebo-controlled trial
Participants 18 years or older with multiple myeloma or lymphoma due to receive high-dose chemotherapy (with or without
TBI) followed by autologous HSCT
Interventions Recombinant human FGF-20 (velafermin) (3 arms with different dosages) versus placebo
Outcomes • Oral mucositis: WHO 0 to 4 scale - incidence and duration of severe (grade 3 to 4)
• Adverse events
Notes Abstract only (we were unable to link this abstract to a full-text report)
Trials registry number: NCT00104065
Schuster 2007b
Methods Multicentre, double-blind, randomised placebo-controlled trial
Participants 18 years or older with multiple myeloma or lymphoma undergoing high-dose chemotherapy (with or without TBI)
followed by autologous HSCT
Interventions Recombinant human FGF-20 (velafermin) (3 arms with different dosages) versus placebo
Outcomes • Oral mucositis: WHO 0 to 4 scale - incidence of severe (grade 3 to 4)
• Adverse events
Notes Abstract only (we were unable to link this abstract to a full-text report)
Trials registry number: NCT00323518
Shea 2007
Methods Randomised controlled trial (no placebo)
Participants Aged 18 to 74 years with lymphoma, leukaemia or multiple myeloma; TBI plus high-dose chemotherapy followed
by autologous peripheral blood stem cell transplantation
Interventions KGF (4 arms with different schedules)
Outcomes • Oral mucositis: WHO 0 to 4 scale
• Mouth and throat pain: OMDQ
• Opioid analgesic use
• Adverse events
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Notes Abstract only (we were unable to link this abstract to a full-text report)
Trials registry number: NCT00109031
Spielberger 2001
Methods Multicentre, double-blind, randomised placebo-controlled trial
Participants Haematologic malignancies; eligible for TBI plus high-dose chemotherapy followed by autologous peripheral blood
stem cell transplantation; aged 12 to 65 years
Interventions KGF (7 doses) versus KGF (4 doses + 3 doses of placebo) versus placebo (7 doses)
Outcomes • Oral mucositis: WHO 0 to 4 scale - incidence and duration of severe (grade 3 to 4)
• Use of opioid analgesics
• Quality of life
• Febrile neutropenia
• Use of IV antifungals or antibiotics
• Diarrhoea
Notes Abstract only (we were unable to link this abstract to a full-text report)
Trials registry number: NCT00004132
5FU = fluorouracil; EGF = epidermal growth factor; EORTC QLQ-H&N35 = European Organisation for Research and Treatment
of Cancer, Quality of Life Questionnaire, Head and Neck Module; G-CSF = granulocyte-colony stimulating factor; GM-CSF
= granulocyte-macrophage colony-stimulating factor; HSCT = haematopoietic stem cell transplantation; IV = intravenous; KGF
= keratinocyte growth factor; NCI-CTC = National Cancer Institute common toxicity criteria; OMDQ = oral mucositis daily
questionnaire; FGF-20 = fibroblast growth factor-20; TBI = total-body irradiation; VAS = visual analogue scale; WHO = World
Health Organization.
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D A T A A N D A N A L Y S E S
Comparison 1. KGF versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral mucositis (any) 8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 BMT/SCT after
conditioning for
haematological cancers
4 655 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.88, 1.05]
1.2 RT to head & neck with
cisplatin
2 374 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.90, 1.00]
1.3 CT alone for mixed
cancers
2 215 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.60, 0.85]
2 Oral mucositis (moderate +
severe)
13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 BMT/SCT after
conditioning for
haematological cancers
6 852 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.80, 0.99]
2.2 RT to head & neck with
cisplatin/5FU
3 471 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.83, 1.00]
2.3 CT alone for mixed
cancers
4 344 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.45, 0.70]
3 Oral mucositis (severe) 12 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 BMT/SCT after
conditioning for
haematological cancers
6 852 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.65, 1.11]
3.2 RT to head & neck with
cisplatin/5FU
3 471 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.69, 0.90]
3.3 CT alone for mixed
cancers
3 263 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.14, 0.65]
4 Interruptions to cancer treatment
(unscheduled RT breaks of 5 or
more days)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 RT to head & neck with
cisplatin/5FU
3 473 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.65, 1.59]
5 Interruptions to cancer
treatment (chemotherapy
delays/discontinuations)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 RT to head & neck with
cisplatin
2 374 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.62, 1.47]
6 Oral pain 3 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 BMT/SCT after
conditioning for
haematological cancers
1 42 Mean Difference (IV, Random, 95% CI) -0.85 [-3.00, 1.30]
6.2 RT to head & neck with
cisplatin
2 374 Mean Difference (IV, Random, 95% CI) -0.12 [-0.27, 0.02]
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7 Normalcy of diet (use of
supplemental nutrition)
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 BMT/SCT after
conditioning for
haematological cancers
4 714 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.58, 1.34]
7.2 RT to head & neck with
cisplatin/5FU
3 473 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.77, 1.37]
8 Normalcy of diet (worst ability
to eat score - 1 to 4 scale)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 BMT/SCT after
conditioning for
haematological cancers
1 42 Mean Difference (IV, Random, 95% CI) -0.5 [-1.21, 0.21]
9 Number of days in hospital 1 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 BMT/SCT after
conditioning for
haematological cancers
1 281 Mean Difference (IV, Random, 95% CI) 0.0 [-1.64, 1.64]
10 Number of days of treatment
with opioid analgesics
2 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 BMT/SCT
after conditioning for
haematological cancers
2 323 Mean Difference (IV, Random, 95% CI) -1.41 [-3.33, 0.51]
Comparison 2. KGF (dose comparison)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral mucositis (any) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 BMT/SCT after
conditioning for
haematological cancers
1 224 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.75, 1.03]
2 Oral mucositis (moderate +
severe)
3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 BMT/SCT after
conditioning for
haematological cancers
2 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 CT alone for metastatic
colorectal cancer
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Oral mucositis (severe) 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 BMT/SCT after
conditioning for
haematological cancers
2 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Oral pain (maximum score on 0
to 10 VAS)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 BMT/SCT after
conditioning for
haematological cancers
1 28 Mean Difference (IV, Random, 95% CI) 0.70 [-1.90, 3.30]
5 Normalcy of diet (use of TPN) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
133Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5.1 BMT/SCT after
conditioning for
haematological cancers
1 224 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.63, 1.02]
6 Normalcy of diet (worst ability
to eat score - 1 to 4 scale)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 BMT/SCT after
conditioning for
haematological cancers
1 28 Mean Difference (IV, Random, 95% CI) 0.40 [-0.41, 1.21]
7 Number of days in hospital 1 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 BMT/SCT after
conditioning for
haematological cancers
1 224 Mean Difference (IV, Random, 95% CI) 0.0 [-1.78, 1.78]
8 Number of days of treatment
with opioid analgesics
2 Mean Difference (IV, Random, 95% CI) Totals not selected
8.1 BMT/SCT after
conditioning for
haematological cancers
2 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. KGF versus chlorhexidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral mucositis (any) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 CT alone for
haematological cancer
1 90 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.54, 0.85]
2 Oral mucositis (moderate +
severe)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 CT alone for
haematological cancer
1 90 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.05, 0.28]
3 Oral mucositis (severe) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 CT alone for
haematological cancer
1 90 Risk Ratio (M-H, Random, 95% CI) 0.01 [0.00, 0.19]
Comparison 4. GM-CSF versus placebo/no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral mucositis (any) 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 BMT/SCT after
conditioning for mixed cancers
1 90 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.80, 1.04]
1.2 RT to head & neck 1 29 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.82, 1.23]
2 Oral mucositis (moderate +
severe)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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2.1 BMT/SCT after
conditioning for
haematological cancers
1 109 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.79, 1.13]
2.2 RT to head & neck 1 29 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.49, 1.06]
3 Oral mucositis (severe) 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 BMT/SCT after
conditioning for mixed cancers
3 235 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.33, 1.67]
3.2 RT to head & neck 1 29 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.01, 7.09]
3.3 CT alone for mixed
cancers
2 65 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.05, 7.11]
4 Oral pain (maximum score on 0
to 10 VAS)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 BMT/SCT after
conditioning for mixed cancers
1 90 Mean Difference (IV, Random, 95% CI) 0.60 [-0.85, 2.05]
5 Normalcy of diet (use of feeding
tube/parenteral nutrition)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 BMT/SCT after
conditioning for
haematological cancers
1 36 Risk Ratio (M-H, Random, 95% CI) 1.1 [0.63, 1.91]
5.2 RT to head & neck 1 29 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.01, 7.09]
6 Number of days of treatment
with opioid analgesics
1 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 BMT/SCT after
conditioning for mixed cancers
1 90 Mean Difference (IV, Random, 95% CI) -1.10 [-1.91, -0.29]
Comparison 5. GM-CSF (dose comparison)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral mucositis (severe) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 CT alone for breast cancer 1 36 Risk Ratio (M-H, Random, 95% CI) 2.75 [1.07, 7.04]
Comparison 6. GM-CSF versus sucralfate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral mucositis (moderate +
severe)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 RT to head & neck 1 40 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.80, 1.14]
2 Oral mucositis (severe) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 RT to head & neck 1 40 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.24, 1.21]
3 Interruptions to cancer treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 RT to head & neck 1 40 Risk Ratio (M-H, Random, 95% CI) 0.13 [0.01, 2.36]
4 Normalcy of diet (use of PEG
tube)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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4.1 RT to head & neck 1 40 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.01, 3.56]
Comparison 7. G-CSF versus placebo/no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral mucositis (any) 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 RT to head & neck 2 54 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.86, 1.22]
1.2 CT alone for lung cancer 1 195 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.40, 0.87]
2 Oral mucositis (moderate +
severe)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 CT alone for breast cancer 1 14 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.12, 0.95]
3 Oral mucositis (severe) 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 RT to head & neck 2 54 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.15, 0.87]
4 Interruptions to cancer treatment
(RT interruption)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 RT to head & neck 1 40 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.01, 4.31]
5 Normalcy of diet (use of PEG
tube)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 RT to head & neck 1 40 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.01, 2.86]
Comparison 8. G-CSF (pegfilgrastim) versus G-CSF (filgrastim)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral mucositis (any) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 BMT/SCT after
conditioning for mixed cancers
1 61 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.27]
2 Oral mucositis (moderate +
severe)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 BMT/SCT after
conditioning for mixed cancers
1 61 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.55, 1.11]
3 Normalcy of diet (use of
supplemental nutrition)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 BMT/SCT after
conditioning for mixed cancers
1 61 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.94, 1.06]
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Comparison 9. EGF versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral mucositis (moderate +
severe)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 BMT/SCT after
conditioning for
haematological cancers
1 136 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.78, 1.43]
1.2 RT to head & neck +/-
cisplatin
1 103 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.45, 0.99]
2 Oral mucositis (severe) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 BMT/SCT after
conditioning for
haematological cancers
1 136 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.59, 1.80]
3 Interruptions to cancer treatment
(RT breaks > 2 consecutive
days)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 RT to head & neck +/-
cisplatin
1 113 Risk Ratio (M-H, Random, 95% CI) 4.38 [0.25, 75.44]
4 Normalcy of diet (use of
supplemental nutrition)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 BMT/SCT after
conditioning for
haematological cancers
1 136 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.55, 1.94]
Comparison 10. ITF versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral mucositis (any) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 CT alone for colorectal
cancer
1 99 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.35, 0.79]
2 Oral mucositis (moderate +
severe)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 CT alone for colorectal
cancer
1 99 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.10, 0.48]
3 Oral mucositis (severe) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 CT alone for colorectal
cancer
1 99 Risk Ratio (M-H, Random, 95% CI) 1.52 [0.06, 36.39]
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Comparison 11. ITF (dose comparison)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral mucositis (any) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 CT alone for colorectal
cancer
1 66 Risk Ratio (M-H, Random, 95% CI) 1.3 [0.67, 2.54]
2 Oral mucositis (moderate +
severe)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 CT alone for colorectal
cancer
1 66 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.18, 3.09]
3 Oral mucositis (severe) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 CT alone for colorectal
cancer
1 66 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 7.90]
Comparison 12. Erythropoietin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral mucositis (any) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 BMT/SCT after
conditioning for
haematological cancers
1 80 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.21, 0.60]
2 Oral mucositis (moderate +
severe)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 BMT/SCT after
conditioning for
haematological cancers
1 80 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.24, 0.79]
3 Oral mucositis (severe) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 BMT/SCT after
conditioning for
haematological cancers
1 80 Risk Ratio (M-H, Random, 95% CI) 0.4 [0.14, 1.17]
4 Number of days in hospital 1 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 BMT/SCT after
conditioning for
haematological cancers
1 80 Mean Difference (IV, Random, 95% CI) -2.95 [-7.73, 1.83]
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Analysis 1.1. Comparison 1 KGF versus placebo, Outcome 1 Oral mucositis (any).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 1 KGF versus placebo
Outcome: 1 Oral mucositis (any)
Study or subgroup KGF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Blazar 2006 60/65 31/31 30.1 % 0.93 [ 0.86, 1.01 ]
Blijlevens 2013 167/224 43/57 16.8 % 0.99 [ 0.84, 1.17 ]
Fink 2011 24/30 32/36 12.2 % 0.90 [ 0.73, 1.11 ]
Spielberger 2004 106/106 106/106 40.9 % 1.00 [ 0.98, 1.02 ]
Subtotal (95% CI) 425 230 100.0 % 0.96 [ 0.88, 1.05 ]
Total events: 357 (KGF), 212 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 10.05, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 0.80 (P = 0.42)
2 RT to head % neck with cisplatin
Henke 2011 85/92 89/94 43.4 % 0.98 [ 0.90, 1.05 ]
Le 2011 86/94 93/94 56.6 % 0.92 [ 0.87, 0.99 ]
Subtotal (95% CI) 186 188 100.0 % 0.95 [ 0.90, 1.00 ]
Total events: 171 (KGF), 182 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.13, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 2.04 (P = 0.041)
3 CT alone for mixed cancers
Bradstock 2014 46/73 67/78 78.3 % 0.73 [ 0.60, 0.89 ]
Rosen 2006 15/28 30/36 21.7 % 0.64 [ 0.44, 0.93 ]
Subtotal (95% CI) 101 114 100.0 % 0.71 [ 0.60, 0.85 ]
Total events: 61 (KGF), 97 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 3.80 (P = 0.00015)
0.1 0.2 0.5 1 2 5 10
Favours KGF Favours placebo
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Analysis 1.2. Comparison 1 KGF versus placebo, Outcome 2 Oral mucositis (moderate + severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 1 KGF versus placebo
Outcome: 2 Oral mucositis (moderate + severe)
Study or subgroup KGF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Blazar 2006 53/65 31/31 22.5 % 0.82 [ 0.73, 0.93 ]
Blijlevens 2013 135/224 33/57 12.2 % 1.04 [ 0.81, 1.33 ]
Fink 2011 12/30 20/36 3.8 % 0.72 [ 0.43, 1.22 ]
Freytes 2004 16/28 14/14 8.1 % 0.59 [ 0.42, 0.82 ]
Jagasia 2012 69/77 69/78 24.0 % 1.01 [ 0.91, 1.13 ]
Spielberger 2004 98/106 106/106 29.4 % 0.92 [ 0.87, 0.98 ]
Subtotal (95% CI) 530 322 100.0 % 0.89 [ 0.80, 0.99 ]
Total events: 383 (KGF), 273 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 14.82, df = 5 (P = 0.01); I2 =66%
Test for overall effect: Z = 2.05 (P = 0.040)
2 RT to head % neck with cisplatin/5FU
Brizel 2008 60/65 31/32 36.6 % 0.95 [ 0.87, 1.05 ]
Henke 2011 77/92 83/94 30.7 % 0.95 [ 0.84, 1.06 ]
Le 2011 75/94 91/94 32.7 % 0.82 [ 0.74, 0.92 ]
Subtotal (95% CI) 251 220 100.0 % 0.91 [ 0.83, 1.00 ]
Total events: 212 (KGF), 205 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.83, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 2.01 (P = 0.044)
3 CT alone for mixed cancers
Bradstock 2014 25/73 45/78 34.7 % 0.59 [ 0.41, 0.86 ]
Meropol 2003 23/54 18/27 28.5 % 0.64 [ 0.42, 0.96 ]
Rosen 2006 8/28 22/36 11.6 % 0.47 [ 0.25, 0.89 ]
Vadhan-Raj 2010 14/32 14/16 25.2 % 0.50 [ 0.32, 0.77 ]
Subtotal (95% CI) 187 157 100.0 % 0.56 [ 0.45, 0.70 ]
Total events: 70 (KGF), 99 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.06, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 5.13 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours KGF Favours placebo
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Analysis 1.3. Comparison 1 KGF versus placebo, Outcome 3 Oral mucositis (severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 1 KGF versus placebo
Outcome: 3 Oral mucositis (severe)
Study or subgroup KGF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Blazar 2006 43/65 24/31 22.3 % 0.85 [ 0.66, 1.11 ]
Blijlevens 2013 70/224 21/57 17.5 % 0.85 [ 0.57, 1.25 ]
Fink 2011 7/30 11/36 7.7 % 0.76 [ 0.34, 1.72 ]
Freytes 2004 4/28 1/14 1.5 % 2.00 [ 0.25, 16.26 ]
Jagasia 2012 62/77 57/78 25.1 % 1.10 [ 0.93, 1.31 ]
Spielberger 2004 67/106 104/106 25.9 % 0.64 [ 0.56, 0.75 ]
Subtotal (95% CI) 530 322 100.0 % 0.85 [ 0.65, 1.11 ]
Total events: 253 (KGF), 218 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 22.22, df = 5 (P = 0.00047); I2 =78%
Test for overall effect: Z = 1.20 (P = 0.23)
2 RT to head % neck with cisplatin/5FU
Brizel 2008 43/65 26/32 32.6 % 0.81 [ 0.64, 1.04 ]
Henke 2011 47/92 63/94 31.5 % 0.76 [ 0.60, 0.97 ]
Le 2011 51/94 65/94 35.9 % 0.78 [ 0.62, 0.99 ]
Subtotal (95% CI) 251 220 100.0 % 0.79 [ 0.69, 0.90 ]
Total events: 141 (KGF), 154 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 3.41 (P = 0.00064)
3 CT alone for mixed cancers
Bradstock 2014 3/73 8/78 34.5 % 0.40 [ 0.11, 1.45 ]
Rosen 2006 1/28 4/36 12.6 % 0.32 [ 0.04, 2.72 ]
Vadhan-Raj 2010 4/32 8/16 53.0 % 0.25 [ 0.09, 0.71 ]
Subtotal (95% CI) 133 130 100.0 % 0.30 [ 0.14, 0.65 ]
Total events: 8 (KGF), 20 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.09 (P = 0.0020)
0.1 0.2 0.5 1 2 5 10
Favours KGF Favours placebo
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Analysis 1.4. Comparison 1 KGF versus placebo, Outcome 4 Interruptions to cancer treatment
(unscheduled RT breaks of 5 or more days).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 1 KGF versus placebo
Outcome: 4 Interruptions to cancer treatment (unscheduled RT breaks of 5 or more days)
Study or subgroup KGF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 RT to head % neck with cisplatin/5FU
Brizel 2008 7/67 4/32 15.2 % 0.84 [ 0.26, 2.65 ]
Henke 2011 14/92 13/94 41.5 % 1.10 [ 0.55, 2.21 ]
Le 2011 14/94 14/94 43.3 % 1.00 [ 0.50, 1.98 ]
Subtotal (95% CI) 253 220 100.0 % 1.01 [ 0.65, 1.59 ]
Total events: 35 (KGF), 31 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
0.1 0.2 0.5 1 2 5 10
Favours KGF Favours placebo
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Analysis 1.5. Comparison 1 KGF versus placebo, Outcome 5 Interruptions to cancer treatment
(chemotherapy delays/discontinuations).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 1 KGF versus placebo
Outcome: 5 Interruptions to cancer treatment (chemotherapy delays/discontinuations)
Study or subgroup KGF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 RT to head % neck with cisplatin
Henke 2011 28/92 38/94 45.5 % 0.75 [ 0.51, 1.12 ]
Le 2011 49/94 42/94 54.5 % 1.17 [ 0.87, 1.57 ]
Subtotal (95% CI) 186 188 100.0 % 0.96 [ 0.62, 1.47 ]
Total events: 77 (KGF), 80 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.07, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.21 (P = 0.84)
0.1 0.2 0.5 1 2 5 10
Favours KGF Favours placebo
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Analysis 1.6. Comparison 1 KGF versus placebo, Outcome 6 Oral pain.
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 1 KGF versus placebo
Outcome: 6 Oral pain
Study or subgroup KGF Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BMT/SCT after conditioning for haematological cancers
Freytes 2004 (1) 28 3.25 (3.4586) 14 4.1 (3.3) 100.0 % -0.85 [ -3.00, 1.30 ]
Subtotal (95% CI) 28 14 100.0 % -0.85 [ -3.00, 1.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
2 RT to head % neck with cisplatin
Henke 2011 (2) 92 1.52 (0.69) 94 1.57 (0.63) 51.7 % -0.05 [ -0.24, 0.14 ]
Le 2011 (3) 94 1.66 (0.73) 94 1.86 (0.65) 48.3 % -0.20 [ -0.40, 0.00 ]
Subtotal (95% CI) 186 188 100.0 % -0.12 [ -0.27, 0.02 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 1.63 (P = 0.10)
-4 -2 0 2 4
Favours KGF Favours placebo
(1) 0 (no pain) to 10 (worst pain) scale reporting mean worst score experienced
(2) 0 (no pain) to 4 (worst pain) reporting overall mean
(3) 0 (no pain) to 4 (worst pain) reporting overall mean
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Analysis 1.7. Comparison 1 KGF versus placebo, Outcome 7 Normalcy of diet (use of supplemental
nutrition).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 1 KGF versus placebo
Outcome: 7 Normalcy of diet (use of supplemental nutrition)
Study or subgroup KGF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Blijlevens 2013 123/224 23/57 25.4 % 1.36 [ 0.97, 1.91 ]
Fink 2011 14/30 25/36 22.8 % 0.67 [ 0.43, 1.04 ]
Jagasia 2012 43/77 38/78 26.3 % 1.15 [ 0.85, 1.55 ]
Spielberger 2004 33/106 58/106 25.5 % 0.57 [ 0.41, 0.79 ]
Subtotal (95% CI) 437 277 100.0 % 0.89 [ 0.58, 1.34 ]
Total events: 213 (KGF), 144 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 17.23, df = 3 (P = 0.00063); I2 =83%
Test for overall effect: Z = 0.57 (P = 0.57)
2 RT to head % neck with cisplatin/5FU
Brizel 2008 43/67 20/32 36.7 % 1.03 [ 0.74, 1.42 ]
Henke 2011 13/92 21/94 16.2 % 0.63 [ 0.34, 1.19 ]
Le 2011 63/94 52/94 47.1 % 1.21 [ 0.96, 1.53 ]
Subtotal (95% CI) 253 220 100.0 % 1.03 [ 0.77, 1.37 ]
Total events: 119 (KGF), 93 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.08, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.17 (P = 0.86)
0.1 0.2 0.5 1 2 5 10
Favours KGF Favours placebo
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Analysis 1.8. Comparison 1 KGF versus placebo, Outcome 8 Normalcy of diet (worst ability to eat score - 1
to 4 scale).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 1 KGF versus placebo
Outcome: 8 Normalcy of diet (worst ability to eat score - 1 to 4 scale)
Study or subgroup KGF Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BMT/SCT after conditioning for haematological cancers
Freytes 2004 (1) 28 2 (1.0985) 14 2.5 (1.1) 100.0 % -0.50 [ -1.21, 0.21 ]
Subtotal (95% CI) 28 14 100.0 % -0.50 [ -1.21, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
-10 -5 0 5 10
Favours KGF Favours placebo
(1) Scale: 1 = normal, 2 = only soft solids, 3 = only liquids, 4 = no solids or liquids
Analysis 1.9. Comparison 1 KGF versus placebo, Outcome 9 Number of days in hospital.
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 1 KGF versus placebo
Outcome: 9 Number of days in hospital
Study or subgroup KGF Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BMT/SCT after conditioning for haematological cancers
Blijlevens 2013 224 23 (6.7823) 57 23 (5.3) 100.0 % 0.0 [ -1.64, 1.64 ]
Subtotal (95% CI) 224 57 100.0 % 0.0 [ -1.64, 1.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
-10 -5 0 5 10
Favours KGF Favours placebo
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Analysis 1.10. Comparison 1 KGF versus placebo, Outcome 10 Number of days of treatment with opioid
analgesics.
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 1 KGF versus placebo
Outcome: 10 Number of days of treatment with opioid analgesics
Study or subgroup KGF Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BMT/SCT after conditioning for haematological cancers
Blijlevens 2013 224 11 (13.9686) 57 12 (13) 25.1 % -1.00 [ -4.84, 2.84 ]
Freytes 2004 28 2.35 (3.1609) 14 3.9 (3.6) 74.9 % -1.55 [ -3.77, 0.67 ]
Subtotal (95% CI) 252 71 100.0 % -1.41 [ -3.33, 0.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
-10 -5 0 5 10
Favours KGF Favours placebo
Analysis 2.1. Comparison 2 KGF (dose comparison), Outcome 1 Oral mucositis (any).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 2 KGF (dose comparison)
Outcome: 1 Oral mucositis (any)
Study or subgroup 180 g/kg total dose
360
g/kg
total dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Blijlevens 2013 76/109 91/115 100.0 % 0.88 [ 0.75, 1.03 ]
Subtotal (95% CI) 109 115 100.0 % 0.88 [ 0.75, 1.03 ]
Total events: 76 (180 g/kg total dose), 91 (360 g/kg total dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
0.1 0.2 0.5 1 2 5 10
Favours 180 g/kg total Favours 360 g/kg total
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Analysis 2.2. Comparison 2 KGF (dose comparison), Outcome 2 Oral mucositis (moderate + severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 2 KGF (dose comparison)
Outcome: 2 Oral mucositis (moderate + severe)
Study or subgroup Lower dose Higher dose Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Blijlevens 2013 (1) 56/109 79/115 0.75 [ 0.60, 0.93 ]
Freytes 2004 (2) 9/14 7/14 1.29 [ 0.67, 2.47 ]
2 CT alone for metastatic colorectal cancer
Meropol 2003 (3) 12/25 11/29 1.27 [ 0.68, 2.35 ]
0.1 0.2 0.5 1 2 5 10
Favours lower dose Favours higher dose
(1) Total dose: 180 vs 360 g/kg
(2) Total dose: 325 vs 650 g/kg
(3) Total dose: 3 to 60 vs 120 to 240 g/kg
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Analysis 2.3. Comparison 2 KGF (dose comparison), Outcome 3 Oral mucositis (severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 2 KGF (dose comparison)
Outcome: 3 Oral mucositis (severe)
Study or subgroup Lower dose Higher dose Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Blijlevens 2013 (1) 26/109 44/115 0.62 [ 0.41, 0.94 ]
Freytes 2004 (2) 3/14 1/14 3.00 [ 0.35, 25.46 ]
0.1 0.2 0.5 1 2 5 10
Favours lower dose Favours higher dose
(1) Total dose: 180 vs 360 g/kg
(2) Total dose: 325 vs 650 g/kg
Analysis 2.4. Comparison 2 KGF (dose comparison), Outcome 4 Oral pain (maximum score on 0 to 10
VAS).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 2 KGF (dose comparison)
Outcome: 4 Oral pain (maximum score on 0 to 10 VAS)
Study or subgroup 325 g/kg total dose
650
g/kg
total dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BMT/SCT after conditioning for haematological cancers
Freytes 2004 14 3.6 (3.7) 14 2.9 (3.3) 100.0 % 0.70 [ -1.90, 3.30 ]
Subtotal (95% CI) 14 14 100.0 % 0.70 [ -1.90, 3.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
-10 -5 0 5 10
Favours 325 g/kg total Favours 650 g/kg total
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Analysis 2.5. Comparison 2 KGF (dose comparison), Outcome 5 Normalcy of diet (use of TPN).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 2 KGF (dose comparison)
Outcome: 5 Normalcy of diet (use of TPN)
Study or subgroup 180 g/kg total dose
360
g/kg
total dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Blijlevens 2013 53/109 70/115 100.0 % 0.80 [ 0.63, 1.02 ]
Subtotal (95% CI) 109 115 100.0 % 0.80 [ 0.63, 1.02 ]
Total events: 53 (180 g/kg total dose), 70 (360 g/kg total dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
0.1 0.2 0.5 1 2 5 10
Favours 180 g/kg total Favours 360 g/kg total
Analysis 2.6. Comparison 2 KGF (dose comparison), Outcome 6 Normalcy of diet (worst ability to eat
score - 1 to 4 scale).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 2 KGF (dose comparison)
Outcome: 6 Normalcy of diet (worst ability to eat score - 1 to 4 scale)
Study or subgroup 325 g/kg total dose
650
g/kg
total dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BMT/SCT after conditioning for haematological cancers
Freytes 2004 14 2.2 (1.1) 14 1.8 (1.1) 100.0 % 0.40 [ -0.41, 1.21 ]
Subtotal (95% CI) 14 14 100.0 % 0.40 [ -0.41, 1.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
-10 -5 0 5 10
Favours 325 g/kg total Favours 650 g/kg total
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Analysis 2.7. Comparison 2 KGF (dose comparison), Outcome 7 Number of days in hospital.
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 2 KGF (dose comparison)
Outcome: 7 Number of days in hospital
Study or subgroup 180 g/kg total dose
360
g/kg
total dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BMT/SCT after conditioning for haematological cancers
Blijlevens 2013 109 23 (7) 115 23 (6.6) 100.0 % 0.0 [ -1.78, 1.78 ]
Subtotal (95% CI) 109 115 100.0 % 0.0 [ -1.78, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
-10 -5 0 5 10
Favours 180 g/kg total Favours 360 g/kg total
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Analysis 2.8. Comparison 2 KGF (dose comparison), Outcome 8 Number of days of treatment with opioid
analgesics.
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 2 KGF (dose comparison)
Outcome: 8 Number of days of treatment with opioid analgesics
Study or subgroup Lower dose Higher dose
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BMT/SCT after conditioning for haematological cancers
Blijlevens 2013 (1) 109 11 (14) 115 11 (14) 0.0 [ -3.67, 3.67 ]
Freytes 2004 (2) 14 4.3 (3.5) 14 3.9 (3.5) 0.40 [ -2.19, 2.99 ]
-10 -5 0 5 10
Favours lower dose Favours higher dose
(1) Total dose: 180 vs 360 g/kg
(2) Total dose: 325 vs 650 g/kg
Analysis 3.1. Comparison 3 KGF versus chlorhexidine, Outcome 1 Oral mucositis (any).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 3 KGF versus chlorhexidine
Outcome: 1 Oral mucositis (any)
Study or subgroup KGF Chlorhexidine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CT alone for haematological cancer
Gholizadeh 2016 29/45 43/45 100.0 % 0.67 [ 0.54, 0.85 ]
Subtotal (95% CI) 45 45 100.0 % 0.67 [ 0.54, 0.85 ]
Total events: 29 (KGF), 43 (Chlorhexidine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.42 (P = 0.00063)
0.1 0.2 0.5 1 2 5 10
Favours KGF Favours chlorhexidine
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Analysis 3.2. Comparison 3 KGF versus chlorhexidine, Outcome 2 Oral mucositis (moderate + severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 3 KGF versus chlorhexidine
Outcome: 2 Oral mucositis (moderate + severe)
Study or subgroup KGF Chlorhexidine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CT alone for haematological cancer
Gholizadeh 2016 5/45 41/45 100.0 % 0.12 [ 0.05, 0.28 ]
Subtotal (95% CI) 45 45 100.0 % 0.12 [ 0.05, 0.28 ]
Total events: 5 (KGF), 41 (Chlorhexidine)
Heterogeneity: not applicable
Test for overall effect: Z = 4.96 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours KGF Favours chlorhexidine
Analysis 3.3. Comparison 3 KGF versus chlorhexidine, Outcome 3 Oral mucositis (severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 3 KGF versus chlorhexidine
Outcome: 3 Oral mucositis (severe)
Study or subgroup KGF Chlorhexidine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CT alone for haematological cancer
Gholizadeh 2016 0/45 40/45 100.0 % 0.01 [ 0.00, 0.19 ]
Subtotal (95% CI) 45 45 100.0 % 0.01 [ 0.00, 0.19 ]
Total events: 0 (KGF), 40 (Chlorhexidine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.12 (P = 0.0018)
0.1 0.2 0.5 1 2 5 10
Favours KGF Favours chlorhexidine
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Analysis 4.1. Comparison 4 GM-CSF versus placebo/no treatment, Outcome 1 Oral mucositis (any).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 4 GM-CSF versus placebo/no treatment
Outcome: 1 Oral mucositis (any)
Study or subgroup GM-CSF Placebo/NT Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for mixed cancers
Dazzi 2003 40/46 42/44 100.0 % 0.91 [ 0.80, 1.04 ]
Subtotal (95% CI) 46 44 100.0 % 0.91 [ 0.80, 1.04 ]
Total events: 40 (GM-CSF), 42 (Placebo/NT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2 RT to head % neck
McAleese 2006 14/15 13/14 100.0 % 1.01 [ 0.82, 1.23 ]
Subtotal (95% CI) 15 14 100.0 % 1.01 [ 0.82, 1.23 ]
Total events: 14 (GM-CSF), 13 (Placebo/NT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
0.1 0.2 0.5 1 2 5 10
Favours GM-CSF Favours placebo/NT
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Analysis 4.2. Comparison 4 GM-CSF versus placebo/no treatment, Outcome 2 Oral mucositis (moderate +
severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 4 GM-CSF versus placebo/no treatment
Outcome: 2 Oral mucositis (moderate + severe)
Study or subgroup GM-CSF Placebo/NT Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Nemunaitis 1995 42/53 47/56 100.0 % 0.94 [ 0.79, 1.13 ]
Subtotal (95% CI) 53 56 100.0 % 0.94 [ 0.79, 1.13 ]
Total events: 42 (GM-CSF), 47 (Placebo/NT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 RT to head % neck
McAleese 2006 10/15 13/14 100.0 % 0.72 [ 0.49, 1.06 ]
Subtotal (95% CI) 15 14 100.0 % 0.72 [ 0.49, 1.06 ]
Total events: 10 (GM-CSF), 13 (Placebo/NT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.093)
0.1 0.2 0.5 1 2 5 10
Favours GM-CSF Favours placebo/NT
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Analysis 4.3. Comparison 4 GM-CSF versus placebo/no treatment, Outcome 3 Oral mucositis (severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 4 GM-CSF versus placebo/no treatment
Outcome: 3 Oral mucositis (severe)
Study or subgroup GM-CSF Placebo/NT Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for mixed cancers
Dazzi 2003 15/46 17/44 37.7 % 0.84 [ 0.48, 1.47 ]
Nemunaitis 1995 4/53 16/56 26.5 % 0.26 [ 0.09, 0.74 ]
van der Lelie 2001 11/18 8/18 35.8 % 1.38 [ 0.73, 2.59 ]
Subtotal (95% CI) 117 118 100.0 % 0.74 [ 0.33, 1.67 ]
Total events: 30 (GM-CSF), 41 (Placebo/NT)
Heterogeneity: Tau2 = 0.38; Chi2 = 7.86, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 0.73 (P = 0.47)
2 RT to head % neck
McAleese 2006 0/15 1/14 100.0 % 0.31 [ 0.01, 7.09 ]
Subtotal (95% CI) 15 14 100.0 % 0.31 [ 0.01, 7.09 ]
Total events: 0 (GM-CSF), 1 (Placebo/NT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
3 CT alone for mixed cancers
Cartee 1995 15/36 2/9 53.8 % 1.88 [ 0.52, 6.76 ]
Chi 1995 1/9 8/11 46.2 % 0.15 [ 0.02, 1.00 ]
Subtotal (95% CI) 45 20 100.0 % 0.59 [ 0.05, 7.11 ]
Total events: 16 (GM-CSF), 10 (Placebo/NT)
Heterogeneity: Tau2 = 2.58; Chi2 = 4.81, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.42 (P = 0.68)
0.1 0.2 0.5 1 2 5 10
Favours GM-CSF Favours placebo/NT
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Analysis 4.4. Comparison 4 GM-CSF versus placebo/no treatment, Outcome 4 Oral pain (maximum score
on 0 to 10 VAS).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 4 GM-CSF versus placebo/no treatment
Outcome: 4 Oral pain (maximum score on 0 to 10 VAS)
Study or subgroup GM-CSF Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BMT/SCT after conditioning for mixed cancers
Dazzi 2003 46 4.8 (3.5) 44 4.2 (3.5) 100.0 % 0.60 [ -0.85, 2.05 ]
Subtotal (95% CI) 46 44 100.0 % 0.60 [ -0.85, 2.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
-10 -5 0 5 10
Favours GM-CSF Favours placebo
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Analysis 4.5. Comparison 4 GM-CSF versus placebo/no treatment, Outcome 5 Normalcy of diet (use of
feeding tube/parenteral nutrition).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 4 GM-CSF versus placebo/no treatment
Outcome: 5 Normalcy of diet (use of feeding tube/parenteral nutrition)
Study or subgroup GM-CSF No treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
van der Lelie 2001 11/18 10/18 100.0 % 1.10 [ 0.63, 1.91 ]
Subtotal (95% CI) 18 18 100.0 % 1.10 [ 0.63, 1.91 ]
Total events: 11 (GM-CSF), 10 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
2 RT to head % neck
McAleese 2006 0/15 1/14 100.0 % 0.31 [ 0.01, 7.09 ]
Subtotal (95% CI) 15 14 100.0 % 0.31 [ 0.01, 7.09 ]
Total events: 0 (GM-CSF), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
0.1 0.2 0.5 1 2 5 10
Favours GM-CSF Favours no treatment
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Analysis 4.6. Comparison 4 GM-CSF versus placebo/no treatment, Outcome 6 Number of days of
treatment with opioid analgesics.
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 4 GM-CSF versus placebo/no treatment
Outcome: 6 Number of days of treatment with opioid analgesics
Study or subgroup GM-CSF Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BMT/SCT after conditioning for mixed cancers
Dazzi 2003 46 2.7 (2) 44 3.8 (1.9) 100.0 % -1.10 [ -1.91, -0.29 ]
Subtotal (95% CI) 46 44 100.0 % -1.10 [ -1.91, -0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.68 (P = 0.0075)
-10 -5 0 5 10
Favours GM-CSF Favours placebo
Analysis 5.1. Comparison 5 GM-CSF (dose comparison), Outcome 1 Oral mucositis (severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 5 GM-CSF (dose comparison)
Outcome: 1 Oral mucositis (severe)
Study or subgroup 12.6 to 126 g total
1260 to
12,600
g total Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CT alone for breast cancer
Cartee 1995 11/18 4/18 100.0 % 2.75 [ 1.07, 7.04 ]
Subtotal (95% CI) 18 18 100.0 % 2.75 [ 1.07, 7.04 ]
Total events: 11 (12.6 to 126 g total), 4 (1260 to 12,600 g total)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
0.1 0.2 0.5 1 2 5 10
Favours 12.6 to 126 g total Favours 1260 to 12,600 g total
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Analysis 6.1. Comparison 6 GM-CSF versus sucralfate, Outcome 1 Oral mucositis (moderate + severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 6 GM-CSF versus sucralfate
Outcome: 1 Oral mucositis (moderate + severe)
Study or subgroup GM-CSF Sucralfate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 RT to head % neck
Saarilahti 2002 19/21 18/19 100.0 % 0.96 [ 0.80, 1.14 ]
Subtotal (95% CI) 21 19 100.0 % 0.96 [ 0.80, 1.14 ]
Total events: 19 (GM-CSF), 18 (Sucralfate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.61)
0.1 0.2 0.5 1 2 5 10
Favours GM-CSF Favours sucralfate
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Analysis 6.2. Comparison 6 GM-CSF versus sucralfate, Outcome 2 Oral mucositis (severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 6 GM-CSF versus sucralfate
Outcome: 2 Oral mucositis (severe)
Study or subgroup GM-CSF Sucralfate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 RT to head % neck
Saarilahti 2002 6/21 10/19 100.0 % 0.54 [ 0.24, 1.21 ]
Subtotal (95% CI) 21 19 100.0 % 0.54 [ 0.24, 1.21 ]
Total events: 6 (GM-CSF), 10 (Sucralfate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
0.1 0.2 0.5 1 2 5 10
Favours GM-CSF Favours sucralfate
Analysis 6.3. Comparison 6 GM-CSF versus sucralfate, Outcome 3 Interruptions to cancer treatment.
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 6 GM-CSF versus sucralfate
Outcome: 3 Interruptions to cancer treatment
Study or subgroup GM-CSF Sucralfate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 RT to head % neck
Saarilahti 2002 0/21 3/19 100.0 % 0.13 [ 0.01, 2.36 ]
Subtotal (95% CI) 21 19 100.0 % 0.13 [ 0.01, 2.36 ]
Total events: 0 (GM-CSF), 3 (Sucralfate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
0.1 0.2 0.5 1 2 5 10
Favours GM-CSF Favours sucralfate
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Analysis 6.4. Comparison 6 GM-CSF versus sucralfate, Outcome 4 Normalcy of diet (use of PEG tube).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 6 GM-CSF versus sucralfate
Outcome: 4 Normalcy of diet (use of PEG tube)
Study or subgroup GM-CSF Sucralfate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 RT to head % neck
Saarilahti 2002 0/21 2/19 100.0 % 0.18 [ 0.01, 3.56 ]
Subtotal (95% CI) 21 19 100.0 % 0.18 [ 0.01, 3.56 ]
Total events: 0 (GM-CSF), 2 (Sucralfate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
0.1 0.2 0.5 1 2 5 10
Favours GM-CSF Favours sucralfate
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Analysis 7.1. Comparison 7 G-CSF versus placebo/no treatment, Outcome 1 Oral mucositis (any).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 7 G-CSF versus placebo/no treatment
Outcome: 1 Oral mucositis (any)
Study or subgroup G-CSF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 RT to head % neck
Schneider 1999 8/8 6/6 44.6 % 1.00 [ 0.77, 1.30 ]
Su 2006 17/19 18/21 55.4 % 1.04 [ 0.83, 1.32 ]
Subtotal (95% CI) 27 27 100.0 % 1.02 [ 0.86, 1.22 ]
Total events: 25 (G-CSF), 24 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
2 CT alone for lung cancer
Crawford 1999 26/93 48/102 100.0 % 0.59 [ 0.40, 0.87 ]
Subtotal (95% CI) 93 102 100.0 % 0.59 [ 0.40, 0.87 ]
Total events: 26 (G-CSF), 48 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.65 (P = 0.0082)
0.1 0.2 0.5 1 2 5 10
Favours G-CSF Favours placebo
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Analysis 7.2. Comparison 7 G-CSF versus placebo/no treatment, Outcome 2 Oral mucositis (moderate +
severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 7 G-CSF versus placebo/no treatment
Outcome: 2 Oral mucositis (moderate + severe)
Study or subgroup G-CSF No treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CT alone for breast cancer
Katano 1995 2/7 7/7 100.0 % 0.33 [ 0.12, 0.95 ]
Subtotal (95% CI) 7 7 100.0 % 0.33 [ 0.12, 0.95 ]
Total events: 2 (G-CSF), 7 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.039)
0.1 0.2 0.5 1 2 5 10
Favours G-CSF Favours no treatment
Analysis 7.3. Comparison 7 G-CSF versus placebo/no treatment, Outcome 3 Oral mucositis (severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 7 G-CSF versus placebo/no treatment
Outcome: 3 Oral mucositis (severe)
Study or subgroup G-CSF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 RT to head % neck
Schneider 1999 1/8 3/6 18.8 % 0.25 [ 0.03, 1.85 ]
Su 2006 4/19 11/21 81.2 % 0.40 [ 0.15, 1.05 ]
Subtotal (95% CI) 27 27 100.0 % 0.37 [ 0.15, 0.87 ]
Total events: 5 (G-CSF), 14 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
0.1 0.2 0.5 1 2 5 10
Favours G-CSF Favours placebo
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Analysis 7.4. Comparison 7 G-CSF versus placebo/no treatment, Outcome 4 Interruptions to cancer
treatment (RT interruption).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 7 G-CSF versus placebo/no treatment
Outcome: 4 Interruptions to cancer treatment (RT interruption)
Study or subgroup G-CSF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 RT to head % neck
Su 2006 0/19 2/21 100.0 % 0.22 [ 0.01, 4.31 ]
Subtotal (95% CI) 19 21 100.0 % 0.22 [ 0.01, 4.31 ]
Total events: 0 (G-CSF), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
0.1 0.2 0.5 1 2 5 10
Favours G-CSF Favours placebo
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Analysis 7.5. Comparison 7 G-CSF versus placebo/no treatment, Outcome 5 Normalcy of diet (use of PEG
tube).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 7 G-CSF versus placebo/no treatment
Outcome: 5 Normalcy of diet (use of PEG tube)
Study or subgroup G-CSF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 RT to head % neck
Su 2006 0/19 3/21 100.0 % 0.16 [ 0.01, 2.86 ]
Subtotal (95% CI) 19 21 100.0 % 0.16 [ 0.01, 2.86 ]
Total events: 0 (G-CSF), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
0.1 0.2 0.5 1 2 5 10
Favours G-CSF Favours placebo
Analysis 8.1. Comparison 8 G-CSF (pegfilgrastim) versus G-CSF (filgrastim), Outcome 1 Oral mucositis
(any).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 8 G-CSF (pegfilgrastim) versus G-CSF (filgrastim)
Outcome: 1 Oral mucositis (any)
Study or subgroup Pegfilgrastim Filgrastim Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for mixed cancers
Cesaro 2013 27/32 24/29 100.0 % 1.02 [ 0.82, 1.27 ]
Subtotal (95% CI) 32 29 100.0 % 1.02 [ 0.82, 1.27 ]
Total events: 27 (Pegfilgrastim), 24 (Filgrastim)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
0.1 0.2 0.5 1 2 5 10
Favours pegfilgrastim Favours filgrastim
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Analysis 8.2. Comparison 8 G-CSF (pegfilgrastim) versus G-CSF (filgrastim), Outcome 2 Oral mucositis
(moderate + severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 8 G-CSF (pegfilgrastim) versus G-CSF (filgrastim)
Outcome: 2 Oral mucositis (moderate + severe)
Study or subgroup Pegfilgrastim Filgrastim Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for mixed cancers
Cesaro 2013 19/32 22/29 100.0 % 0.78 [ 0.55, 1.11 ]
Subtotal (95% CI) 32 29 100.0 % 0.78 [ 0.55, 1.11 ]
Total events: 19 (Pegfilgrastim), 22 (Filgrastim)
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
0.1 0.2 0.5 1 2 5 10
Favours pegfilgrastim Favours filgrastim
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Analysis 8.3. Comparison 8 G-CSF (pegfilgrastim) versus G-CSF (filgrastim), Outcome 3 Normalcy of diet
(use of supplemental nutrition).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 8 G-CSF (pegfilgrastim) versus G-CSF (filgrastim)
Outcome: 3 Normalcy of diet (use of supplemental nutrition)
Study or subgroup Pegfilgrastim Filgrastim Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for mixed cancers
Cesaro 2013 32/32 29/29 100.0 % 1.00 [ 0.94, 1.06 ]
Subtotal (95% CI) 32 29 100.0 % 1.00 [ 0.94, 1.06 ]
Total events: 32 (Pegfilgrastim), 29 (Filgrastim)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
0.1 0.2 0.5 1 2 5 10
Favours pegfilgrastim Favours filgrastim
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Analysis 9.1. Comparison 9 EGF versus placebo, Outcome 1 Oral mucositis (moderate + severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 9 EGF versus placebo
Outcome: 1 Oral mucositis (moderate + severe)
Study or subgroup EGF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Kim 2017 38/67 37/69 100.0 % 1.06 [ 0.78, 1.43 ]
Subtotal (95% CI) 67 69 100.0 % 1.06 [ 0.78, 1.43 ]
Total events: 38 (EGF), 37 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 RT to head % neck +/- cisplatin
Wu 2009 32/76 17/27 100.0 % 0.67 [ 0.45, 0.99 ]
Subtotal (95% CI) 76 27 100.0 % 0.67 [ 0.45, 0.99 ]
Total events: 32 (EGF), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
0.1 0.2 0.5 1 2 5 10
Favours EGF Favours placebo
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Analysis 9.2. Comparison 9 EGF versus placebo, Outcome 2 Oral mucositis (severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 9 EGF versus placebo
Outcome: 2 Oral mucositis (severe)
Study or subgroup EGF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Kim 2017 18/67 18/69 100.0 % 1.03 [ 0.59, 1.80 ]
Subtotal (95% CI) 67 69 100.0 % 1.03 [ 0.59, 1.80 ]
Total events: 18 (EGF), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
0.1 0.2 0.5 1 2 5 10
Favours EGF Favours placebo
Analysis 9.3. Comparison 9 EGF versus placebo, Outcome 3 Interruptions to cancer treatment (RT breaks
> 2 consecutive days).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 9 EGF versus placebo
Outcome: 3 Interruptions to cancer treatment (RT breaks > 2 consecutive days)
Study or subgroup EGF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 RT to head % neck +/- cisplatin
Wu 2009 6/85 0/28 100.0 % 4.38 [ 0.25, 75.44 ]
Subtotal (95% CI) 85 28 100.0 % 4.38 [ 0.25, 75.44 ]
Total events: 6 (EGF), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
0.1 0.2 0.5 1 2 5 10
Favours EGF Favours placebo
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Analysis 9.4. Comparison 9 EGF versus placebo, Outcome 4 Normalcy of diet (use of supplemental
nutrition).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 9 EGF versus placebo
Outcome: 4 Normalcy of diet (use of supplemental nutrition)
Study or subgroup EGF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Kim 2017 15/67 15/69 100.0 % 1.03 [ 0.55, 1.94 ]
Subtotal (95% CI) 67 69 100.0 % 1.03 [ 0.55, 1.94 ]
Total events: 15 (EGF), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
0.1 0.2 0.5 1 2 5 10
Favours EGF Favours placebo
Analysis 10.1. Comparison 10 ITF versus placebo, Outcome 1 Oral mucositis (any).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 10 ITF versus placebo
Outcome: 1 Oral mucositis (any)
Study or subgroup ITF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CT alone for colorectal cancer
Peterson 2009 23/66 22/33 100.0 % 0.52 [ 0.35, 0.79 ]
Subtotal (95% CI) 66 33 100.0 % 0.52 [ 0.35, 0.79 ]
Total events: 23 (ITF), 22 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.11 (P = 0.0019)
0.1 0.2 0.5 1 2 5 10
Favours ITF Favours placebo
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Analysis 10.2. Comparison 10 ITF versus placebo, Outcome 2 Oral mucositis (moderate + severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 10 ITF versus placebo
Outcome: 2 Oral mucositis (moderate + severe)
Study or subgroup ITF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CT alone for colorectal cancer
Peterson 2009 7/66 16/33 100.0 % 0.22 [ 0.10, 0.48 ]
Subtotal (95% CI) 66 33 100.0 % 0.22 [ 0.10, 0.48 ]
Total events: 7 (ITF), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.80 (P = 0.00014)
0.1 0.2 0.5 1 2 5 10
Favours ITF Favours placebo
Analysis 10.3. Comparison 10 ITF versus placebo, Outcome 3 Oral mucositis (severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 10 ITF versus placebo
Outcome: 3 Oral mucositis (severe)
Study or subgroup ITF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CT alone for colorectal cancer
Peterson 2009 1/66 0/33 100.0 % 1.52 [ 0.06, 36.39 ]
Subtotal (95% CI) 66 33 100.0 % 1.52 [ 0.06, 36.39 ]
Total events: 1 (ITF), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
0.1 0.2 0.5 1 2 5 10
Favours ITF Favours placebo
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Analysis 11.1. Comparison 11 ITF (dose comparison), Outcome 1 Oral mucositis (any).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 11 ITF (dose comparison)
Outcome: 1 Oral mucositis (any)
Study or subgroup 336 mg total dose 2688 mg total dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CT alone for colorectal cancer
Peterson 2009 13/33 10/33 100.0 % 1.30 [ 0.67, 2.54 ]
Subtotal (95% CI) 33 33 100.0 % 1.30 [ 0.67, 2.54 ]
Total events: 13 (336 mg total dose), 10 (2688 mg total dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
0.1 0.2 0.5 1 2 5 10
Favours 336 mg total Favours 2688 mg total
Analysis 11.2. Comparison 11 ITF (dose comparison), Outcome 2 Oral mucositis (moderate + severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 11 ITF (dose comparison)
Outcome: 2 Oral mucositis (moderate + severe)
Study or subgroup 336 mg total dose 2688 mg total dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CT alone for colorectal cancer
Peterson 2009 3/33 4/33 100.0 % 0.75 [ 0.18, 3.09 ]
Subtotal (95% CI) 33 33 100.0 % 0.75 [ 0.18, 3.09 ]
Total events: 3 (336 mg total dose), 4 (2688 mg total dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
0.1 0.2 0.5 1 2 5 10
Favours 336 mg total Favours 2688 mg total
173Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 11.3. Comparison 11 ITF (dose comparison), Outcome 3 Oral mucositis (severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 11 ITF (dose comparison)
Outcome: 3 Oral mucositis (severe)
Study or subgroup 336 mg total dose 2688 mg total dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CT alone for colorectal cancer
Peterson 2009 0/33 1/33 100.0 % 0.33 [ 0.01, 7.90 ]
Subtotal (95% CI) 33 33 100.0 % 0.33 [ 0.01, 7.90 ]
Total events: 0 (336 mg total dose), 1 (2688 mg total dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
0.1 0.2 0.5 1 2 5 10
Favours 336 mg total Favours 2688 mg total
Analysis 12.1. Comparison 12 Erythropoietin versus placebo, Outcome 1 Oral mucositis (any).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 12 Erythropoietin versus placebo
Outcome: 1 Oral mucositis (any)
Study or subgroup Erythropoietin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Hosseinjani 2017 11/40 31/40 100.0 % 0.35 [ 0.21, 0.60 ]
Subtotal (95% CI) 40 40 100.0 % 0.35 [ 0.21, 0.60 ]
Total events: 11 (Erythropoietin), 31 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.83 (P = 0.00013)
0.1 0.2 0.5 1 2 5 10
Favours erythropoietin Favours placebo
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Analysis 12.2. Comparison 12 Erythropoietin versus placebo, Outcome 2 Oral mucositis (moderate +
severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 12 Erythropoietin versus placebo
Outcome: 2 Oral mucositis (moderate + severe)
Study or subgroup Erythropoietin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Hosseinjani 2017 10/40 23/40 100.0 % 0.43 [ 0.24, 0.79 ]
Subtotal (95% CI) 40 40 100.0 % 0.43 [ 0.24, 0.79 ]
Total events: 10 (Erythropoietin), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0064)
0.1 0.2 0.5 1 2 5 10
Favours erythropoietin Favours placebo
Analysis 12.3. Comparison 12 Erythropoietin versus placebo, Outcome 3 Oral mucositis (severe).
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 12 Erythropoietin versus placebo
Outcome: 3 Oral mucositis (severe)
Study or subgroup Erythropoietin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMT/SCT after conditioning for haematological cancers
Hosseinjani 2017 4/40 10/40 100.0 % 0.40 [ 0.14, 1.17 ]
Subtotal (95% CI) 40 40 100.0 % 0.40 [ 0.14, 1.17 ]
Total events: 4 (Erythropoietin), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.094)
0.1 0.2 0.5 1 2 5 10
Favours erythropoietin Favours placebo
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Analysis 12.4. Comparison 12 Erythropoietin versus placebo, Outcome 4 Number of days in hospital.
Review: Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
Comparison: 12 Erythropoietin versus placebo
Outcome: 4 Number of days in hospital
Study or subgroup Erythropoietin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BMT/SCT after conditioning for haematological cancers
Hosseinjani 2017 40 22.52 (5.28) 40 25.47 (14.49) 100.0 % -2.95 [ -7.73, 1.83 ]
Subtotal (95% CI) 40 40 100.0 % -2.95 [ -7.73, 1.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
-10 -5 0 5 10
Favours erythropoietin Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Adverse events: KGF
Study ID Adverse events results
Blazar 2006 • AEs with incidence ≥ 10% greater in KGF group: higher rate of skin rash in KGF group (65/69 versus
21/31; RR 1.39, 95% CI 1.08 to 1.79; P = 0.01). Insufficient evidence of a difference in edema, infection, or
local pain
• Grade 3 to 4 (WHO and NCI-CTC 0 to 4 toxicities scales) AEs with higher incidence in KGF group:
insufficient evidence of a difference in skin reactions, diarrhoea, local pain, or cardiac events
Blijlevens 2013 • KGF-related AE (NCI-CTC): higher rate in KGF group (141/220 versus 17/57; RR 2.15, 95% CI 1.43
to 3.24; P = 0.0003)
• KGF-related serious AE (no definition of ’serious’ given) (NCI-CTC): insufficient evidence of a difference
(4/220 versus 0/57; P = 0.56)
• KGF-related severe AE (NCI-CTC grade 3, 4 or 5) (grade 5 = death): insufficient evidence of a difference
(23/220 versus 0/57; P = 0.08)
Bradstock 2014 Insufficient evidence of a difference in infection or Grade 3 to 4 (NCI-CTC 0 to 4 toxicity scale) skin rash/
desquamation
Brizel 2008 The study authors state that most adverse events were considered to be caused by the cancer treatment or the
underlying cancer itself and not related to study treatment. 2 participants in the palifermin group had serious
adverse events considered to be related to the intervention: 1 had increased sputum production; the other had
dehydration, dysphagia, pain (including abdominal), pancreatitis, and subsequently had schistosomiasis
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Table 1. Adverse events: KGF (Continued)
Fink 2011 Total of 28 side effects in palifermin group occurring in 11 of 22 patients (50%) who received at least 4 of the
6 doses. Most frequent (90.9%) were cases of erythema or exanthema, often associated with itching (54.5%)
. Often (54.5%) a swelling of the oral mucosa including the tongue occurred. In 4 out of 6 patients, this was
accompanied by taste disturbance. The severity of side effects were classified as mild to moderate. The CTC
Grade 3 occurred only once in the form of a strong heat sensation
In 1 of the 11 cases, there was premature discontinuation of palifermin due to severe facial swelling with eyelid
and laryngeal pain as well as painful swelling of the hands following the second injection
Freytes 2004 25 different adverse events were reported and were mostly not KGF-related. There was insufficient evidence of
a difference for diarrhoea, abdominal pain, infection or rash
Gholizadeh 2016 “..two patients reported knee joint pain, skin rash was observed in one patient, two patients had abnormal taste,
and one showed lingual mucosal thickening” (control group was chlorhexidine mouthrinse. The authors do not
report the events by treatment group)
Henke 2011 • “Initially, patients were allocated to three arms: palifermin (180 g/kg/wk) throughout radiochemotherapy
(ie, for at least seven doses); palifermin (180 g/kg/wk) for four doses and then placebo throughout the
remainder of radiochemotherapy; or placebo throughout radiochemotherapy. However, after one serious
adverse event of respiratory insufficiency was reported in one of the first 10 patients, the data monitoring
committee concluded that the study should be restarted with a lower palifermin dose (120 g/kg/wk)”
• “Most patients (97%) experienced at least one adverse event......One serious adverse event (febrile
neutropenia) considered related to study drug was reported for one patient in the palifermin arm”
Jagasia 2012 KGF-related AEs with incidence ≥ 5% in KGF group: higher rate of gastrointestinal disorders in KGF group
(18/78 versus 2/73; RR 8.42, 95% CI 2.02 to 35.04; P = 0.003). Insufficient evidence of a difference in any AE,
tongue coating, tongue disorder, skin and subcutaneous tissue disorders, rash, pruritus, or erythema
Le 2011 “Study drug-related AEs were reported for 35% of palifermin and 11% of placebo patients. The most frequent
study drug-related AEs (palifermin, placebo) were rash (9%, 2%), flushing (5%, 0%), dysgeusia (5%, 1%),
nausea (4%, 1%),and vomiting (3%, 1%). None of these events led to study withdrawal. Serious AEs considered
related to study treatment were reported for five palifermin patients (5%; one each with necrotic pancreatitis,
hypersensitivity, tracheostomy malfunction, peritoneal carcinoma, and convulsion) and two placebo patients
(2%; one each with hepatitis/hepatic enzyme increase and cryptogenic organizing pneumonia)”
Lucchese 2016a “The administration of palifermin was generally safe and without considerable complications. The only adverse
reactions were rashes (lasting for 48-72 hours) localized to the face, upper neck and shoulders, erythema, and
altered taste (consistent with the pharmacologic action of palifermin of oral epithelium and skin), most of which
were of NCI grade 1 or 2 severity”
Lucchese 2016b “The administration of palifermin was mostly safe and without substantial complications. The mean duration
of the OM and the number of adverse event was significant less in the palifermin group (Tables II, III, Figure
1). The main adverse episodes were erythema, cutaneous rashes and altered taste and three of the patients in the
palifermin group showed a light thickness of the tongue, mouth and palate”
Meropol 2003 “Although the predefined frequency of DLTs attributable to KGF was not reached with KGF doses between 1
and 80 µg/kg/d, there were three adverse reactions involving the skin that required discontinuation of KGF in the
18 patients treated with 60 or 80 µg/kg (Table 5). Overall, skin and oral adverse events (rash, flushing, pruritis,
edema, hypoesthesia, paresthesia, tongue disorder [thickening], and alteration in taste sensation) attributed to
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Table 1. Adverse events: KGF (Continued)
KGF occurred in 13 of 18 patients treated with 60 and 80 µg/kg of KGF (eight patients, grade 1; four patients,
grade 2; and one patient, grade 3) and in three of 11 patients treated with 40 µg/kg (all grade 1). These events
were reported in 16 of 39 patients (41%) dosed with KGF at > 20 µg/kg/d, whereas these symptoms were
reported in only two of 21 subjects (10%) treated with placebo. The skin and oral toxicities associated with KGF
were generally mild to moderate in severity, with onset approximately 36 hours after the first dose of KGF and
resolution 7 to 10 days thereafter”
Rosen 2006 • “As expected based on the pharmacologic activity of palifermin, oral-related AEs were reported more
frequently in palifermin than in patients receiving placebo (Table 3). During cycle 1, 50% of patients receiving
palifermin experienced an oral-related AE, compared with 33% of patients receiving placebo (P = 0.13).
Similarly, 56% of patients receiving palifermin during the second chemotherapy cycle had at least one oral-
related AE, compared with 38% of patients receiving placebo (P = 0.26). The overall incidences of skin-related
AEs, reported as a palifermin-related AE in other clinical settings, were comparable between the two treatment
groups (Table 3). During cycle 1, skin-related AEs were 56% in the placebo group versus 43% in patients
receiving palifermin. During cycle 2, these incidences between the two groups were comparable (palifermin,
52%; placebo, 50%)”
• There were no serious KGF-related AEs in either group and either cycle
Spielberger 2004 “The incidence, frequency, and severity of adverse events were similar in the two groups, and most were at-
tributable to the underlying cancer, cytotoxic chemotherapy, or total-body irradiation. Those that occurred with
an incidence that was at least 5 percentage points higher in the palifermin group than in the placebo group
are listed in Table 3. Most of these adverse events were consistent with the pharmacologic action of palifermin
on skin and oral epithelium (e.g., rash, pruritus, erythema, paresthesia, mouth and tongue disorders, and taste
alteration). All these events were mild to moderate in severity, transient (occurring approximately three days after
the third dose of palifermin and lasting approximately three days), and not a cause for the discontinuation of
study drug. Serious adverse events considered to be related to treatment occurred in one palifermin recipient
(rash) and one placebo recipient (hypotension)”
Vadhan-Raj 2010 • “Many patients who received palifermin sensed thickening of the oral mucosa and tongue” (first 2 blinded
cycles: 72% versus 31%, P = 0.007)
• “Treatment with palifermin was well tolerated. Table 3 shows the common adverse effects that occurred
during the first 2 blinded cycles, which included symptoms of thickness of oral mucosa, tongue, and lips (Figure
4); altered taste; flushing; warm sensation; and increased saliva. These adverse effects were mild to moderate and
transient in nature. Similar side effects were observed during later cycles...but they did not worsen in severity”
AE = adverse event; CI = confidence interval; KGF = keratinocyte growth factor; NCI-CTC = National Cancer Institute common
toxicity criteria; RR = risk ratio; WHO = World Health Organization.
Table 2. Adverse events: GM-CSF
Study ID Adverse events results
Cartee 1995 2 participants (group allocation not reported) withdrew by day 3 due to intolerance to their mouthwash (dry
mouth); 1 participant receiving GM-CSF (1 µg/mL) hadmouthwash withdrawn by day 3 due to possible allergic
reaction (sensation of fullness in the posterior pharyngeal area) but resolved within 4 hours (the participant was
withdrawn but appears to have been included in the analysis)
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Table 2. Adverse events: GM-CSF (Continued)
Chi 1995 “One patient had fever and chills, and twopatients had generalmalaise andheadache duringGM-CSF treatment.
No patient had evidence of fluid retention after GM-CSF”
Dazzi 2003 Not reported
Makkonen 2000 (Sucralfate given to both groups) “Only 2 of the 20 patients treated with GM-CSF and sucralfate did not
experience any side effects related to the drugs, but most side effects were mild (WHOGrade 1 or 2). The most
common side effects were local skin reactions, fever, bone pain, and mild nausea...In the control group only 1
patient complained of nausea possibly related to the use of sucralfate, and another patient interrupted sucralfate
treatment because of the same reason”
McAleese 2006 “12 patients who received GM-CSF had elevated white cell counts (WCC). The range of maximal WCC was
7.2-30.5 (median 19.7). All WCC had returned to normal within 3 weeks of completing injections (median 2
weeks). Three patients developed influenza-like symptoms with the GM-CSF and in one patient the injections
were stopped because of this symptom. One patient developed an erythematous rash at his injection sites after
completing his course of 14 injections (Figure 3). He had a past history of allergy to radiographic contrast
medium”
Nemunaitis 1995 • “The incidences of grades III or IV toxicities between rhGM-CSF or placebo occurring with a > 10%
frequency included anorexia (38% vs. 36%), nausea (26% vs. 29%), diarrhea (19% vs. 7%), stomatitis (19%
vs. 14%) and hypertension (13% vs. 20%)”
• “The following events were reported with higher frequency in the rhGM-CSF group compared with
placebo: diarrhea (81% vs. 66%), bone pain (21% vs. 5%), abdominal pain (38% vs. 23%), vomiting (70%
vs. 57%), pharyngitis (23% vs. 13%), pruritis (23% vs. 13%) and occular hemorrhage (11% vs. 0%)”
• “Placebo-treated patients had higher occurrence of unspecified pain (36% vs. 17%), back pain (18% vs.
9%), peripheral edema (21% vs. 15%), hematuria (21% vs. 9%) and pneumonia (7% vs. 0%)”
Saarilahti 2002 (Comparator was sucralfate) “Both mouthwashes were well tolerated, and none of the patients reported any
adverse effects related to the mouthwashes. Adverse effects commonly associated with subcutaneous GM-CSF
administration, such as nausea, vomiting, bone pain, headaches, and fever, were not observed”
van der Lelie 2001 Not reported
GM-CSF = granulocyte-macrophage colony-stimulating factor.
Table 3. G-CSF versus placebo
Study ID Population Outcome GM-CSF Placebo Result
Linch 1993 BMT/SCT after con-
ditioning for haema-
tological cancers
Oral mucositis: no
scale described
No data No data “There was no difference in the frequency of
stomatitis (defined as a sore, infected or ulcer-
ated mouth, lips or pharynx), the incidence
being between 29 and 33% in all groups”
BMT = bone marrow transplantation; G-CSF: granulocyte-colony stimulating factor; SCT = stem cell transplantation.
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Table 4. Adverse events: G-CSF
Study ID Adverse events results
Cesaro 2013 “Both pegfilgrastim and filgrastim were well tolerated and no significant adverse effects were associated with their
use” (G-CSF versus G-CSF)
Crawford 1999 Approximately 20%of participants receivingG-CSF experiencedmild tomoderate skeletal pain whichwas resolved
by using oral analgesics; 6% of participants in both groups reported mild generalised rash/itching; 3 participants
experienced an event thought to be G-CSF-related and which caused them to request withdrawal from the study:
abdominal pain, diffuse aches and pains, and a flare-up of pre-existing eczema
Katano 1995 Not reported
Linch 1993 “There was no difference in the overall frequency of adverse clinical or laboratory events between the groups or in
the frequency of adverse events thought by the clinicians to be possibly or probably due to study medication”
Schneider 1999 Not reported
Su 2006 “In general, toxicities typical of postoperative RT to the head and neck were observed. Additional toxicities
attributable to G-CSF and/or daily injections were as follows: elevated WBC requiring G-CSF dose reduction by
prospectively planned guidelines occurred in nine patients in the GCSF arm; grade 2-3 bone pain was observed in
two patients in the G-CSF arm; three patients refused injection (2 G-CSF, 1 placebo)”
G-CSF = granulocyte-colony stimulating factor.
Table 5. Adverse events: EGF
Study ID Adverse events results
Kim 2017 “Adverse events were similar in both groups (Table 3). The most common adverse event in the rhEGF group was nausea
(n = 7, 10.4%). The incidence of other adverse events including oral pain, dry mouth, and taste alteration was low. All
the adverse events were mild and transient. No grade 3 or 4 adverse events were noted during the study period” (there
were no differences between groups in any adverse event)
Wu 2009 “The frequency of minor and serious adverse events was similar in all groups. Most adverse events were related to primary
disease status and treatment modalities”
EGF = epidermal growth factor.
Table 6. Adverse events: ITF
Study ID Adverse events results
Peterson 2009 “Only a minority of patients (six [6.1%] of 99 patients) reported mild to moderate treatment-emergent adverse
events on the study. The symptoms included abdominal pain, diarrhea, oral pain, headache, and hypertension (Table
2). Of these, four were considered related to study drug: one (3%) was in the placebo group, two (6%) were in
the low-dose rhITF group, and one (3%) was in the high-dose rhITF group. The events were isolated and resolved
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Table 6. Adverse events: ITF (Continued)
spontaneously without sequelae”
ITF = intestinal trefoil factor.
Table 7. TGF-beta(2) versus placebo
Study ID Population Outcome TGF-beta(2) Placebo Result
Antoun 2009 CT alone for colorec-
tal cancer
Oral mucositis
(WHO 0 to 4 scale):
any oral mucositis
0/9 2/4 RR 0.10 (95% CI 0.01 to 1.71); P = 0.
11
CI = confidence interval; CT = chemotherapy; RR = risk ratio; TGF = transforming growth factor;WHO =WorldHealthOrganization.
A P P E N D I C E S
Appendix 1. Cochrane Oral Health’s Trials Register search strategy
1 ((neoplasm* or cancer* or leukaemi* or leukemi* or tumour* or tumor* or malignan* or neutropeni* or neutropeni* or carcino* or
adenocarcinoma* or lymphoma*):ti,ab) AND (INREGISTER)
2 ((radioth* or radiat* or irradiat*):ti,ab) AND (INREGISTER)
3 (((“bone marrow” and transplant*) or “hematopoietic stem cell transplant*” or “haematopoietic stem cell transplant*” or HSCT):
ti,ab) AND (INREGISTER)
4 (chemo*:ti,ab) AND (INREGISTER)
5 (#1 or #2 or #3 or #4) AND (INREGISTER)
6 ((stomatitis or mucositis):ti,ab) AND (INREGISTER)
7 ((oral and mucos*):ti,ab) AND (INREGISTER)
8 ((mycosis or mycotic):ti,ab) AND (INREGISTER)
9 (mIAS:ti,ab) AND (INREGISTER)
10 (#6 or #7 or #8 or #9) AND (INREGISTER)
11 ((“growth factor*” or “growth substance*” or “immunologic factor*”):ti,ab) AND (INREGISTER)
12 (“fibroblast growth factor*”:ti,ab) AND (INREGISTER)
13 ((keratinocyte* or cytokine*):ti,ab) AND (INREGISTER)
14 ((palifermin* or KGF or FGF):ti,ab) AND (INREGISTER)
15 ((keprivance or velafermin or repifermin):ti,ab) AND (INREGISTER)
16 (glycoprotein*:ti,ab) AND (INREGISTER)
17 ((colony-stimulat* or “macrophage-granulocyte inducer*” or “myeloid cell-growth inducer*” or “protein inducerMGI”):ti,ab) AND
(INREGISTER)
18 ((GM-CSF or G-CSF):ti,ab) AND (INREGISTER)
19 ((molgramostim or Growgen-GM or Leucomax or Molcass or Gramostim or Leucocitim or Mielogen or Meustim or Bagomol or
Gramal):ti,ab) AND (INREGISTER)
20 ((rhEGF or “recombinant epithelial growth factor*” or “epidermal growth factor*” or EGF):ti,ab) AND (INREGISTER)
21 ((“platelet-derived growth factor*” or PDGF or “platelet lysate”):ti,ab) AND (INREGISTER)
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22 ((“transforming growth factor*” or “bone-derived transforming growth factor*” or “milk growth factor*” or “platelet transforming
growth factor*” or TGF-beta or TGFBeta):ti,ab) AND (INREGISTER)
23 ((“hepatocyte growth factor*” or hepatopoietin or “scatter factor”):ti,ab) AND (INREGISTER)
24 ((somatomedin* or “insulin-like growth factor*” or “sulfation factor*” or Mecasermin or Increlex or Iplex or IGF-1 or IGF1):ti,ab)
AND (INREGISTER)
25 (erythropoietin*:ti,ab) AND (INREGISTER)
26 ((thrombopoietin* or “mpl Ligand” or “megakaryocyte colony stimulating factor*” or “megakaryocyte growth and development
factor*” or “MGDF factor” or “myeloproliferative leukemia virus oncogene ligand” or “thrombocytopoiesis-stimulating factor” or
thrombocytopoietin*):ti,ab) AND (INREGISTER)
27 ((“interleukin 11” or “adipogenesis inhibitory factor*” or IL-11 or IL11):ti,ab) AND (INREGISTER)
28 ((ghrelin* or “GHRL protein” or obestatin):ti,ab) AND (INREGISTER)
29 ((ATL-104 or ATL104):ti,ab) AND (INREGISTER)
30 ((whey or “milk derived protein” or “milk derived growth factor”):ti,ab) AND (INREGISTER)
31 ((“glucagon-like peptide 2” or “amino acid*” or proglucagon or GLP-2 or teduglutide or Gattex or Revestive):ti,ab) AND (IN-
REGISTER)
32 ((“trefoil factor” or “carcinoembryonic antigen cell adhesion molecule 1” or glutathione or isethion):ti,ab) AND (INREGISTER)
33 ((“vascular endothelial growth factor*” or VEGF*):ti,ab) AND (INREGISTER)
34 ((“targeted therap*” or “targeted agent*”):ti,ab) AND (INREGISTER)
35 (“biologic* therap*”:ti,ab) AND (INREGISTER)
36 ((#11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35)) AND (INREGISTER)
37 (#5 and #10 and #36) AND (INREGISTER)
Appendix 2. Cochrane Central Register of Controlled Clinical Trials (CENTRAL) search strategy
#1 [mh neoplasms]
#2 [mh radiotherapy]
#3 [mh “antineoplastic agents”]
#4 [mh “ˆbone marrow transplantation”]
#5 [mh ˆ“hematopoietic stem cell transplantation”]
#6 MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] explode all trees
#7 (neoplasm* or cancer* or leukaemi* or leukemi* or tumour* or tumor* or malignan* or neutropeni* or neutropeni* or carcino* or
adenocarcinoma* or lymphoma*)
#8 (radioth* or radiat* or irradiat*)
#9 ((“bone marrow” and transplant*) or “hematopoietic stem cell transplant*” or “haematopoietic stem cell transplant*” or HSCT)
#10 chemo*
#11 {or #1-#10}
#12 [mh Stomatitis]
#13 [mh ˆ“oral candidiasis”]
#14 stomatitis
#15 mucositis
#16 (oral near/6 mucos*)
#17 (mycosis or mycotic)
#18 mIAS
#19 {or #12-#18}
#20 (“growth factor*” or “growth substance*” or “immunologic factor*”)
#21 [mh ˆ“Fibroblast growth factor 7”]
#22 “fibroblast growth factor*”
#23 (keratinocyte* or cytokine*)
#24 (palifermin* or KGF or FGF)
#25 (keprivance or velafermin or repifermin)
#26 glycoprotein*
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#27 [mh “colony-stimulating factors”]
#28 (colony-stimulat* or “macrophage-granulocyte inducer*” or “myeloid cell-growth inducer*” or “protein inducer MGI”)
#29 (GM-CSF or G-CSF)
#30 (molgramostim or Growgen-GM or Leucomax or Molcass or Gramostim or Leucocitim or Mielogen or Meustim or Bagomol or
Gramal)
#31 [mh ˆ“Epidermal growth factor”]
#32 (rhEGF or “recombinant epithelial growth factor*” or “epidermal growth factor*” or EGF)
#33 [mh ˆ“Platelet-derived growth factor”]
#34 (“platelet-derived growth factor*” or PDGF or “platelet lysate”)
#35 [mh ˆ“Transforming growth factor beta”]
#36 (“transforming growth factor*” or “bone-derived transforming growth factor*” or “milk growth factor*” or “platelet transforming
growth factor*” or TGF-beta or TGFBeta)
#37 [mh ˆ“Hepatocyte growth factor”]
#38 (“hepatocyte growth factor*” or hepatopoietin or “scatter factor”)
#39 [mh Somatomedin]
#40 (somatomedin* or “insulin-like growth factor*” or “sulfation factor*” or Mecasermin or Increlex or Iplex or IGF-1 or IGF1)
#41 erythropoietin*
#42 [mh ˆThrombopoietin]
#43 (thrombopoietin* or “mpl Ligand” or “megakaryocyte colony stimulating factor*” or “megakaryocyte growth and development
factor*” or “MGDF factor” or “myeloproliferative leukemia virus oncogene ligand” or “thrombocytopoiesis-stimulating factor” or
thrombocytopoietin*)
#44 [mh ˆGhrelin]
#45 [mh “Interleukin 11”]
#46 (“interleukin 11” or “adipogenesis inhibitory factor*” or IL-11 or IL11)
#47 (ghrelin* or “GHRL protein” or obestatin)
#48 (ATL-104 or ATL104)
#49 (whey or (“milk derived” next (protein or “growth factor”)))
#50 [mh ˆ“Glucagon-like peptide 2”]
#51 (“glucagon-like peptide 2” or “amino acid*” or proglucagon or GLP-2 or teduglutide or Gattex or Revestive)
#52 [mh ˆGlutathione]
#53 (“trefoil factor” or “carcinoembryonic antigen cell adhesion molecule 1” or glutathione or isethion)
#54 [mh ˆ“Vascular endothelial growth factors”]
#55 (“vascular endothelial growth factor*” or VEGF*)
#56 [mh ˆ“Molecular targeted therapy”]
#57 (targeted near/3 (therap* or agent*))
#58 (biologic* next therap*)
#59 {or #20-#58}
#60 #11 and #19 and #59
Appendix 3. MEDLINE Ovid search strategy
1. exp NEOPLASMS/
2. exp RADIOTHERAPY/
3. exp Antineoplastic agents/
4. Anti-neoplastic combined chemotherapy protocols/
5. Bone Marrow Transplantation/
6. Hematopoietic Stem Cell Transplantation/
7. (neoplasm$or cancer$ or leukaemi$or leukemi$ or tumour$ or tumor$ ormalignan$ or neutropeni$ or carcino$ or adenocarcinoma$
or lymphoma$).ti,ab.
8. (radioth$ or radiat$ or irradiat$).ti,ab.
9. ((bone adj marrow adj5 transplant$) or “hematopoietic stem cell transplant$” or “haematopoietic stem cell transplant$” or
HSCT).ti,ab.
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10. chemo$.ti,ab.
11. or/1-10
12. exp STOMATITIS/
13. Candidiasis, Oral/
14. stomatitis.ti,ab.
15. mucositis.ti,ab.
16. (oral adj6 mucos$).ti,ab.
17. (mycosis or mycotic).ti,ab.
18. mIAS.ti,ab.
19. or/12-18
20. ((growth adj factor$) or (growth adj substance$) or (immunologic adj factor$)).ti,ab.
21. Fibroblast growth factor 7/
22. “fibroblast growth factor$”.ti,ab.
23. (keratinocyte$ or cytokine$).ti,ab.
24. (palifermin$ or KGF or FGF).ti,ab.
25. (kepivance or velafermin or repifermin).ti,ab.
26. glycoprotein$.ti,ab.
27. exp Colony-stimulating factors/
28. (“colony-stimulat$” or “macrophage-granulocyte inducer$” or “myeloid cell-growth inducer$” or “protein inducer MGI”).ti,ab.
29. (GM-CSF or G-CSF).ti,ab.
30. (molgramostim or Growgen-GM or Leucomax or Molcass or Gramostim or Leucocitim or Mielogen or Meustim or Bagomol or
Gramal).ti,ab.
31. Epidermal growth factor/
32. (rhEGF or “recombinant epithelial growth factor$” or “epidermal growth factor$” or EGF).ti,ab.
33. Platelet-derived growth factor/
34. (“platelet-derived growth factor$” or PDGF or “platelet lysate”).ti,ab.
35. Transforming Growth Factor beta/
36. (“transforming growth factor$” or “bone-derived transforming growth factor$” or “milk growth factor$” or “platelet transforming
growth factor” or TGF-beta or TGFbeta).ti,ab.
37. Hepatocyte growth factor/
38. (“hepatocyte growth factor$” or hepatopoietin or “scatter factor”).ti,ab.
39. exp Somatomedin/
40. (somatomedin$ or “insulin-like growth factor$” or “sulfation factor” or Mecasermin or Increlex or Iplex or IGF-1 or IGF1).ti,ab.
41. erythropoietin$.ti,ab.
42. Thrombopoietin/
43. (thrombopoietin$ or “mpl Ligand” or “megakaryocyte colony stimulating factor$” or “megakaryocyte growth and development
factor$” or “MGDF factor” or “myeloproliferative leukemia virus oncogene ligand” or “thrombocytopoiesis-stimulating factor” or
thrombocytopoietin$).ti,ab.
44. Ghrelin/
45. Interleukin 11/
46. (“interleukin 11” or “Adipogenesis Inhibitory Factor$” or IL-11 or IL11).ti,ab.
47. (ghrelin$ or “GHRL protein” or obestatin).ti,ab.
48. (ATL-104 or ATL104).ti,ab.
49. (whey or (“milk derived” adj (protein or growth factor))).ti,ab.
50. Glucagon-Like Peptide 2/
51. (“glucagon-like peptide 2” or (amino adj acid$) or proglucagon or GLP-2 or teduglutide or Gattex or Revestive).ti,ab.
52. Glutathione/
53. (“trefoil factor” or “carcinoembryonic antigen cell adhesion molecule 1” or glutathione or isethion).ti,ab.
54. Vascular endothelial growth factors/
55. (“vascular endothelial growth factor$” or VEGF$).ti,ab.
56. Molecular targeted therapy/
57. (targeted adj3 (therap$ or agent$)).ti,ab.
58. (biologic$ adj therap$).ti,ab.
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59. or/20-58
60. 11 and 19 and 59
The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials
(RCTs) in MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of
theCochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) (Higgins 2011).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
Appendix 4. Embase Ovid search strategy
1. exp NEOPLASM/
2. exp RADIOTHERAPY/
3. exp Antineoplastic agent/
4. Bone Marrow Transplantation/
5. Hematopoietic Stem Cell Transplantation/
6. (neoplasm$or cancer$ or leukaemi$or leukemi$ or tumour$ or tumor$ ormalignan$ or neutropeni$ or carcino$ or adenocarcinoma$
or lymphoma$).ti,ab.
7. (radioth$ or radiat$ or irradiat$).ti,ab.
8. ((bone adj marrow adj5 transplant$) or “hematopoietic stem cell transplant$” or “haematopoietic stem cell transplant$” or
HSCT).ti,ab.
9. chemo$.ti,ab.
10. or/1-9
11. exp STOMATITIS/
12. Thrush/
13. stomatitis.ti,ab.
14. mucositis.ti,ab.
15. (oral adj6 mucos$).ti,ab.
16. (mycosis or mycotic).ti,ab.
17. mIAS.ti,ab.
18. or/11-17
19. ((growth adj factor$) or (growth adj substance$) or (immunologic adj factor$)).ti,ab.
20. “fibroblast growth factor$”.ti,ab.
21. (keratinocyte$ or cytokine$).ti,ab.
22. (palifermin$ or KGF or FGF).ti,ab.
23. (kepivance or velafermin or repifermin).ti,ab.
24. glycoprotein$.ti,ab.
25. exp Colony-stimulating factor/
26. (“colony-stimulat$” or “macrophage-granulocyte inducer$” or “myeloid cell-growth inducer$” or “protein inducer MGI”).ti,ab.
27. (GM-CSF or G-CSF).ti,ab.
28. (molgramostim or Growgen-GM or Leucomax or Molcass or Gramostim or Leucocitim or Mielogen or Meustim or Bagomol or
Gramal).ti,ab.
29. Epidermal growth factor/
30. (rhEGF or “recombinant epithelial growth factor$” or “epidermal growth factor$” or EGF).ti,ab.
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31. Platelet derived growth factor/
32. (“platelet-derived growth factor$” or PDGF or “platelet lysate”).ti,ab.
33. Transforming Growth Factor beta/
34. (“transforming growth factor$” or “bone-derived transforming growth factor$” or “milk growth factor$” or “platelet transforming
growth factor” or TGF-beta or TGFbeta).ti,ab.
35. Scatter factor/
36. (“hepatocyte growth factor$” or hepatopoietin or “scatter factor”).ti,ab.
37. exp Somatomedin/
38. (somatomedin$ or “insulin-like growth factor$” or “sulfation factor” or Mecasermin or Increlex or Iplex or IGF-1 or IGF1).ti,ab.
39. erythropoietin$.ti,ab.
40. Thrombopoietin/
41. (thrombopoietin$ or “mpl Ligand” or “megakaryocyte colony stimulating factor$” or “megakaryocyte growth and development
factor$” or “MGDF factor” or “myeloproliferative leukemia virus oncogene ligand” or “thrombocytopoiesis-stimulating factor” or
thrombocytopoietin$).ti,ab.
42. Ghrelin/
43. Interleukin 11/
44. (“interleukin 11” or “Adipogenesis Inhibitory Factor$” or IL-11 or IL11).ti,ab.
45. (ghrelin$ or “GHRL protein” or obestatin).ti,ab.
46. (ATL-104 or ATL104).ti,ab.
47. (whey or (“milk derived” adj (protein or growth factor))).ti,ab.
48. (“glucagon-like peptide 2” or (amino adj acid$) or proglucagon or GLP-2 or teduglutide or Gattex or Revestive).ti,ab.
49. Glutathione/
50. (“trefoil factor” or “carcinoembryonic antigen cell adhesion molecule 1” or glutathione or isethion).ti,ab.
51. Vasculotropin/
52. (“vascular endothelial growth factor$” or VEGF$).ti,ab.
53. Molecularly targeted therapy/
54. (targeted adj3 (therap$ or agent$)).ti,ab.
55. (biologic$ adj therap$).ti,ab.
56. or/19-55
57. 10 and 18 and 56
The above subject search was linked to adapted version of the Cochrane Embase Project filter for identifying RCTs in EMBASE via
OVID (see www.cochranelibrary.com/help/central-creation-details.html for information).
1. Randomized controlled trial/
2. Controlled clinical study/
3. Random$.ti,ab.
4. randomization/
5. intermethod comparison/
6. placebo.ti,ab.
7. (compare or compared or comparison).ti.
8. ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab.
9. (open adj label).ti,ab.
10. ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab
11. double blind procedure/
12. parallel group$1.ti,ab.
13. (crossover or cross over).ti,ab.
14. ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or partici-
pant$1)).ti,ab.
15. (assigned or allocated).ti,ab.
16. (controlled adj7 (study or design or trial)).ti,ab.
17. (volunteer or volunteers).ti,ab.
18. trial.ti.
19. or/1-18
20. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
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21. 19 not 20
Appendix 5. CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature) search
strategy
S53 S10 and S18 and S52
S52 S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36
or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49 or S50 or S51
S51 (biologic* N1 therap*)
S50 (targeted N3 (therap* or agent*))
S49 (“vascular endothelial growth factor*” or VEGF*)
S48 (mh Vascular endothelial growth factors)
S47 (“trefoil factor” or “carcinoembryonic antigen cell adhesion molecule 1” or glutathione or isethion)
S46 (mh Glutathione)
S45 (“glucagon-like peptide 2” or “amino acid*” or proglucagon or GLP-2 or teduglutide or Gattex or Revestive)
S44 (mh Glucagon-like peptide 2)
S43 (whey or (“milk derived” N1 (protein or “growth factor”)))
S42 (ATL-104 or ATL104)
S41 (ghrelin* or “GHRL protein” or obestatin)
S40 (“interleukin 11” or “adipogenesis inhibitory factor*” or IL-11 or IL11)
S39 (mh Ghrelin)
S38 (thrombopoietin* or “mpl Ligand” or “megakaryocyte colony stimulating factor*” or “megakaryocyte growth and development
factor*” or “MGDF factor” or “myeloproliferative leukemia virus oncogene ligand” or “thrombocytopoiesis-stimulating factor” or
thrombocytopoietin*)
S37 erythropoietin*
S36 (somatomedin* or “insulin-like growth factor*” or “sulfation factor*” or Mecasermin or Increlex or Iplex or IGF-1 or IGF1)
S35 (“hepatocyte growth factor*” or hepatopoietin or “scatter factor”)
S34 (“transforming growth factor*” or “bone-derived transforming growth factor*” or “milk growth factor*” or “platelet transforming
growth factor*” or TGF-beta or TGFBeta)
S33 (mh Transforming growth factor beta)
S32 (“platelet-derived growth factor*” or PDGF or “platelet lysate”)
S31 (mh Platelet-derived growth factor)
S30 (rhEGF or “recombinant epithelial growth factor*” or “epidermal growth factor*” or EGF)
S29 (MH “Epidermal Growth Factors”)
S28 (molgramostim or Growgen-GM or Leucomax or Molcass or Gramostim or Leucocitim or Mielogen or Meustim or Bagomol or
Gramal)
S27 (GM-CSF or G-CSF)
S26 (colony-stimulat* or “macrophage-granulocyte inducer*” or “myeloid cell-growth inducer*” or “protein inducer MGI”)
S25 (mh colony-stimulating factors)
S24 glycoprotein*
S23 (keprivance or velafermin or repifermin)
S22 (palifermin* or KGF or FGF)
S21 (keratinocyte* or cytokine*)
S20 “fibroblast growth factor*”
S19 (“growth factor*” or “growth substance*” or “immunologic factor*”)
S18 S11 or S12 or S13 or S14 or S15 or S16 or S17
S17 mIAS
S16 (mycosis or mycotic)
S15 (oral N6 mucos*)
S14 mucositis
S13 stomatitis
S12 (MH “Candidiasis, Oral”)
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S11 (mh stomatitis+)
S10 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9
S9 chemo*
S8 ((“bone marrow” and transplant*) or “hematopoietic stem cell transplant*” or “haematopoietic stem cell transplant*” or HSCT)
S7 (radioth* or radiat* or irradiat*)
S6 (neoplasm* or cancer* or leukaemi* or leukemi* or tumour* or tumor* or malignan* or neutropeni* or neutropeni* or carcino* or
adenocarcinoma* or lymphoma*)
S5 (mh hematopoietic stem cell transplantation)
S4 (mh bone marrow transplantation)
S3 (mh antineoplastic agents+)
S2 (mh radiotherapy+)
S1 (mh neoplasms+)
The above subject search was linked to Cochrane Oral Health’s filter for CINAHL via EBSCO.
S1 MH Random Assignment or MH Single-blind Studies or MHDouble-blind Studies or MH Triple-blind Studies or MH Crossover
design or MH Factorial Design
S2 TI (“multicentre study” or “multicenter study” or “multi-centre study” or “multi center study”) or AB (“multicentre study” or
“multicenter study” or “multi centre study” or “multi-center study”) or SU (“multicentre study” or “multicenter study” or “multi-
centre study” or “multi-center study”)
S3 TI random* or AB random*
S4 AB “latin square” or TI “latin square”
S5 TI (crossover or cross-over) or AB (crossover or cross-over) or SU (crossover or cross-over)
S6 MH Placebos
S7 AB (singl* or doubl* or trebl* or tripl*) or TI (singl* or doubl* or trebl* or tripl*)
S8 TI blind* or AB mask* or AB blind* or TI mask*
S9 S7 and S8
S10 TI Placebo* or AB Placebo* or SU Placebo*
S11 MH Clinical Trials
S12 TI (Clinical AND Trial) or AB (Clinical AND Trial) or SU (Clinical AND Trial)
S13 S1 or S2 or S3 or S4 or S5 or S6 or S9 or S10 or S11 or S12
Appendix 6. CANCERLIT PubMed search strategy
We searched CANCERLIT by limiting a PubMed search with the Cancer subject filter and the following search strategy.
#60 (#11 and #19 and #59)
#59 (#20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37
or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or
#56 or #57 or #58)
#58 “biologic* therap*”
#57 (“targeted therap*” or “targeted agent*”)
#56 Molecular targeted therapy [mh:noexp]
#55 ((“vascular endothelial growth factor*” or VEGF*))
#54 Vascular endothelial growth factors [mh:noexp]
#53 ((“trefoil factor” or “carcinoembryonic antigen cell adhesion molecule 1” or glutathione or isethion))
#52 Glutathione [mh:noexp]
#51 ((“glucagon-like peptide 2” or “amino acid*” or proglucagon or GLP-2 or teduglutide or Gattex or Revestive))
#50 Glucagon-like peptide 2 [mh:noexp]
#49 ((whey or “milk derived protein” or “milk derived growth factor”))
#48 ((ATL-104 or ATL104))
#47 ((ghrelin* or “GHRL protein” or obestatin))
#46 ((“interleukin 11” or “adipogenesis inhibitory factor*” or IL-11 or IL11))
#45 Interleukin 11 [mh:exp]
#44 Ghrelin [mh:noexp]
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#43 ((thrombopoietin* or “mpl Ligand” or “megakaryocyte colony stimulating factor*” or “megakaryocyte growth and development
factor*” or “MGDF factor” or “myeloproliferative leukemia virus oncogene ligand” or “thrombocytopoiesis-stimulating factor” or
thrombocytopoietin*))
#42 Thrombopoietin [mh:noexp]
#41 erythropoietin*
#40 ((somatomedin* or “insulin-like growth factor*” or “sulfation factor*” or Mecasermin or Increlex or Iplex or IGF-1 or IGF1))
#39 Somatomedin [mh:exp]
#38 ((“hepatocyte growth factor*” or hepatopoietin or “scatter factor”))
#37 Hepatocyte growth factor [mh:noexp]
#36 ((“transforming growth factor*” or “bone-derived transforming growth factor*” or “milk growth factor*” or “platelet transforming
growth factor*” or TGF-beta or TGFBeta))
#35 Transforming growth factor beta [mh:noexp]
#34 ((“platelet-derived growth factor*” or PDGF or “platelet lysate”))
#33 Platelet-derived growth factor [mh:noexp]
#32 ((rhEGF or “recombinant epithelial growth factor*” or “epidermal growth factor*” or EGF))
#31 Epidermal growth factor [mh:noexp]
#30 ((molgramostim or Growgen-GM or Leucomax or Molcass or Gramostim or Leucocitim or Mielogen or Meustim or Bagomol or
Gramal))
#29 ((GM-CSF or G-CSF))
#28 ((colony-stimulat* or “macrophage-granulocyte inducer*” or “myeloid cell-growth inducer*” or “protein inducer MGI”))
#27 colony-stimulating factors [mh:exp]
#26 glycoprotein*
#25 ((keprivance or velafermin or repifermin))
#24 ((palifermin* or KGF or FGF))
#23 ((keratinocyte* or cytokine*))
#22 “fibroblast growth factor*”
#21 Fibroblast growth factor 7 [mh:noexp]
#20 ((“growth factor*” or “growth substance*” or “immunologic factor*”))
#19 (#12 or #13 or #14 or #15 or #16 or #17 or #18)
#18 mIAS
#17 ((mycosis or mycotic))
#16 “oral mucos*”
#15 mucositis
#14 stomatitis
#13 oral candidiasis [mh:noexp]
#12 Stomatitis [mh:exp]
#11 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10)
#10 chemo*
#9 (((“bone marrow” and transplant*) or “hematopoietic stem cell transplant*” or “haematopoietic stem cell transplant*” or HSCT))
#8 ((radioth* or radiat* or irradiat*))
#7 ((neoplasm* or cancer* or leukaemi* or leukemi* or tumour* or tumor* or malignan* or neutropeni* or neutropeni* or carcino* or
adenocarcinoma* or lymphoma*))
#6 Antineoplastic Combined Chemotherapy Protocols [mh:noexp]
#5 “hematopoietic stem cell transplantation” [mh:noexp]
#4 bone marrow transplantation [mh:noexp]
#3 antineoplastic agents [mh:exp]
#2 radiotherapy [mh:exp]
#1 neoplasms [mh:exp]
This search was linked with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE:
sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.a of the Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) (Lefebvre 2011).
#1 randomized controlled trial [pt]
#2 controlled clinical trial [pt]
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#3 randomized [tiab]
#4 placebo [tiab]
#5 drug therapy [sh]
#6 randomly [tiab]
#7 trial [tiab]
#8 groups [tiab]
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#10 animals [mh] not humans [mh]
#11 #9 NOT #10
Appendix 7. US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) search
strategy
oral mucositis and cytokines
oral mucositis and growth factor
oral mucositis and palifermin
oral mucositis and GM-CSF
Appendix 8. World Health Organization International Clinical Trials Registry Platform search
strategy
oral mucositis and cytokines
oral mucositis and growth factor
oral mucositis and palifermin
oral mucositis and GM-CSF
Appendix 9. Oral mucositis measurement scales
Oral mucositis assessment scale (OMAS)
(as reported in Freytes 2004)
Oral cavity ulceration Oral cavity erythema
Grade 0 No lesion Grade 0 None
Grade 1 Lesion < 1 cm2 Grade 1 Not severe
Grade 2 Lesion 1 cm2 to 3 cm2 Grade 2 Severe
Grade 3 Lesion > 3 cm2 - -
Ulceration and erythema are measured at 9 different sites (upper and lower labial mucosa, right and left buccal mucosa, right and left
lateral and ventral portions of the tongue, floor of the mouth, soft palate (fauces), and hard palate (gingival)) and summated to give a
total mucositis score. Therefore score could range from 0 to 45.
Radiation Therapy Oncology Group (RTOG) scale
(physician-rated objective gross score as reported in Chi 1995)
190Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Grade 0 None
Grade 1 Erythematous sores
Grade 2 Patchy mucositis (< 1/2 mucosa)
Grade 3 Confluent fibrinous mucositis (> 1/2 mucosa)
Grade 4 Haemorrhage and necrosis
Radiation Therapy Oncology Group (RTOG) scale
(as reported in Wu 2009)
Grade 0 None
Grade 1 Injection; may experience mild pain not requiring analgesia
Grade 2 Patchy mucositis that may produce an inflammatory serosanguineous discharge; may experience moderate pain requiring
analgesia
Grade 3 Confluent fibrinous mucositis; may include severe pain requiring narcosis
Grade 4 Ulceration, haemorrhage, or necrosis
Cancer and Leukemia Group B (CALGB) scale
(as reported in Turhal 2000)
Grade 0 No mucositis
Grade 1 Painless ulcers, erythema or mild soreness
Grade 2 Painful erythema, edema, or ulcers, but can eat
Grade 3 Painful erythema, edema, or ulcers, and cannot eat
Grade 4 Requires parenteral or enteral support
National Cancer Institute common toxicity criteria (NCI-CTC)
(as reported in Dazzi 2003)
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Grade 0 No mucositis
Grade 1 Painless ulcers, erythema or mild soreness in the absence of lesions
Grade 2 Painful erythema, edema or ulcers, but can eat or swallow
Grade 3 Painful erythema, edema or ulcers requiring intravenous hydration
Grade 4 Severe ulceration or requires parenteral or enteral nutritional support
World Health Organization (WHO) scale
(as reported in Vadhan-Raj 2010)
Grade 0 No mucositis
Grade 1 Soreness ± erythema
Grade 2 Erythema, ulcers. Patient can swallow solid diet
Grade 3 Ulcers, extensive erythema. Patient cannot swallow solid diet
Grade 4 Mucositis to the extent that alimentation is not possible
H I S T O R Y
Protocol first published: Issue 12, 2015
Review first published: Issue 11, 2017
Date Event Description
26 January 2016 Amended Minor edit (hyperlink)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• For the ’Summary of findings’ tables, we decided to limit the outcomes to the incidence of moderate to severe, and the incidence
of severe oral mucositis, and also adverse events. This was partly because the scales used to assess oral mucositis often incorporate
aspects of some of the secondary outcomes, and it is the most clinically relevant outcome, and partly because the tables would become
unwieldy and difficult to read once the secondary outcomes had been divided into their subgroups based on cancer treatment type.
We also eliminated the incidence of any oral mucositis from the tables because ulcerative and severe grades are more important.
• We decided not to report data from secondary outcomes that were not suitable for meta-analysis in additional tables as we felt
that this would not be helpful and could result in ’vote-counting’ i.e. xx studies reported a difference and yy studies reported no
difference.
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